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       Alzheimer’s Disease (AD) is a devastating neurodegenerative condition with 
synaptic  impairment  at the onset of disease.   Previously, our group have shown that 
the p25 molecule  is changed in the post mortem brain of mild stage AD patients. A 
mass spectrometric analysis of p25 transgenic mouse brain provided us with a set of 
potential p25 downstream molecules.  Three of these candidate molecules which had 
synaptic/dendritic localization – CYFIP2, CYFIP1 and CSPα were selected to be 
studied in the post-mortem brain of Alzheimer’s patients. CYFIP2 is a dendritically 
localised molecule with biological role in local translation modulation and cytoskeleton 
remodelling. Our case –control studies revealed that CYFIP2 is downregulated in 
severe stages of disease in hippocampus.  We showed a similar CYFIP2 
downregulation in Tg2576 mouse model of AD.   We performed functional studies of 
this molecule, using CYFIP2 heterozygous knockout mice.  We found that these 
mutants suffer from memory loss after Pavlovian conditioning. CYFIP1 has similar 
cellular function as CYFIP2.  Our studies showed that CYFIP1 is upregulated in AD 
hippocampus. However, this upregulation is unlikely to be compensation for CYFIP2 
downregulation, as it was not observed in superior temporal gyrus.  CSPα, a synaptic 
vesicle protein that has been implicated in neurodegeneration in Kufs disease, was 
found to be downregulated in AD hippocampus, but, surprisingly, upregulated in 
cerebellum. This suggests that CSPα may protect neurons from degeneration. In 
agreement, we found that CSPα upregulation in htau mutant mice correlates with 
absence of neuronal loss. Taken together, analysis of candidate p25-regulated synaptic 
proteins have provided novel insights into mechanisms underlying synaptic 
degeneration and memory impairment in AD.  
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Chapter 1: Introduction 
 
1.1. Alzheimer’s Disease 
 
Alzheimer’s Disease  (AD) was  reported first by the German psychiatrist Alois 
Alzheimer in 1906 in Tübingen, Germany (Alzheimer et al., 1995). He reported the 
correlation between cognitive deficits of a 51 year-old woman and cortical 
histopathology of plaques and   neurofibrillary changes on her death at the age of 55 
years. 106 years after this revelation, much has been discovered about the pathology of 
the disease and yet a lot remains to be understood in terms of the molecular 
mechanisms leading to AD and associated dementia. 
 
1.1.1. Significance of AD research 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder and it is the most prominent 
cause of dementia in the elderly. The prevalence of AD is evident from the 
epidemiological statistics for the year 2011 in the US population (Alzheimer’s 
Association statistics) –  
• 5.4 million Americans irrespective of the age group have been diagnosed with 
AD. This group includes 5.2 million people above the age of 65 years and 
200,000 below the age of 65 years diagnosed with early onset AD. Therefore 
approximately 1 in every 8 individuals (or 13%) above the age of 65 years has 
been diagnosed with AD. If untreated, the prevalence of this disease in people 
above 65 years is projected to triple by 2050 to about 11 to 16 million. 
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• It is the sixth leading cause of death amongst all ages in the US population 
• With the current growth in prevalence of AD in the US population, the annual 
economic burden of the disease is estimated to inflate from $183 billion in 2011 
to $1.1 trillion by 2050. 
Due to the current lack of knowledge about the mechanisms underlying AD aetiology 
and poor diagnostic as well as therapeutic tools for AD, it is emerging as a major social 
and economic burden in our modern ageing society. Hence there is an urgent need to 
understand this disease in as much detail as possible to develop better early stage 
diagnostic markers as well as therapies. 
 
1.1.2. Disease - Pathology and Diagnosis 
 
AD is characterized by the presence of extracellular amyloid β plaques, intracellular 
neurofibrillary tangles (NFT), and loss of synapses and neurons. AD progression  has 
been divided into three stages based on the spread of hyperphosphorylated tau protein – 
mild (Braak stages 1-2), moderate (Braak stages 3-4) and severe (Braak stages 5-6) 
(Braak and Braak, 1991b). The mild stage lasts 2-5 years and is characterized by the 
onset of memory impairment with impairment in short-term memory, deficits in 
problem solving ability, depression, aphasia (inability to effectively communicate) and 
other cognitive impairments (Holtzman et al., 2011). However, the patient at this stage 
can perform daily tasks and has perfect motor co-ordination. In the moderate stage of 
AD, lasting 2-4 years, there is progressive memory impairment that now includes long-
term memory deficits, agnosia (inability to recognize others) and apraxia (loss of motor 
skills). The patient becomes more and more dependent on friends and relatives for 
performing everyday work (Holtzman et al., 2011). In the severe stages, the patient is 
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totally dependent on others and has severe cognitive and memory deficits, problems 
with swallowing, bowel movement and bladder function (Holtzman et al., 2011). When 
the patient is alive, diagnosis of AD is still not conclusive with post-mortem 
neuropathological analysis required to unequivocally diagnose AD. Apart from lack of 
efficient biomarkers of the disease, there is also no cure or effective symptomatic 
treatment available for AD. 
 
1.1.3. Mechanistic understanding of Disease 
 
The cause of the development of AD is still unknown. Prior the 1970s AD was 
considered to be a case of presenile dementia (affecting people aged < 65 years), 
distinct from senile dementia (with age onset > 65 years). However, by the 1970s it was 
realized that the biology behind both dementias is the same with identical pathological 
hallmarks and symptoms. There are several hypotheses that have been proposed to 
explain the causes of early onset and late onset forms of AD. One of the first 
hypotheses was based on the observation that cholinergic transmission is essential for 
memory formation (Bartus, 1979) and loss of cholinergic neuron occurs in AD (Davies 
and Maloney, 1976). Thus, impaired cholinergic transmission was proposed to cause 
AD. This hypothesis has led to the development of a widely used acetylcholinesterase 
inhibitor-based therapy, which provided moderate symptomatic relief in clinical use 
(Farlow et al., 2008). However, in AD most of the cortical pyramidal neurons, which 
are glutamatergic, are affected and hence the cholinergic neuron-based hypothesis and 




Being the pathological hallmarks of AD, NFT and amyloid β plaques attracted 
significant attention as possible causes for the disease. Intracellular NFTs are composed 
of aggregates of  paired helical filaments (Kidd, 1963) and these filaments are made up 
of hyperphosphorylated tau protein (Kosik et al., 1986, Wood et al., 1986). The normal 
function of tau protein is to stabilize the microtubule assembly (Weingarten et al., 
1975). Amyloid plaques are extracellular aggregates of amyloid β peptide fragments 
and are derived from the cleavage of transmembrane amyloid precursor protein (APP) 
(Golde et al., 2000, Hardy and Selkoe, 2002). The cleavage of APP to amyloid β 
peptide is mediated by β-secretase and γ-secretase (Holtzman et al., 2011)  as shown in 
Fig.1.1. The cellular function of APP is not yet well known. The APP gene has been 
localized to chromosome 21 in humans (and chromosome 16 in mouse) (Goldgaber et 
al., 1987, Beyreuther et al., 1993, Cheng et al., 1988) and explains the high correlation 
between trisomy 21 (Down’s syndrome) and AD pathology of amyloid plaques.  
 
1.1.3.1. APP – production and processing  
 
As a key protein implicated in AD it is important to understand APP production and 
processing  mechanisms ( Fig.1.2). APP production goes through a series of steps from 
gene transcription, posttranscriptional modification, translation and finally 
posttranslational modification during its production pathway (Westmark, 2013, 
Westmark and Malter, 2012). This is then followed by complex processing by 
enzymes, which leads to production of amyloid peptide amongst other products. 
 There are several isoforms of APP ranging in size from 695 to 775 amino acids, 
which includes the fragment from which the amyloidβ is derived.  APP695 is the most 
abundant isoform in brain (Kummer and Heneka, 2014). APP mRNA binds to Fragile 
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X Mental Retardation Protein (FMRP) – a protein important for mRNA transport into 
dendrites and regulation of local dendritic/synaptic mRNA translation. FMRP represses 
mRNA translation. This repression is released through an mGluR5 –dependent 
signalling pathway at synapses (Sokol et al., 2011, Lee et al., 2010, Darnell et al., 
2011).  APP is reported to be synthesized in a developmentally regulated manner with 
expression reaching maximum levels during neuronal differentiation, particularly 
synaptogenesis, and declining with the final establishment of major neural circuits 
(Loffler and Huber, 1992, Moya et al., 1994). Changes in the expression profile (both 
quantitative levels and localization) of RNA binding proteins like FMRP are expected 
to influence APP and amyloidβ synthesis and expression during the course of 
development. This has been  shown in neonatal brains, whereby the APP levels reach 
their maximum during postnatal weeks 2-6, a period when crucial sensory neural 
circuits are being established  in rodents, and the FMRP levels decline after the 1st 
postnatal week (Berardi et al., 2000, Lu et al., 2004).  A decrease in FMRP levels (or 
other dendritic translation regulators) will eventually lead to an increase in APP levels 
during synpatogenesis as reported by Westmark’s group (Westmark and Malter, 2012, 
Westmark, 2013) since FMRP levels regulate the translation of APP mRNA. During 
synaptogenesis this translational repression is removed by a decrease in FMRP levels 
leading to elevation of APP levels (Westmark and Malter, 2007).  At the other extreme 
of the development phase, Prasad’s group has reported that FMRP levels decrease in an 
age-dependent manner in rodents (Singh et al., 2007). Hence, with ageing, the decrease 
in FMRP levels could be contributing to an age-dependent increase of APP or amyloidβ 
production.  
 At the posttranslational level, APP processing happens through two pathways – 
amyloidogenic and non-amyloidogenic ( Fig1.1 and Fig.1.2). In the amyloidogenic 
pathway, APP is cleaved by β-secretase (BACE-1) followed by γ-secretase (the 
21 
 
catalytic component of which is presenilin) leading to amyloidβ synthesis. Presenilin 1 
(PS1) and Presenilin 2 (PS2) are gamma-secretases that cleave APP (Takasugi et al., 
2003). They are multiple transmembrane proteins  and span membrane 6-9 times(Kim 
and Schekman, 2004, Oh and Turner, 2005). Both β-secretase and γ-secretase are 
transmembrane proteins that have aspartic protease catalytic domains that cleave APP 
to generate an internal fragment – amyloid β (Westmark, 2013). BACE1 expression is 
high in brain and BACE1 knockout mice do not show  detectable amyloidβ levels 
which may have therapeutic use (Vassar et al., 1999, Bennett et al., 2000, Vassar and 
Citron, 2000)). Amyoid β begins about 99 residues from the C-terminus of APP and 
extends from the extracellular domain into middle of membrane spanning domain 
(Westmark, 2013). The γ secreatse activity in both amyloidogenic and 
nonamyloidogenic pathway releases APP intracellular  cytoplasmic domain (AICD) 
apart from amyloidβ in amyloidogenic pathway and p3 fragment in non-amyloidogenic 
pathway (Selkoe, 2002). AICD binds to different proteins and may be involved in gene 
regulation, neuronal growth and apoptosis (Raychaudhuri and Mukhopadhyay, 2007). 
The best characterized of these AICD binding proteins are Fe65 family members. 
These protein contain two domains that physically interact with C- terminal of APP 
regulating AICD formation (Fiore et al., 1995, Duilio et al., 1998, Huysseune et al., 
2007). Mint/X11 family bind to AICD and modulate AICD mediated transcription in 
isoform specific manner (Borg et al., 1996, Biederer et al., 2002). Members of JIP 
family activate AICD-mediated signalling (Scheinfeld et al., 2003). AICD modulates 
calcium homeostasis , cellular trafficking and cell death (Hamid et al., 2007, Ghosal et 
al., 2009, Passer et al., 2000). Finally, AICD undergoes  two step proteolytic fate – 
rapid inactivation by endosomal insulin degrading enzyme – insulysin (Farris et al., 
2003) and  cleavage at C-terminal end by caspase 3 activity to yield C31 fragment (Lu 
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et al., 2000). Both the pathway contribute to certain extent in the final AICD 
degradation. 
The formation of amyloidβ peptide is a multiple step process. Amyloidβ is a mix of 
peptides of 39 to 43 amino acids (Wang et al., 1996, Lamb et al., 1997). The 
endoproteolysis is believed to occur in stepwise manner cleaving the C-terminal stub 
multiple times within its transmembrane domain. The cleavage occurs approximately 3 
amino acid apart – the first one at position 48/49 (ε-cleavage  site)  , followed by at 
position 45/46 (ζ-cleavage site ) , and the last one at position 38/40 or 42 (γ-cleavage 
site) (Takami et al., 2009, Qi-Takahara et al., 2005, Gu et al., 2001, Sastre et al., 2001). 
So, ε cleavage is a limiting step for γ cleavage occurrence. Depending on the cleavage 
site of γ-secretase at the C-terminus end of amyloidβ, different forms of amyloidβ are 
generated (Steiner et al., 2008) and some of them are shorter isoforms than the ones 
mentioned before ( Amyloidβ - 17,18) depending on the γ secretase activity(Portelius et 
al., 2011). The ε cleavage site is considered equivalent to S3 site in Notch 1(Schroeter 
et al., 1998), Also , a new study revealed that S4 cleavage site in Notch1 could be 
homologous to γ cleavage site in APP(Okochi et al., 2002). This suggest that the 
intramembrane cleavages that  APP and Notch 1  undergo are similar  atleast at two 
sites : ε/S3 cleavage and γ /S4 cleavage , releasing amyloidβ/notch-1β and APP 
intracellular cytoplasmic domain(AICD)/ Notch-1 intracellular cytoplasmic domain 
(NICD)(Okochi et al., 2002, Tagami et al., 2008).  Just as NICD transcription factor , 
there are increasing evidence that AICD is also trafficked to nucleus where it could be 
acting as a transcription factor (Kopan, 2002, Goodger et al., 2009, Roncarati et al., 
2002). Though amyloidβ peptide is produced throughout life, it has been recently 
reported that the production of amyloid β42 (both the soluble and insoluble form) 
increases with ageing relative to amyloid β40 (after 50 years of age), possibly 
contributing to AD pathology (Miners et al., 2014). The increase in amyloidβ42 with 
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respect to amyloidβ40  levels have been reported in familial AD as well as transgenic 
animal models of AD (Wolfe, 2007, Selkoe, 1998). The alternate mechanism of APP 
processing is the non-amyloidogenic pathway whereby another secretase, α-secretase 
(ADAM 17), cleaves within the amyloidβ domain ( between position 16 and 17 ) of 
APP leading to formation and release of an 82kDa neuroprotective protein, soluble 
APPα, into the extracellular matrix , an αC-terminal fragment stub and avoids the 
formation of the amyloidβ fragment (Gandy et al., 1993, Westmark, 2013). APP 
overexpression leads to increased processing of APP through the amyloidogenic 
pathway (Mattson, 1997) leading to increased production of amyloidβ. Though 
amyloidβ is present in body fluids under physiological conditions, an increased 
production or reduced clearance of amyloidβ leads to toxic formation of amyloid 
oligomers and amyloid plaques (Klein et al., 2004, Westmark, 2013).  
           Amyloidβ species undergo various kind of post-translational modifications. 
Pyroglutamylation is an important modification , which was identified at the glutamic 
acid on position 3 at N-terminal end (Mori et al., 1992) . This species was weakly 
soluble (Saido et al., 1995) and was present in small amount in plaques. Another 
amyloid species with pyroglutamate modification showed the pyroglutamylation at 
aspartate 11(Naslund et al., 1994, Liu et al., 2006). Conversion of glutamate to 
pyroglutamte is a dehydration reaction which can be catalyzed by the enzyme 
glutaminyl cyclase (Schilling et al., 2004). In AD glutaminyl cyclase expression has 
been reported to be increased (Schilling et al., 2008). Both in vitro and in vivo, reduced 
glutaminyl cyclase results in reduced pyroglutamate amyloidβ formation(Schilling et 
al., 2008) (Cynis et al., 2008, Jawhar et al., 2011). The in vitro toxicological profile of 
amyloidβ42 and amyloidβ pyroglutamated at position 3 is same in neuronal cells. 
Various mouse models of AD show the presence of pyroglutamated AD but its time of 
first appearance varies (Christensen et al., 2008, Kawarabayashi et al., 2001). 
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          Oxidation of amyloidβ occurs at methionine at position 35. Methionine 35 is 
oxidized to methionine sulfoxide  and was reported in AD by Greengard’s group 
(Naslund et al., 1994) There are three potential phosphorylation sites on amyloidβ – 
serine at position 8 and 26 , tyrosine at position 10. Amyloidβ serine 26 
phosphorylation has been reported in AD brains (Milton, 2001). Serine 8 
phosphorylated species is found in plaques as well as intracellularly and increases 
oligomeric aggregate formation (Kumar et al., 2011, Kumar et al., 2013a). Many post-
translational modifications in amyloidβ are induced by Nitric oxide, like the dityrosine 
formation and nitration at tyrosine residues, S-nitrothiols at cysteine residues (Radi et 
al., 2002, Butterfield et al., 2007, Castegna et al., 2003). In APP/PS1 mice, nitrated 
amyloidβ initiates plaque formation which may have a role in early phase of AD 
(Kummer et al., 2011). The presence of  O-glycosylated amyloidβ species in the CSF of 
AD patients have been shown by mass spectrometric analysis (Halim et al., 2011). 
Isomerization at asparagine residue and racemization at aspartly residues are other 
mode of post translational modification in amyloidβ species (Szendrei et al., 1994, 
Roher et al., 1993). 
 Familial, early onset forms of AD are due to point mutations in the gene 
encoding APP, PS1 or PS2 (Murrell et al., 1991, Levy-Lahad et al., 1995a, Sherrington 
et al., 1995). These point mutations shift APP cleavage from the non-amyloidogenic 
pathway to the amyloidogenic pathway, leading to toxic amyloid production. These 
point mutants are sufficient to induce AD pathology. Thus, abnormal processing can 
lead to tau hyperphosphorylation and formation of neurofibrillary tangles. 
Amyloidβ species activate a number of intracellular signalling pathways (Sheng et al., 
2012). They may directly or indirectly activate a mitchondrial apoptotic pathway 
leading to neuronal toxicity or synaptic impairments by caspase-3 activation (D'Amelio 
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et al., 2011). They also trigger a number of signalling pathways that lead to increased 
Ca2+ influx, impaired energy metabolism and increased oxidative stress, all of which 
will contribute to synaptotoxicity and neurodegeneration (Bezprozvanny and Mattson, 
2008). Pharmacological studies reveal an amyloidβ induced Ca 2+ influx by interaction 
with NMDA receptors that leads to the formation of reactive oxygen species (De Felice 
et al., 2007). Amyloidβ also stimulates glycogen synthase kinase 3 (GSK3), which has 
been implicated in AD due to its role in tau phosphorylation (Bhat et al., 2004). In the 
hippocampus, GSK3 activation has been reported to lead to increased NMDA receptor 
dependent long term depression (LTD) and inhibition of LTP, which is similar to the 
activity of amyloidβ (Peineau et al., 2007, Sheng et al., 2012). A recent report has also 
shown that inhibition of GSK3 leads to an increase in lysosomal number, causing 
autophagic degradation of APP (Parr et al., 2012). According to the most recently 
accepted form of the amyloid cascade hypothesis of AD (Fig.1.1 and Fig.1.2), 
proposed in 1991 by Hardy and Selko (Hardy and Selkoe, 2002), it is most likey the 
soluble oligomeric forms of amyloidβ that lead to neurodegeneration in AD and that the 
toxic amyloid species could be propagated by a prion-like mechanism from one cell to 
another (Sheng et al., 2012).  
 
1.1.3.2. Tau and APP 
 
Hyperphosphorylation of tau contributes to AD pathology. Tau belongs to a family of 
microtubule–associated proteins. Apart from its well known function in microtubule 
polymerization and stabilization, tau is also implicated in the regulation of axonal 
transport by motor protein regulation. Mutations in the Tau gene have linked tau 
abnormalities to neurodegenerative diseases; however, there is no report of a Tau 
mutation in AD (Poorkaj et al., 2001). The human Tau/MAPT gene has 16 exons and is 
26 
 
located on chromosome 17 at band position 17q21 (Neve et al., 1986, Andreadis et al., 
1992). Alternative splicing of the human tau gene gives rise to six tau isoforms 
(Goedert et al., 1989a, Goedert et al., 1989b). The inclusion or exclusion of a coded 
exon 10 region determines the classification of these isoforms as 3 repeat (3R) or 4 
repeat (4R) (Poorkaj et al., 2001). In the adult human brain the 3R and 4R levels are 
almost equal whereas adult mouse brain contains the 4R isoforms exclusively. There 
are 14 amino acids difference at the N-terminal end between mouse and human tau 
sequences (Andorfer et al., 2003). Tau is a neuronal protein with axonal localization 
and the primary sequence of tau can be sub-divided into an amino-terminal region, a 
proline-rich domain followed by microtubule-binding repeat motifs and the carboxy-
terminal tail (Weingarten et al., 1975, Schweers et al., 1994).  There are 79 potential 
phosphorylation sites on the longest tau isoform (441 amino acids) (Buee et al., 2000). 
About 20 protein kinases are reported to phosphorylate tau, which includes glycogen 
kinase 3 (GSK3) and cyclin-dependent protein kinases 5 (Sergeant et al., 2008, 
Hamdane et al., 2003, Tomizawa et al., 2001). In AD, tau  pathology follows a cortico-
cortical connection sequential pathway starting from entorhinal cortex and ending in 
motor-sensory cortex (Braak and Braak, 1991b). Mice overexpressing human tau show 
synaptotoxicity even in the absence of NFT, leading to the conclusion that soluble 
oligomeric tau protein could be an important synaptotoxic  molecule downstream of 
amyloid β (Pooler et al., 2014). Hyperphosphorylated tau aggregates have been shown 
to be interacting  with post-synaptic signalling complexes modulating axonal 
mitochondrial transport and glutamatergic receptor levels in dendritic spines (Ittner et 





1.1.3.3. Other factors implicated in the onset of AD 
 
There are various other risk factors that have been considered important for the onset of 
AD. Positional cloning strategies have revealed a number of other genes that are risk 
factors or contributors to AD onset. For the early onset forms of AD (age of onset <65 
years) that are mostly familial, presenilin1 and presenilin 2 on chromosomes 14 and 1 
respectively, have been identified as a major locus linked to the AD (Schellenberg et 
al., 1992, St George-Hyslop et al., 1992, Levy-Lahad et al., 1995a, Levy-Lahad et al., 
1995b). Presenilin, along with other components, form the core functional complex of 
γ-secretase, which is important for cleavage of Notch, APP and other transmembrane 
protein (Edbauer et al., 2003). 
     Apolipoprotein E is an amyloid β binding protein and it is proposed to bind soluble 
forms of amyloid peptide (Kim et al., 2009). An allele of the apolipoprotein E (apoE) 
gene on chromosome 19 has been linked with late onset AD (onset age >65 years), 
which is mostly sporadic (Pericak-Vance et al., 1991, Strittmatter et al., 1993). The 
apoE4 variant of this gene is considered a major risk factor for late onset AD (Corder et 
al., 1993). About a quarter of the population carries this allele, raising the question of 
the contribution of this risk factor to AD. Another variant, apoE2, is thought to have a 
protective function against the disease as it negatively correlates with AD (Chartier-





Figure 1.1. Interaction of amyloid β, Tau and other factors involved in AD 
pathogenesis. The cleavage of APP by β secretases and γ secretases in the 
amyloidogenic pathway leads to formation of amyloid peptides of various lengths. 
These amyloid peptides aggregate to form plaques. The plaques (possibly acting as a 
reservoir of toxic amyloid species) and the oligomers are the possible cause of 
subsequent toxicity, inflammation and downstream toxic tau hyperphosphorylation. 
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This is the most basic pathway of Hardy-Selko’s amyloid cascade hypothesis. Taken 


















Figure 1.2. APP processing and amyloid β accumulation. Mature APP (center, 
inside dashed box) is metabolized by 2 competing pathways, the α-secretase pathway 
that generates sAPPα and C83 (also known as CTFα; left) and the β-secretase pathway 
that generates sAPPβ and C99 (right). Some β-secretase cleavage is displaced by 10 
amino acid residues and generates sAPPβ′ and C89. All carboxy terminal fragments 
(C83, C99, and C89) are substrates for γ-secretase, generating the APP intracellular 
domain (AICD) and the secreted peptides p3 (not shown), Aβ (right), and Glu11 Aβ. Aβ 






Figure 1.3. APP processing and feed forward model. This model has been proposed 
by Westmark on the basis of their findings that indicate that amyloid β stimulates 
dendritic APP synthesis and can be inhibited by anisomycin or MPEP, indicating the 
relevance of an mGlur5 dependent and protein translation dependent pathway for APP 
synthesis at dendrites. Thus APP processing and cleavage leads to amyloid β formation, 
which in turn initiates a feed forward loop resulting in further APP synthesis through an 
mGluR5 and protein translation dependent mechanism. This generates more APP 
molecules to be processed by the amyloidogenic pathway into amyloid β peptides. 





Figure 1.4. Molecular model of an average synaptic vesicle containing CSP 
protein. 
The model is based on space-filling models of all macromolecules at near atomic 
resolution. 
(A) Outside view of a vesicle. CSP is one of the proteins visible on the surface. 
(B) View of a vesicle sectioned in the middle (the dark-colored membrane components 
represent cholesterol). 
(C) Model containing only synaptobrevin to show the surface density of the most 
abundant vesicle component. Taken from (Takamori et al., 2006). 
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1.2. The Synapse and Alzheimer’s disease 
  
Loss of synapses is an important pathology of AD, which occurs at the earliest stages 
of disease preceding the neuronal loss (discussed in detail later). To understand 
synaptic degeneration in AD was the primary objective of this PhD study. Which 
mechanisms lead to synaptic loss in AD is an important unanswered question in 
neurodegeneration research. To better understand the factors leading to synaptic and 
subsequent neuronal losses in AD it is essential to understand broadly the significance 
of APP (and its catabolites) and Tau at the synapses or dendrites. 
 
1.2.1. Role of APP and its catabolites at synapses 
 
1.2.1.1. APP at synapse 
 
APP has been reported to play a role in synapse formation, synaptic transmission, 
dendritic spine formation, learning and memory (Hoe et al., 2012).  Apart from the 
important amyloid β (discussed in section 1.2.1.2), other catabolites of APP have 
distinct functions. Soluble APPα (sAPP α, produced as a result of α secretase cleavage 
of APP in the non-amyloidogenic pathway) interacts with and disrupts APP dimers in 
the membrane preventing starvation-induced cell death, hence performing a 
neuroprotective function (Gralle et al., 2009).  CPEB (Cytoplasmic Polyadenylation 
Element Binding) factor is anchored to membrane by APP promoting polyadenylation 
induced translation (Cao et al., 2005). sAPPα also has been reported to enhance LTP 
and enhance the de novo protein synthesis in rat synaptoneurosomes (Claasen et al., 
2009, Taylor et al., 2008). Whereas sAPPα is neuroprotective, soluble APPβ (sAPPβ) 
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on the other hand could be neurotoxic. Tessier-Lavigne’s group has reported that 
sAPPβ binds to death receptor 6 (DR6) causing axonal degeneration (Nikolaev et al., 
2009). In the amyloidogenic pathway of APP processing, β-secretase cleavage of APP 
produces a 104 amino acid long fragment at the carboxy terminal end, which has been 
shown to be important for spatial learning and LTP maintenance (Nalbantoglu et al., 
1997). γ-secretase further cleaves this fragment producing different lengths of amyloid  
β and an intracellular carboxy terminal fragment.  The latter intracellular fragment of 
APP has been shown to be important in cellular signaling, protein-protein interactions 
and apoptosis (Zheng and Koo, 2011).  
 
1.2.1.2. Amyloid β at synapse 
 
Amyloid β has been reported to be involved in increasing LTD, decreasing LTP, 
enhancing calcium influx and enhancing membrane depolarization (Koffie et al., 2011, 
Blanchard et al., 2002). Amyloid β binds to number of cell surface receptors, which 
also includes APP and NMDA receptors (Verdier et al., 2004). At the excitatory 
synapses, the lateral diffusion and accumulation of Amyloid β causes peptide clustering 
leading to a decreased mobility but increased activity of mGluR5 at synapses (Renner et 
al., 2010). Amyloid β also activates two signaling molecules, GSK3β and mTOR, both 
of which are relevant to AD pathology (Takashima et al., 1996, Caccamo et al., 2011, 
Mines et al., 2011). Westmark et al. have shown that Amyloid β stimulates dendritic 
APP synthesis (Westmark et al., 2011). Primary cultured neurons that were treated with 
Amyloid β42 showed increased expression of APP, MAP1B and RhoB. The Amyloid  
β42 mediated overexpression of dendritic APP can be blocked by MPEP (an mGluR5 
antagonist) or anisomycin (a translation inhibitor) indicating that the mGluR5 and the 
translation dependent pathway are involved. Amyloid β has been reported to increase 
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the levels of APP in neuronal hybrid cells as well as induce secretion of amyloid β in 
rat cortical neurons (Le et al., 1995, Marsden et al., 2011). On the basis of the above 
facts, Westmark has proposed a feed forward loop for amyloid β action at the synapses 
whereby increased APP translation leads to increased release of amyloid β (by the 
amyloidogenic pathway), which stimulates mGluR5 signalling dependent dendritic 
translation of APP mRNA (Fig.1.3) (Westmark et al., 2011, Westmark, 2013).  
 
1.2.1.3. Soluble oligomers and plaques at synapse 
 
In earlier versions of the amyloid cascade hypothesis, amyloid plaques were considered 
to be the toxic entity responsible for synaptic and neuronal losses (Hardy and Higgins, 
1992). However, reports have shown the presence of soluble active oligomeric forms 
(dimers, trimers, tetramers, dodecamers, etc.) of amyloid β in synthetic amyloid β 
peptide preparation (Kayed et al., 2003), in APP transgenic mouse brains (Shankar et 
al., 2009) and in AD brain tissue (Shankar et al., 2008), which is potentially neurotoxic. 
In addition, the insoluble amyloid fibrils as well as their aggregate plaques might be 
inactive, acting simply as reservoir of these oligomers.  Protofibrils from synthetic 
amyloid β which are thinner than classical 8nm amyloid fibrils have been reported to be 
neurotoxic in in vitro condition (Hartley et al., 1999). However, the plaques acting as 
reservoirs at the synapse do lead to distortions of neurites in their vicinity (Hyman et 
al., 1995). A recent array tomography study by Spires-Jones et al in APP transgenic 
mice , shows a radial gradient  of excitatory synapse loss and neuritic dystrophy 
(Spires-Jones et al., 2007). This synaptic loss and dystrophy  is highest in the region 
closest to the plaques and reduces in a radial fashion, reaching normal levels at about 
30-50 μm away from plaque core edge (Spires-Jones et al., 2007). The same group used 
array tomography with post-mortem tissue and they shows that oligomeric amyloid β 
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binds to the pre- and post-synapse. Further the signal is much higher in close proximity 
to a plaque (Koffie et al., 2012). These morphological studies reveal that insoluble 
plaques may be having synaptotoxic and neuritic effects by acting as a reservoir of 
toxic soluble oligomers. Biochemical isolation of soluble amyloid oligomers and 
insoluble plaques from same AD cortex and electrophysiologically assay of their 
effects on mouse brain slices have shown that soluble oligomers block LTP whereas 
washed amyloid cores do not (Shankar et al., 2008). However, washing the amyloid 
core in harsh solvent (formic acid) before the assay made them toxic as it releases their 
constituent oligomers (Shankar et al., 2008). Hence, it is becoming more widely 
accepted that insoluble plaques or amyloid fibrils might be locally neurotoxic by being 
in a dynamic equilibrium with the soluble oligomers and protofibrils in the vicinity. 
 
1.2.2. Synaptic defects in AD 
 
Synaptic loss can be detected in the earliest stages of AD.  Various groups have 
reported the loss of pre-synaptic proteins like VAMP2 and SNAP25 and post-synaptic 
proteins like PSD95, and Shank1 (Pham et al., 2010, Arendt, 2009). Microscopy 
studies have reported alterations in synaptic structure in the early stages of AD as well 
as APP transgenic mice (Scheff et al., 2013, Masliah et al., 1994, Alonso-Nanclares et 
al., 2013). Studies have shown more severe losses of glutamatergic terminals but not 
GABAergic terminals in AD hippocampus and animal models (Canas et al., 2014, 
Mitew et al., 2013). At the same time Cuello’s group suggest that GABAergic synapses 
degenerate equally to glutamatergic synapses in AD from animal model studies (Bell et 
al., 2006). Consistent with studies using neuropathological and structural studies, gene 
expression studies have revealed a number of genes that are altered in early AD that 
includes the genes involved in synaptic vesicle trafficking, postsynaptic density 
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scaffolding, neurotransmitter receptors, etc. (Berchtold et al., 2013, Chang et al., 2013).  
Synaptic losses in the cortex and limbic system have been shown to correlate best with 
memory impairments in AD and the synaptic losses precede neuronal losses as 
suggested by a greater extent of synaptic loss compared to neuronal loss during AD. 
Post mortem brain immunohistochemical studies have shown that neurons in AD have 
reduced synaptic staining (Terry et al., 1991, DeKosky and Scheff, 1990, Scheff et al., 
1990, DeKosky et al., 1996, Ingelsson et al., 2004). An increased level of amyloid β42 
is expected to be involved in synaptic losses during AD (Sisodia and Price, 1995, 
Selkoe, 1989, Selkoe, 1993).  However the mechanism by which amyloid β and other 
APP metabolites lead to synaptotoxicity is not yet known (Overk and Masliah, 2014). 
Monomeric amyloid β aggregates to form amyloid fibrils and smaller order oligomeric 
species (Glabe, 2008, Selkoe, 2008). The oligomers of amyloid β organize into dimers, 
trimers and higher order arrays (Mucke and Selkoe, 2012, Tsigelny et al., 2014). More 
recent studies have reported these oligomers to be the toxic species and a trigger for the 
synaptic pathogenesis in AD (Klein, 2002, Glabe, 2005). However, understanding the 
precise nature and mode of action of this oligomeric species is an active field of 
research. 
      Based on the positive feedback loop model (Fig.1.3), Westmark has suggested that 
increased processing of APP through the amyloidogenic pathway, at the expense of 
non-amyloidogenic pathway, promotes amyloid β accumulation and synaptic loss 
before plaque accumulation in AD (Westmark, 2013). Excessive amyloid β could be 
leading to synaptic failure in AD by altering the molecular composition of postsynaptic 
density (a site where scaffolding protein recruit and anchor receptors) and thus altering 
the downstream signaling (Westmark, 2013). Experiments by Dineley’s group have 
strengthened this hypothesis and had shown that the form of the oligomeric species as 
well as the treatment time determines the downstream signaling (Bell et al., 2004). 
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Acute treatment with oligomeric amyloid β42 activates ERK (extracellular regulated 
kinase) mitogen activated protein kinase (MAPKERK) and its downstream target, 
ribosomal S6 kinase, but not c-JNK (Jun N-terminal kinase) mitogen activated protein 
kinase (MAPKJNK). On the other hand, chronic treatment with oligomeric form or high 
molecular weight aggregates of amyloid β42  leads to MAPK
ERK  downregulation and 
MAPKJNK activation (Bell et al., 2004, Westmark, 2013). Hence, amyloid β induced 
alteration at PSD could be leading to synapse failure in AD.  
 
1.2.3. Molecular Mechanism of synaptic degeneration in AD 
 
Dysregulation of glutamate receptors has been shown to be one of the processes 
upstream of synaptic degeneration that could cause alterations in axonal transport of 
synaptic vesicles and mitochondria leading to dendritic and spine alterations (Mota et 
al., 2014, Hsieh et al., 2006). Therefore aberrations in synaptic function may precede 
the loss of pre-synaptic terminals and dendritic spines culminating into synaptic loss. 
Neuronal loss occurs in the late stages of AD.  Downstream of amyloid β accumulation 
at synaptic sites, many receptors and signaling cascades have been identified those are 
affected. mGluR5 (Renner et al., 2010), ephrin (ephR2) (Cisse et al., 2011) and prion 
protein (PrP) (Lauren et al., 2009) are some of the molecules that have been reported to 
be acting as amyloid β oligomer receptors. At the PSD, binding of extracellular 
amyloid β oligomers to lipid anchored PrP(C) activates intracellular Fyn kinase 
affecting synaptic activity (Chin et al., 2005, Um and Strittmatter, 2013). Strittmatter’s 
group has shown that this activation requires mGluR5, where mGluR5 interacts with an 
amyloid β oligomer-PrP(C) complex (Um et al., 2013). This amyloid β-PrP(C)-
mGluR5 complex activates a signaling pathway causing eEF2 phosphorylation and 
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ultimately dendritic spine loss (Um et al., 2013). Binding of amyloid β oligomers at the 
synapse leads to the dysregulation of activity and expression of NMDA and AMPA 
receptors, which in turn leads to defects in synaptic activity (Paula-Lima et al., 2013, 
Sivanesan et al., 2013). Lipton’s group has shown that amyloid β induces the glutamate 
release from astrocytes. This causes activation of extrasynaptic NMDA receptors 
(eNMDAR) on neurons and eNMDA is the glutamate receptor system involved in 
synaptotoxicity in AD (Talantova et al., 2013). eNMDAR activation causes synaptic 
transmission dysregulation, caspase-3 activation and tau phosphorylation, which leads 
to spine loss (Talantova et al., 2013).  
     Downstream of amyloid β, tau is also considered to be an important factor leading to 
synaptic loss. Reports of the relevance of tau interacting proteins like spastin and α1 
Takusan in amyloid-induced synaptic and spine loss further supports this point (Zempel 
et al., 2013, Nakanishi et al., 2013).  Apart from indirect interactions between amyloid 
β and Tau mediated by receptors/ signaling pathways (spastin, α1 Takusan, GSK3, 
CDK5, Fyn Kinase), the monomeric and oligomeric amyloid β directly interacts with 
Tau in AD affected neurons. These interactions increase in number as cognitive decline 
and synaptic loss increase with disease progression (Manczak and Reddy, 2013).  
     Studies in transgenic mouse lines carrying mutant forms of human APP have been 
important for understanding mechanisms related to synaptotoxicity in AD, although 
these mouse models do not show overt neuronal loss (Gandy et al., 2010, Malthankar-
Phatak et al., 2012, Wirths and Bayer, 2010). However, they do show substantial 
synaptic loss and neuritic dystrophy. Also, the manipulations that rescue synaptic loss 
also rescue memory impairment in these models again suggest that  β causes cognitive 
impairments in AD by inducing synaptic deficits (Roberson et al., 2011). Since, the AD 
mouse models do not have significant neuronal loss and develop synaptic loss as well 
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as memory impairment before the appearance of plaques, it can be suggested that the 
soluble amyloid β entities are the ones causing synaptic deficits. Also, the impairments 
in the earlier stages of AD are primarily due to synaptotoxicity that leads to neuronal 
degeneration.   
 
1.3. Relevant mouse models in the study  
 
Mouse model of disease are an excellent system to study specific disease mechanisms, 
in spite of the drawbacks of not being able to fully replicate the entire AD pathology. 
There are several mouse model of AD that has been generated in past decades. For our 
project we have used the following animal systems: the hTau mouse model of 
AD(Andorfer et al., 2003), the Tg2576 mouse model of AD (Hsiao et al., 1996) and the 
CYFIP2+/- mouse model (Kumar et al., 2013b) . 
 
1.3.1. Htau mouse model 
 
In humans, the alternative splicing of a single Tau gene leads to six isoforms (Goedert 
et al., 1989a, Goedert et al., 1989b, Kosik et al., 1989). These isoforms are categorized 
as 3R or 4R based on inclusion or exclusion of a nonessential region coded by exon 10 
(Hutton et al., 1998, Poorkaj et al., 2001). Mouse and human tau protein sequences 
differ by 14 amino acids at their N-terminal end. Possibly this species difference in tau 
alternative splicing could be the reason as to why the AD mouse models do not have 
NFTs. In 2003 Peter Davies’s group developed a mouse model that expresses the 6 
human tau isoforms and does not express the 3 mouse tau isoforms.  The htau 
41 
 
transgenic mice from Davies’s group express a human tau transgene under the control 
of a tau promoter and have a null mutation obtained by the insertion of eGFP cDNA 
into exon1 of the mouse tau gene (Andorfer et al., 2003). Htau transgenic mice were 
obtained by crossing 8c mice that carry the human tau gene (Duff et al., 2000) with tau 
knockout mice with a disrupted mouse tau gene (Tucker et al., 2001), leading to an F1 
generation that was backcrossed to tau knockout mice. This produced htau transgenic 
mice on a C57BL/6 background that are homozygous for mouse tau disruptions but 
homozygous for a human tau transgene. The mice express all six isoforms of human tau 
but none of the mouse tau isoforms.   
     These mouse models have been shown to undergo age-related accumulation of AD 
relevant phosphorylated tau in the cell bodies and neuronal dendrites, also showing an 
accumulation of aggregated paired helical filaments. Cell body accumulation 
(redistribution from axons) of phosphorylated tau was detected by 3 months of age and 
the levels increase with age (Andorfer et al., 2003). By 9 months of age the levels of 
phosphorylated tau in htau mice model resemble early stage NFT pathology in human 
brain. The majority of tau pathology in htau mice is located in hippocampus and 
neocortex and is minimal in brain stem and spinal cord (Andorfer et al., 2003). 
Polydoro et al. reported age-dependent synaptic and cognitive impairments in these 
mice model. Basal synaptic transmission as well as LTP induction is impaired in the 
hippocampal CA1 region in 12 month-old mice but not 4 month-old mice (Polydoro et 
al., 2009). Further, spatial memory formation (water maze test) and object recognition 
memory formation (disruption of visual recognition memory of novel object) are 
impaired in 12 month-old htau mice. At this ageing point the mutants have a moderate 




1.3.2. Tg2576 mouse model 
 
Familial AD is an inherited form of AD and its onset is earlier in comparison to 
sporadic AD. In 1996 Karen Hsiao’s group created the Tg2576 mouse line to model 
familial AD using an APP transgene from a large Swedish family with early onset AD 
(Hsiao et al., 1996). Tg2576 mice express human APP695 (K670N, M671; APP770 
numbering), under control of hamster prion protein (PrP). This model was developed 
on a background of C57BL/6 and SJL mouse strains. The mice express the mutant 
human APP at 5.5 times the level of endogenous murine APP (Hsiao et al., 1996). The 
hAPP transgene had a double mutation (amino acid substitution) in APP, with Lys 670 
to Asn and Met671 to Leu. 
      These mutations lead to amyloid β overproduction. The mice display several 
characteristic neuropathologies of AD – plaques, activated microglia, inflammation, 
synaptic deficits, increased amyloid β  soluble as well as insoluble) (Hsiao et al., 1996, 
Chapman et al., 1999, Frautschy et al., 1998, Benzing et al., 1999, Smith et al., 1998). 
The soluble oligomeric forms of amyloid β are considered to be the primary toxic 
species as discussed above. This soluble form is present as early as 4 months of age in 
these mice (Fodero et al., 2002). By 10-11 months, amyloid plaques start to form 
(Hsiao et al., 1996). However, there are many neuropathological features of AD that are 
not faithfully replicated in this model. These include negligible change in the 
cholinergic system (Gau et al., 2002), neurofibrillary tangles are missing (Irizarry et al., 
1997) and neuronal loss or brain atrophy are not detectable (Irizarry et al., 1997). Also, 
the physico-chemical organization of amyloid peptides in Tg2576 mice has been 
reported to be different than that found in AD in humans (Kalback et al., 2002).  
Furthermore, it has been suggested that the overexpression of the C-terminal APP 
fragment may cause unwanted phenotypes in this mouse model (Saito et al., 2014). 
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Taken together, the Tg2576 model does not exactly replicate AD but it models amyloid  
β production and plaque deposition – an important pathology in both sporadic and 
familial forms of AD. The neuropathology in the Tg2576 models is reported to be 
present at 10-12 months of age (Hsiao et al., 1996, Kawarabayashi et al., 2001, Pratico 
et al., 2001) although there, is already a loss of dendritic spines at 3 months of age 
(D'Amelio et al., 2011). 
     The behavioural and memory impairments reported in the Tg2576 animals emerge 
at time points before plaque deposition. Hsiao et al. report an impairment in spatial 
memory (from Morris water maze tests) in these models at 9-10 months of age (Hsiao 
et al., 1996), whereas Westerman et al. report it at 6 months (Westerman et al., 2002).  
In Y-maze tests, Hsiao et al. report an impairment at 9-10 months of  age (Hsiao et al., 
1996) while Ognibene reports it at 7-12 months age (Ognibene et al., 2005). In the 
novel arm recognition test reported by Park et al, the young mice (3-4  months) do not 
show any difference, whereas the aged Tg2576 mice (12-15  months) show 
impairments (Park et al., 2008). 
 
1.4. Target molecules of the study 
 
In this project, we have studied the role of two novel neuronal proteins that are 
dysregulated in AD and they may have a role in synaptic degeneration during AD – 
CYFIP1/2 (Chapter 3) and CSPα (Chapter 4). Previous studies in the laboratory have 






p25 is a 209 amino acid long proline rich cleavage product of the cyclin-dependent 
kinase 5 (Cdk5) activator p35. p35 protein‘s cleavage into the C-terminus 25kDa p25 
fragment and N-terminus 10kDa p10 fragment is mediated by calpain, a calcium-
dependent protein protease (Patrick et al., 1999, Tang et al., 1997). p25 is a more stable 
Cdk5 activator protein with a longer half life in comparison to ubiquitin degradation 
prone p35 (Patrick et al., 1999). Also whereas p35 is membrane bound, p25 is localized 
in the cytosol and nucleus, leading to the suggestion of p25 acting as a signal between 
the synapse and the nucleus (Patrick et al., 1999, O'Hare et al., 2005). Not much is 
known about the function of p25 at the synapse. Tsai’s group has reported that p25 is 
upregulated in AD (Patrick et al., 1999). However, reports from several groups, 
including ours, have shown that p25 might be downregulated in the earlier stages of 
AD and continue to be so until the severe stages (Engmann et al., 2011, Tandon et al., 
2003, Yoo and Lubec, 2001). Studies with a p25 transgenic mouse model have shown 
that p25 overexpression is neurotoxic and leads to memory impairments (Fischer et al., 
2005). However, our group has shown in AD postmortem tissue that p25 levels are 
downregulated in milder stages of AD, so p25 overexpression-based models are not 
relevant for AD (Engmann et al., 2011).  p25 has been reported to be involved in LTP, 
synaptic functions and memory formation (Fischer et al., 2005, Engmann et al., 2011, 
Ris et al., 2005, Angelo et al., 2003), however the pathway by which it influences these 
processes is under active investigation. 
      p25 has been reported to be essential for memory formation and synaptogenesis. 
Both the Giese group and Tsai group have shown the importance of p25 in memory 
formation. Overexpression of p25 leads to improved spatial memory in mouse models 
(Angelo et al., 2003, Fischer et al., 2005) and p25 transgenic mice have enhanced late 
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phase hippocampal CA1 LTP as well as increased synapse density (Angelo et al., 2003, 
Ris et al., 2005, Engmann et al., 2011). Hence, p25 has been shown to be involved in 
regulation of molecules essential for synaptogenesis or synaptic functioning. A 
proteomic study from syaptosomes of p25 transgenic mice yielded a set of synaptic 
proteins (about 20) that are regulated by p25 and includes post synaptically located 
Cytoplasmic FMR interacting proteins2 (CYFIP2) and pre-synaptically located 
Cysteine string protein (CSPα) (Engmann et al., 2011). These molecules might be 
involved in synaptogenesis and LTP during memory formation. At the same time it 
could be speculated that these molecules may be downregulated along with a decrease 
in p25 levels in the initial stages of AD (Tandon et al., 2003, Engmann et al., 2011). 
This has been demonstrated in Optic atrophy 1 (OPA1) – a mitochondrial protein 
involved in mjtochondrial fusion as well as spine formation.(Wang et al., 2009). OPA1 
was also one of the candidate p25 regulated proteins obtained in the aforementioned 
proteomic study from the Giese group that was downregulated in the hippocampus in 
early stages of AD (Engmann et al., 2011). Hence p25 downregulation possibly leads to 
dysregulation of synaptic proteins in the initial stages of AD affecting the synaptic 
structure and function (Giese, 2014).  
 
1.4.2. CYFIP2/ CYFIP1 
 
Cytoplasmic FMR Interacting Protein -1 (CYFIP1) and Cytoplasmic FMR Interacting Protein -2 
(CYFIP2) are FMRP co-activators (Schenck et al., 2001). They are members of a highly 
conserved protein family in humans (Schenck et al., 2001). CYFIP1/2 colocalize with FMRP and 
are found in the cytoplasm as well as synaptosomal extracts (Schenck et al., 2001).  Even 
though the amino acid sequence is 87.7% identical between CYFIP1 and CYFIP2, the binding 
affinities of these proteins differ; CYFIP1 binds only with FMRP whereas CYFIP2 binds FMRP 
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and the FMRP related proteins - FXR1 and FXR2 (Schenck et al., 2001). CYFIP1 acts as an EIF4E 
binding protein (4E-BP) inhibiting the translation of FMRP bound mRNA (Napoli et al., 2008). 
CYFIP family proteins are also part of the actin cytoskeletal modulating WAVE complex (Cory 
and Ridley, 2002, Derivery et al., 2009). The small Rho GTPase, Rac1, binding to CYFIP1/2 
removes CYFIP1/2 from the WAVE complex so that WAVE can activate actin polymerization 
via Arp2/3 (De Rubeis et al., 2013). CYFIP2 has been shown to be a p53-inducible protein that 
causes apoptotic cell death in non-neuronal cells (Jackson et al., 2007). CYFIP1 on the other 
hand is not p53 inducible (Jackson et al., 2007). In Drosophila there is just one orthologue of 
CYFIP family molecules that is exclusively expressed in the nervous system (Schenck et al., 
2003), suggesting that during the course of evolution CYFIP1 and 2 might have acquired 
different functions in humans. The CYFIP1 gene is located on chromosome 15 (Nowicki et al., 
2007) with CYFIP2 located on chromosome 5 (NCBI Gene ID: 26999). CYFIP1 and  CYFIP2  





CSPα (Cysteine String Protein α) is a 34 kDa synaptically located J-domain containing 
protein (Zhao et al., 2008) (Fig.1.4). The CSPα structure contains an N-terminal J-
domain and a string of 13-15 cysteine residues in the middle region (Braun and 
Scheller, 1995). CSPβ and CSPγ are two other protein variants that are homologous to 
the CSPα sequence in the mammalian genome (Evans et al., 2003). However, these 
proteins are not expressed in brain (Fernandez-Chacon et al., 2004). 
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       CSPα has been shown to be involved in the following functions in neurons: (1) 
Exocytosis - it acts as a co-chaperone of a trimeric complex by interacting with two 
other proteins - Heat Shock Protein 70 (Hsc 70) and small glutamine–rich TPR-
containing protein (SGT). Thomas Sudhof’s group has shown that this trimeric 
complex is involved in exocytosis by interacting and co-chaperoning the SNARE 
proteins leading to synaptic vesicle fusion in presynaptic terminals (Sharma et al., 
2011). SNARE proteins are a set of synaptically localized membrane fusion proteins 
involved in vesicle recycling mechanism in presynaptic terminals.  In CSPα knockout 
mice, the levels of SNARE proteins (like α Synuclein and SNAP-25) are reduced 
(Chandra et al., 2005).  (2) Endocytosis – CSPα interacts with dynamin 1 and facilitates 
the polymerization of dynamin, which is important for endocytotic vesicle fission 
(Zhang et al., 2012).  (3) Modulation of calcium dependent K+ channels (BK channels ) 
where CSPα is important for modulation of pre-synaptic BK expression (Kyle et al., 
2013). CSPα knockout mouse show upregulation of BK channels and hence aberrant 
synaptic activity. (4) Modulation of presynaptic calcium levels by regulating calcium 
channels (Ranjan et al., 1998). CSPα have not been reported to have any non-neuronal 
expression in the brain. 
 
 
1.5. Overall objective of the study  
 
As described before, synaptic losses are important feature of AD pathology. However, 
the molecular mechanisms leading to the synaptic losses or synaptic impairments are 
not precisely known. Based on the previous studies in the Giese lab using AD post 
mortem brain as well as a p25 transgenic mouse model (Engmann et al., 2011, Angelo 
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et al., 2003, Giese, 2014), we obtained a set of novel, putative p25 regulated candidate 
molecules that could be relevant to synaptic and neuronal losses in AD. After screening 
these molecules, we narrowed down our targets for further study in AD to three 
synaptic molecules - CYFIP1, CYFIP2 and CSPα.  
So, the broad aim of this study was –  
To investigate the role of three putative p25 regulated molecules in AD – CYFIP1, 
CYFIP2 and CSPα. 
           The methodology and experimental design used to complete this PhD study have 
been described in Chapter 2. Since, CYFIP1 and CYFIP2 belong to the same family of 
proteins, their study has been described in a single chapter (Chapter 3), with the study 
of CSPα described in a separate chapter (Chapter 4). The specific aims and results of 
each of these two parts have been stated in the respective chapters. The broader 
discussion on the overall implications and outlook from the results of this PhD study 













Chapter 2: Materials and methods 
2.1. Samples  
 
2.1.1. Postmortem Human Brain Samples  
 
Human brain samples were obtained from the London Brain Bank for 
Neurodegenerative Diseases, Institute of Psychiatry, King’s College London. They 
were received in two set, which were treated separately. The first set contained 
hippocampal tissue from control subjects, subjects with mild Alzheimer’s disease (AD; 
Braak stages I-II) and subjects with severe AD (Braak stages V- VI) [n = 7 for each 
group],  as well as superior temporal gyrus (STG) samples from control and severe AD 
[n = 7 and n = 9, respectively]. The second set comprised hippocampus, STG and 
cerebellum samples from control, mild and severe AD patients (n = 5 for each group). 
To increase the sample size of cerebellum, a new cohort (n = 5 per group) was added 
later to the analysis. Additionally, cerebellum samples (n=5) were obtained from the 
post mortem brains of patients with Frontotemporal lobar degeneration (FTLD) to 
analyze the levels of CSPα in FTLD, where the cerebellar pathology has been reported.  
Moreover, to analyze the level of CSPα in ageing , cerebellar tissues were obtained 
from subjects who died less than 30 year old - young (n=6 ) and  subjects who died 
more than 90 year old – aged  (n=7). The causes of death were not related to 
neurodegenerative disease in these subjects (see Table 2.1 for details). All human 
tissue samples were handled according to the regulations of Human Tissue Authority 




2.1.2. Tg2576 Mouse Brain Samples 
 
APPswe (Tg2576) mice, expressing mutant human APP (K670N/M671L) under the 
control of the hamster prion promoter (Hsiao et al., 1996) were obtained from Taconic 
farms (Germantown, NY, USA). Mice were maintained by breeding Tg2576 males in 
C57BL/6 x SJL F1 genetic background with C57BL/6 x SJL F1 wild-type females, as 
recommended by the supplier.  
     Mice were housed on 12 h light: 12 h dark cycles with food and water available ad 
libitum. Mice were killed by cervical dislocation; the brains removed, tissue dissected 
and immediately snap frozen on dry ice. All animal procedures were conducted in 
accordance with the UK Animal Scientific Procedures Act 1986. Mice were genotyped 
by PCR using primer set 5′-CGACTCGACCAGGTTCTGGGT-3′, 5′-
ATAACCCCTCCCCCAGCCTAGA-3′.The amplification conditions were as 
following : PCR Reaction mixture  - 1X buffer,  H2O  - 10.7μl, 2mM Mg2Cl2, 0. 2 mM 
dNTP, 0.75μM APP Forward primer, 0.75μM APP Reverse primer, 0.025μM Taq 
polymerase (Invitrogen) , 2μl/reaction DNA  (Total volume  made to 20 μl by addition 
of H2O) . PCR Program -  (1)Initialization - 94⁰C  for 3 minutes  (2) 35 cycles – 
Denaturation - 94⁰C  for 30 seconds ,  Annealing - 60⁰C  for 60 seconds, Extension - 
72⁰C  for 60 seconds  (3) Final hold – 4⁰ C. Cortico-Hippocampal  tissue from 4 month 
(n=3)  and  12 month (n=4)  old Tg2576 mutants  as well as wild type (WT) littermate 
mice (4 month ,n=4; 12 month ,n=4)  were used for analysis by immunoblotting. Sexes 





2.1.3. Htau Mouse Brain Samples 
 
Htau transgenic mice expressing a human tau transgene under control of tau promoter 
and having a null mutation obtained by the insertion of eGFP cDNA in exon1 of the 
mouse tau gene were studied to analyse tau-related neurodegeneration (Andorfer et al., 
2003) . The htau transgenic mice were obtained by crossing  8c mice with human tau 
gene (Duff et al., 2000) and tau knockout mice with disrupted mouse tau gene (Tucker 
et al., 2001) , leading to an F1 generation which was backcrossed to tau knockout mice, 
that produces htau  transgenic mice on a C57BL/6 background which  were obtained 
from Jackson Laboratories (Bar Harbour, Maine, USA; B6.Cg-Mapttm1 (EGFP) Klt 
Tg(MAPT)8cPdav/J. Stock number: 005 491). These mice express all six isoforms of 
human tau, but none of the mouse tau isoforms.  Mice were genotyped by PCR as 
described in (Andorfer et al., 2003) to confirm the presence of the human MAPT ( Tau) 
transgene and the mouse Mapt null background using primers for the human 
MAPT gene (forward 5′-ACTTTGAACCAGGATGGCTGAGCCC-3′, reverse 5′-
CTGTGCATGGCTGTCCCTACCTT-3′), and the mouse Mapt gene (forward 5′-
CTCAGCATCCCACCTGTAAC-3′, reverse 5′-CCAGTTGTGTATGTCCACCC-3′), 
as described in (Andorfer et al., 2003). The primers for the disrupted Mapt gene were: 
Forward:5′AAGTTCATCTGCACCACCG3′, Reverse:5’TCCTTGAAGAAGATGGTG 
CG3’. The amplification conditions were as following : PCR Reaction mixture  - 1X 
buffer,  H2O  - 10.7μl, 2mM Mg2Cl2, 0. 2 mM dNTP, 0.75μM APP Forward 
primer, 0.75μM APP Reverse primer, 0.025μM Taq polymerase (Invitrogen) 
, 2μl/reaction DNA  (Total volume  made to 20 μl by addition of H2O) . PCR Program -
  (1)Initialization - 94⁰C  for 3 minutes  (2) 35 cycles – Denaturation - 94⁰C  for 30 
seconds ,  Annealing - 60⁰C  for 60 seconds, Extension - 72⁰C  for 60 seconds  (3) 
Final hold – 4⁰ C.  
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      Hippocampal, frontal cortex and cerebellar tissue were isolated from 3-4 months-
old and hippocampal-cortical tissue from 24 month-old htau transgenic mice as well as 
wild-type littermates. Sample size for each category is described in the relevant 
chapters.  
       Mice were housed on 12 h light: 12 h dark cycles with food and water available ad 
libitum. Mice were killed by cervical dislocation; the brains removed, tissue dissected 
and immediately snap frozen on dry ice. All animal procedures were conducted in 
accordance with the UK Animals Scientific Procedures Act 1986 
 
2.1.4. CYFIP2+/-Mouse Brain 
 
CYFIP2 null mutants were generated by European Conditional Mouse Mutagenesis 
Program (EUCOMM) having a neo gene insertion in an intron of the CYFIP2 gene. 
This mutant uses a knockout first design.  The knockout allele contains an IRES:lacZ 
trapping cassette. A floxed promoter driven neo cassette inserted into the intron of 
CyFIP2 gene disrupts the gene function (Fig. 2.1.)(Kumar et al., 2013b, Skarnes et 
al., 2011). CYFIP2 heterozygote and wild type mouse with C57BL/6 N background 
were obtained from Wellcome Trust Sanger Institute (Wellcome Trust Genome 
Campus, Hinxton Cambridge, UK). The mice were subsequently bred by crossing 
CyFIP2 +/- males with wild type female in the animal breeding facility at the James 
Black Center, King’s College London. Mice were genotyped by PCR, using genomic 
DNA isolated from ear or tail samples. The mutants were detected by mutant allele 
specific primer (Forward CYFIP2 primer -5’TTCCTTCCTTCCCTTGTCCC3’, 
Reverse CASR1 primer - 5’TGCCAGGAGAGACAGTGGTG3’) and wild type were 










Figure 2.1. CYFIP mutant allele 








 synthesized by Sigma Aldrich). 
cassette. The lacZ-neomycin 
 CYFIP2 allele. 
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The amplification conditions were as following: The wild type band was 461 base pairs 
and mutant band is 248 base pairs. PCR Reaction mixture  - 1X buffer, (0.5μl) 50mM 
Mg2Cl2  (0.5μl) 10mM dNTP , (1.5μ1) 10μM CYFIP2 Forward primer, (1μl) 10 
μMCYFIP2 Reverse primer, (0.5μl) 10 μM CASR1, 0.125μl Taq polymerase 
(Invitrogen)   1μl/reaction DNA  (Total volume was made 25 μl by addition of 17.3μl 
H2O) . PCR Program -  (1)Initialization - 93⁰C  for 2 minutes  (2) 35 cycles – 
Denaturation - 93⁰C  for 30 seconds ,  Annealing - 58⁰C  for 30 seconds, Extension - 
72⁰C  for 30 seconds  (3) Final extension -  72⁰C  for 10 minutes  (4) Final hold – 4⁰ C. 
     Hippocampi from 3-4 months old CYFIP2 heterozygote mice and wild-type 
littermates were isolated. Samples sizes are – n= 9 for CYFIP2+/- mice and n= 7 for 
wild type mice. Mice were housed on 12 h light: 12 h dark cycles with food and water 
available ad libitum. Mice were killed by cervical dislocation; the brains removed, 
tissue dissected and immediately snap frozen on dry ice. All animal procedures were 
conducted in accordance with the UK Animals Scientific Procedures Act 1986. 
 
2.2. Protein preparation  
 
2.2.1. Lysate preparation from Human Brain Sample  
 
The frozen samples were lysed at 4°C in a RIPA lysis buffer system (Santa Cruz 
Biotechnology, Inc., USA). The RIPA buffer contained 0.1 % sodium dodecyl sulfate 
(SDS), 1% Nonidet P-40, 0.5% sodium deoxycholate and 0.004% sodium azide in Tris 
buffered saline (TBS; composed of 6.0 g/l Tris and 8.7 g/l NaCl, adjusted to pH 7.5 
with 37% HCl). Protease inhibitors cocktail, sodium orthovandate, and α-
toluenesulphonyl fluoride were added to the buffer, diluted to 1:100. The SDS 
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concentration was increased by adding 0.25% SDS in the final volume of buffer. About 
100 mg of brain tissue was lysed in 300 μl buffer volume. Samples were homogenized 
using a dounce homogenizer (12 strokes, 700 rpm) and centrifuged at 3,000 rpm for 10 
minutes. Supernatants were then isolated for immunoblotting.   
 
2.2.2. Protein preparation from mouse brain tissues 
 
Frozen tissue was homogenised at 100 mg/ml in 2 x sample buffer (0.5 M Tris-HCl, pH 
6.8, 4.4 % (w/v) sodium dodecyl sulfate (SDS), 20 % (v/v) glycerol, 2 % (v/v) 2-
mercaptoethanol, 0.01 % (w/v) bromophenol blue, and Complete mini-protease 
inhibitor cocktail (Roche Products Ltd., UK), using a mechanical homogenizer. 
Following brief sonication, homogenates were centrifuged at 25,000 g for 20 minutes at 
4ºC, and the supernatant was collected. For mouse samples, a BCA based protein 
quantification procedure (Thermo Fisher) was used to determine the protein amount. 
     Crude synaptosomes were isolated from hippocampus as following – Frozen tissue 
was homogenized at 100 mg / ml in lysis buffer (0.32 M sucrose, 10mM pH7.4 Tris-
HCL, 2mM EDTA, 2mM EGTA, 0.2 mM phenyl methyl sulfonyl fluoride). Following 
centrifugation at 1000g for 10 minutes, 4⁰C to remove nuclei and cell debris, the 
resulting supernatant was centrifuged at 10,000 g for 20 minutes to obtain crude 
synaptosomal pellet. To resuspend the synaptosomal pellets (P2 fraction), for each 10 
mg of starting tissue,  10 μl of 2X sample buffer (No- EC886, Protein loading buffer, 





2.3. Western Blot Analysis 
 
Comparable protein amounts (for mouse samples according to protein determination; 
for human samples an equal volume) were separated on a criterion TGX precast gels 
(BioRad-continous gradient, 4-15 %) and the protein was transferred onto a methanol 
activated Polyvinylidene (PVDF) membrane (BioRad), using standard protocols. One 
hour blocking was carried out in 5% w/v milk powder (Merck ) in 1X TBST (Tris-
Buffer saline - 60g/l Tris, 87 g/l NaCl, 0.05% Tween-20, pH 7.5). Subsequently, 
membranes were incubated in primary antibody solution prepared in blocking buffer 
overnight at 4ºC. After three ten-minute washes in 1X TBST at room temperature,  the 
membrane was incubated with horse-radish peroxidase conjugated secondary 
antibodies in blocking buffer for two hours at room temperature. After three ten-minute 
washes with 1X TBST , the membrane was incubated for 3 minutes in enhanced 
chemiluminescence  (ECL) reagent (Thermo Scientific) and then exposed to an X-ray 
film (Amersham) in the linear range. To probe the membranes with other primary 
antibodies, they were washed in western blot stripping buffer (Santa Cruz 
Biotechnology) for one hour followed by three washes with TBST of 10 minutes 
duration each and incubation as described above.  
Antibody details are given in Table 2.2. CSPα antibody specificity was checked by 
performing western blot analysis of forebrain and cerebellar tissues from CSPα 
knockout mouse. The knockout mouse tissue was a gift from Dr.Fernandez-Chacon 
(IBiS, Seville, Spain). The CSPα band was missing in the knockout forebrain and 
cerebellar tissue , and was prominently and very specifically visible in equal amount of 
protein fraction from wildtype mouse forebrain and cerebellum (Fig.4.3). The CSPα 




Our CYFIP2 and CYFIP1 antibodies were highly specific. Fig.3.4. is a full blotscan 
from the same membrane with post-mortem hippocampal tissue lysates, showing the 
CYFIP2, CYFIP1 and NSE bands ( internal control ). This blot shows the highly 
specific binding of the CYFIP antibodies used by us. Further specificity of CYFIP2 
antibody was demonstrated by the western analysis of the forebrain tissues from 
CYFIP2 heterozygous mice that showed 50 percent downregulation when compared to 
wild type mice as expected assuming the antibodies were CYFIP2 specific Fig.3.11. To 
study if the CYFIP2 is also expressed in the glial cells, lysates from mixed glial cell 
culture ( as explained below ) were probed with CYFIP2 antibodies. There was no 
expression of CYFIP2 in glial cells ( Fig.3.16 ). 
Neuronal Specific Enolase are neuron specific enzymes and are used as neuronal 
markers (McAleese et al., 1988). NSE was used as loading control in our studies and as 
a neuronal protein to normalize the amount of studied proteins.  Synaptophysin are 
presynaptic proteins that are widely used as synaptic markers (Sudhof et al., 1987). In 
our studies, we have used synaptophysin as loading control and normalizing marker 
protein for synapse specific analysis. 
Signals were analyzed with ImageJ software (NIH). For standardization of protein in 
each lane, the proteins of interest were normalized against the neuronal house-keeping 
marker protein neuron-specific enolase (NSE) and the synaptic vesicle protein 
synaptophysin.   
Glial cultures: Glial cells were isolated from post-natal day 1-4 (P1-P4) Cln3-/- or WT 
mouse cerebral cortices, as previously described (Williams and Price, 1995) and 
cultured on poly-D-lysine (PDL, 25μg/ml, Sigma) coated T75 (Corning, Costar) flasks 
at a density of 2-3 cortices per flask in Dulbecco’s Modified Eagles Medium (DMEM, 
Gibco), supplemented with 10% foetal bovine serum (FBS, Biosera) and 
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penicillin/streptomycin (50 U/ml / 50μg/ml, P/S, Sigma). Once these cultures reached 
confluence (12-14 days) they were composed of a base layer of non-dividing astrocytes 





Human brain sections from sample described in the section under post-mortem human 
brain samples were used for immunohistochemistry.    Sections of human brain of 7 µm 
thickness were cut from paraffin-embedded tissue blocks. Sections were deparaffinised 
in xylene and rehydrated in ethanol. Endogenous peroxidase activity was blocked by 
incubation of sections with 2.5% H2O2 in methanol. To enhance antigen retrieval 
sections were exposed to citrate buffer (2.94 g/L, pH 6.0) for 16 minutes microwave 
treatment (6 minutes high, two 5 minutes simmer). After blocking in normal swine 
serum (DAKO Ltd), primary antibodies against CSPα (1:500, AB1576 Merck 
Millipore), and synaptophysin (1:100, SY38 DAKO Ltd) were applied overnight at 
4°C. Following rinsing and two five minutes washes in TBS, sections were incubated 
with appropriate biotinylated secondary antibodies (1:100,Swine anti-rabbit 
immunoglobulin/biotinylated , E0353 DAKO Ltd), followed by incubation with 
avidin:biotin enzyme complex (Vectastatin Elite ABC kit, Vector Laboratories, 
Peterborough, UK). Following washing, sections were incubated for 10 –15 min with 
0.5 mg/ml 3,3′-diaminobenzidine chromogen (Sigma-Aldrich Company Ltd, Dorset 
UK) in Tris-buffered saline (pH 7.6) containing 0.05% H2O2. Sections were 
counterstained with Harris’s haematoxylin.  
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See Table 2.2 for list of antibodies and concentrations used.  
 
2.5. Cloning of CYFIP2 shRNA plasmid 
 
A 65 basepair CYFIP2 shRNA as described by Anitei et al (Anitei et al., 2010) (Sense 
strand:5’CCTTCCTCCATCATGTACC3’;Antisensestrand:5’GGTACATGATGGAGG
AAGG3’) was designed with Bam H1 sites at the terminal positions and Spe1 site 
inside the sequence to confirm the presence of insert (Forwardsequence:5’GATCC-
CCTTCCTCCATCATGTACCTTCAAGAGAGGTACATGATGGAGGAAGGTTTTT
TACTAGTG3’;Reversesequence:5’GATCCACTAGTAAAAAACCTTCCTCCATCA
TGTACCTCTCTTGAAGGTACATGATGGAGGAAGG-G3’). The CYFIP2 shRNA 
oligonucleotide strands were designed by Sigma. The two strands were annealed 
together as following –Forward oligonucleotide ( 2μl,100μM )and Reverese 
oligonucleotide(2μl,100μM)were added in 5μl,10X Buffer 2 (New England Biolab )and 
the volume was made to 50μl by addition of deionized water .This mixture was heated 
at 95⁰C for 3 minutes,80⁰C for 1 minute,70⁰C for 1 minute,60⁰C for 1 minute, 50⁰C for 
1 minute and finally placed in ice.The oligonucleotide starnd were annealed to form an 
shRNA complex. The annealed shRNA was ligated in a pZacU6 plasmid and was 
inserted downstream to a U6 promoter using Bam H1 sites (Fig.2.2). The plasmid also 
had a GFP marker protein downstream to a Synapsin promoter. The resulting plasmid 
correctness was verified by sequencing facility at Santa Cruz Biotechnology using the 
followingprimersequences,Forwardprimer:5’ACGATACAAGGCTGTTAGAGAGA3’,
Reverseprimer:5’GGTGCTGAAGCTGGCAGT3’(IntegratedDNATechnologies). This 
plasmid(pZacU6CYFIP2) was packaged into an Adeno Associated Viral delivery 
sytem (AAV2/9) by Penn Vector Core Facility , Univeristy of Pennsylvania. 
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2.6. CYFIP2+/- Mouse Genotyping 
 
For genotyping the mouse, the genomic DNA was isolated from tail tissues (or ear 
clips).  About 1 cm of tail tissue ( approx 30 mg) or ear clips  from each mice were 
placed in 500 µl ( 100μl for ear clips)  of lysis buffer  ( 1M Tris-HCL,pH8.5 ; 0.5M 
EDTA ;1% SDS; 5M NaCl ; The volume was made up by adding deionized distilled 
water (MilliQ) with an addition of  Proteinase K (18.6 mg/ml) to a final concentration 
of 0.1μg/μl. This mix was incubated at 55˚C overnight. The digested tail mix was 
vortexed for 1 minute and then centrifuged at 13,000 rpm for 10 minutes. The 
supernatant was decanted in a new tube , followed by addition of 500 μl of isopropanol 
at room temperature.  The precipitate was obtained after inverting the tube several 
times. The tube was centrifuged at 13,000 rpm for 2 minutes   and the supernatant is 
discarded. The pellet were washed with 500 μl 70 % ethanol ( 100 μl  for the ear clips)  
by spinning for 1 min  and the ethanol  was  decanted followed by 5 minutes of air 
drying. The DNA was resuspended in about 100 μl deionized water. 
     The isolated genomic DNA was used for CYFIP2 mouse genotyping using the 
mutant and wild type specific primer as described before. The primers were synthesized 
by Integrated DNA Technologies. The PCR mix per sample consisted of 2.5μl 10X 
buffer, 18.375 µl water, 0.5 µl MgCl2 (50 mM), 0.5 µl dNTP (10mM) and 0.125μl Taq 
DNA polymerase (Invitrogen). The PCR protocol consisted of a 2 minute heating at 
93⁰C, followed by 35 cycle of denaturation (30 second, 93⁰C), annealing (30 second, 
56⁰C) and extension (30 second, 72⁰C). At the end of PCR cycle, the sample were 




2.7. Fear Conditioning 
 
 For the fear conditioning trial mouse were handled for three days prior to training by 
the person performing the experiment. The mice were habituated to the experimentalist 
by placing them on hand for 2 minutes per animal per day. The experimentalist was 
blinded to the genotype of the animals. Each mouse was placed in a soundproof 
conditioning chamber (Med Associates Inc, USA). The fear conditioning protocol used 
was carried out simultaneously to observe the contextual memory and cued memory. 3-
4 months aged CYFIP2 mutant and wild type were trained and the same animals were 
trained for tone conditioning and context conditioning. The animal was  placed in the 
fear conditioning chamber for 3 minutes duration in total; after 2 minutes a tone (75dB, 
10KHz)  was presented for 30 s  and the last 2 seconds of tone co-incided with  a mild 
foot shock ( 0.75 mA).  After the tone/ foot shock pairing the animal was left in the 
conditioning chamber for 30 s and then returned back to its home cage.  
 
2.7.1. Testing for Contextual Conditioning  
 
The testing for contextual fear memory was carried out in the training chamber for 5 
minutes duration without any tone presentation or foot shock being provided. The 
readout for the memory was a state of freezing during a pre assigned two second slot in 
every 5 second interval of entire 5 minutes recording. The scoring was done by an 
unbiased genotype blinded experimenter. The testing for memory of contextual 
conditioning at 1 to 5 days interval was carried out with one set of mouse (Wild type n= 
13; CYFIP2+/- n= 15) from the same generation of litters. The testing for memory of 
contextual conditioning at 28 days interval was carried out with another set of mice 




2.7.2. Testing for Tone conditioning 
 
As mentioned previously the mice used for testing the contextual memory were used 
for testing the tone memory as well. They were tested for the tone memory in the same 
fear conditioning chamber, but the contextual cues (Interiors of the box, colour of light 
and odour) inside the chamber were modified.  Each animal was placed in the chamber 
for 6 minutes. The first 3 minutes were meant for acclimatization to the chamber 
environment and for testing whether the animal had a fear response to the modified 
context. In the last 3 minutes the tone used for training (75 dB, 10 KHz) was 
introduced. The readout for the memory was a state of freezing observed during a pre 
assigned two second slot within every 5 second interval (of entire 6 minutes recording). 
The scoring was done by a genotype blinded experimenter. The testing for tone 
conditioning  at 1 hour and 1 day interval post training  was carried out with one set of 
animals from same generation of litters ( Wild type ,n= 18 : CYFIP 2+/- , n= 12 ). The 
testing for tone conditioning at 5 day interval post training was carried out with a 
different set of animals from same generation of litters ( Wild type , n= 13 ;CYFIP2+/- , 
n=15 )  
  
2.8. Morris Water maze test and Visible platform test 
 
The spatial reference memory will be analyzed using Morris watermaze paradigm 
(D'Hooge and De Deyn, 2001) . The watermaze trial was performed in a pool of 1.5 m 
diameter, with water temperature of 24˚C degrees. The platform diameter was 0.1 
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meter and the level of water was 0.1 cm above platform surface. The water was made 
opaque by addition of non toxic white paint (ELC ready mix paint, 44800 White 284).   
     Both  CYFIP2+/-  ( n= 12) and Wild type (n=18)  mouse aged between  3-4 months 
were handled for 2 minutes each for 8 days  before the training commenced.  The 
mouse cages were placed half an hour before the experiment in the watermaze training 
room. On the first day of the trial, each mouse was habituated to the platform 
conditions. 4 trials per day per animal from four different directions were performed. 
Each trial lasted a maximum of 90 seconds, with 60 seconds of interval in between 
each trial whereby the animal stayed on the platform. If the animal was unable to locate 
the platform by the end of 90 seconds, it was guided to the platform. On sixth day, a 
probe trial was carried out for 60 seconds by removing the platform and recording the 
time spent in each quadrant including the target quadrant.  
     The results from water maze revealed that the mice haven’t learned the task during 
the training (Fig.3.14a) until day 6 and further training was discontinued due to time 
limitations. The test will be repeated in future studies. 
      After a resting interval of two days, a visible platform test was carried with the 
same conditions as described in the hidden platform test to avoid any error in the water 
maze hidden platform result by the defects in sensory - motor responses in animal to 
due to genetic manipulation. The water pool was covered on all sides by curtains to 
avoid exposure to any spatial cues and the platform position was highlighted by placing 
a white sphere of about 4 cm diameter on platform as a distinguishable visible object.  
The animal was released in the pool from the farthest location from the visible 
platform. The recording was made in two trials separated   by 60 seconds interval 
where the animal stayed on the platform. The person performing the experiment was 
 blind to the genotype of the mouse. The recording was done by HVS Image tracking 
software (HVS Image 2013)
 
2.9.  Statistical analysis
 
For the post mortem human brain studies
Statistical analysis for the 
time point was performed using 
tissue samples procured from patients in two sets at two different time point was 
performed using a linear regression model based o
Where  is the categorical predictor coding for the group difference (e.g. Control 
versus Severe), and 
experiments (“1st cohort
      This regression mode
set of patients eliminating the  contribution made by the difference in experimental 
conditions (like the scanner used )  to the final result. This analysis was perform
using SPSS (version
result is displayed as an ANOVA score indicating the overall significance. 
contribution and the significance of the factor of interest e.g. the disease 
the overall significance is subsequently provided by a t
analysis strategy helps to identify th




samples where the data wasn’t pooled from two different 
an unpaired t-test analysis. The  pooling of data from 
n following equation 
 
 is the categorical predictor coding for the different 
” versus “2nd cohort”) 
l helps us to pool the CSP or CYFIP score from two different 
 20). SPSS provides the output as an ANOVA score. The final 
-test analysis.  Hence, this 
e significant change of a CSP/
control eliminating any effect induced by the different 
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CYFIP score in 
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experimental conditions when the different set of tissue samples was processed.  The 
level of significance for the analysis was 0.05 and the outliers were decided by using 
mean ± 4*SD as threshold.  
Since the data used in this project involved pooling the data from two different sets , 
and hence utilized the regression analysis model for statistical studies , it was not 
suitable to perform a co-relation  study between different aforesaid parameters and the 
protein levels observed in post-mortem tissues.  Hence, I adopted the strategy of 
comparing the significant difference between the age, PMD and Gender (nonparametric 
analysis) of patient samples grouped into different pathological state of disease– control 
, mild , severe AD. The analysis for pH couldn’t be performed as some of the samples I 
used in my study were from a previous published study in lab where the pH data was 
not recorded or analysed.  
Hippocampus AD samples – 
A) Effect of Gender – Pearson’s chi-square test was performed to discover the 
relationship between the categorical variable ( Gender and Pathological state) . The p = 
0.627 , shows there was no statistically significant association between the individuals 
gender and its pathological state.  
B) Effect of Age – One way ANOVA showed no changes in the age between control , 
mild and severe groups , F( 2,33) = 0.961 , p=0.393. 
C) Effect of Postmortem Delay – One way ANOVA showed an association between 
post-mortem delay and the pathological state of patients, F (2,33) = 4.812, p=0.015. 
Tukey’s posthoc test revealed that the post-mortem delay was not significantly different 
between the control and severe pathological state group (p=0.091). It was also not 
different between the mild and severe pathological state group (p=0.686) . However, 
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the  post-mortem delay between control and mild pathological state showed significant 
difference (p= 0.014 ). The post-mortem delay in control ( 21.4 ±2.3  hours) was 
significantly higher than mild state AD patient hippocampus ( 12.7±1.9 hours) . 
Gender and age do not show any statistically significant difference in various 
pathological states of AD in hippocampus. This result along with the fact that none of 
the molecule ( CYFIP1/2 and CSPα ) used in this study have any sex linked inheritance 
pattern , leads us to conclude that gender does not have any impact on the results. Also 
, the statistical output concludes that the age of the patients across the different 
pathological states was same and hence did not had any impact on the protein level 
analysis in post mortem tissues. The post mortem delay did not had any effect on the 
result between control and severe , as it was not significantly different between the two 
groups. However, the post-mortem delay between the control and mild group was 
significantly different, with an increased delay in control group. This difference could 
have impacted the protein expression profiles. It is unlikely that this delay may have 
impacted our results as there was no change observed in CYFIP1 , a trend of increase 
of CYFIP2 and a significantly increased CSP α in control hippocampus group as 
compared to mild stage AD hippocampus. This shows that the proteolytic degradation 
of hippocampal proteins under investigation was not significant to effect the read out 
from control tissues as compared to mild tissues within the given time frame of post-
mortem delay. 
 
STG AD Samples – 
A) Effect of Gender - Pearson’s chi-square test was performed to discover the 
relationship between the categorical variable (Gender and pathological state) . The p = 
70 
 
0.018 , showed a statistically significant association between the individuals gender and 
its pathological state.  
B) Effect of Age – Independent sample two tailed T test showed there was no 
significant difference in the age between the control and severe STG groups ( t= -0.959 
, p=0.347 ) 
C) Effect of Postmortem delay – Independent sample two tailed T test showed there 
was no significant difference in the post-mortem delay between the control and STG 
groups ( t= 1.046 , p=0.306 ) 
Gender showed significant association with the pathological state of STG. However, 
since none of the studied proteins have been reported to have sex linkages, the 
possibility of gender differences having an impact on results is negligible. 
Unfortunately, the exact co-relation study cannot be performed with our scores as they 
were pooled together from different experimental sets. Age and post-mortem delay was 
not significantly different in the control and severe AD STG. 
Cerebellum AD Samples – 
A) Effect of Gender - Pearson’s chi-square test was performed to discover the 
relationship between the categorical variable (Gender and pathological state) . The p = 
0.585 , showed no statistically significant association between the individuals gender 
and its pathological state. 
B) Effect of Age – One way ANOVA showed there was no significant difference in the 
age between the control , mild and severe AD cerebellum , F (2,27) = 0.756,p=0.479.  
C) Effect of Postmortem delay – One way ANOVA showed that there was no 
significant difference in the post-mortem delay between the control , mild and severe 
AD cerebellum. F(2,27)=2.066, p=0.146. 
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Gender, age or post-mortem delay do not effect the results obtained from cerebellum 
AD tissue. 
Cerebellum FTLD samples –  
A) Effect of Gender - Pearson’s chi-square test was performed to discover the 
relationship between the categorical variable (Gender and pathological state) . The p = 
1.0 , showed no statistically significant association between the individuals gender and 
its pathological state. 
B) Effect of Age –  Independent sample  two tailed T-test showed there was no 
significant difference in the age between the control and FTLD cerebellum , t = - 
0.361,p=0.728.  
 C) Effect of Postmortem delay – Independent sample two tailed T-test showed that 
there was no significant difference in the post-mortem delay between the control and 
FTLD cerebellum. t=1.309, p=0.227. 
Gender, age or post-mortem delay do not effect the results obtained from cerebellum 
FTLD tissue. 
 
Cerebellum ageing study samples –  
Since age was different in the two groups within this study (young and old cerebellum) 
, the effect of gender and post-mortem delay was ascertained. 
 A) Effect of Gender - Pearson’s chi-square test was performed to discover the 
relationship between the categorical variable (Gender and pathological state) . The p = 
0.048, shows a statistically significant association between the individuals gender and 
its pathological state. 
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B) Effect of post-mortem delay - Independent sample two tailed T-test showed that 
there was no significant difference in the post-mortem delay between the young control 
and old control cerebellum. t=-0.701, p=0.498. 
Since CSPα does not shows sex linked inheritance , it is possible that this slight 
significance is due to the small sample size and this significance will disappear with 
increase in the number of cerebellar samples. Post mortem delay is not significantly 
different in the young and old cerebellar tissues. 
 
For the studies with mice model ,  
For normality distribution test - Levene’s test and Histogram normality plots were used 
(refer to Box G.E.P. (1953) - "Non-Normality and Tests on 
Variances". Biometrika 40 (3/4): 318–335). Independent T-test, one way ANOVA and 
Two –way repeated measure ANOVA were performed based on the design of 
experiments. SPSS version 20 (IBM) was used to perform statistical analysis. For Non-
parametric analysis of independent group Mann Whitney U test and for related samples 
Wilcoxon Signed rank test was used. 2-way repeated measure ANOVA was employed 
for analyzing the impact of time and genotype on the behaviour on post training scoring 
at different intervals. The level of significance for the analysis was 0.05 and the outliers 







Table 2. 1. Details of post-mortem brain tissues. PMD refers to post-mortem delay 
 
Hippocampus -  
S.No 
Pathological 
state Sex Age(Years) 
PMD( 
Hours) 
1 Control M 81 18 
2 Control F 92 17 
3 Control M 78 10 
4 Control M 85 16 
5 Control F 76 28 
6 Control M 65 24 
7 Control M 86 6 
8 Control F 72 24 
9 Control F 55 24 
10 Control F 80 31 
11 Control F 71 30 
12 Control M 77 29 
13 Mild AD M 81 12 
14 Mild AD F 92 9 
15 Mild AD F 80 3 
16 Mild AD F 55 12 
17 Mild AD F 81 17 
18 Mild AD F 81 16.5 
19 Mild AD F 82 13 
20 Mild AD M 64 16 
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21 Mild AD F 83 24 
22 Mild AD M 81 3 
23 Mild AD M 90 5.5 
24 Mild AD F 94 21 
25 Severe AD M 64 23 
26 Severe AD F 68 11 
27 Severe AD M 80 15 
28 Severe AD F 69 16 
29 Severe AD M 77 10 
30 Severe AD F 69 16.3 
31 Severe AD F 79 24 
32 Severe AD F 71 21 
33 Severe AD F 82 4.5 
34 Severe AD F 80 4.3 
35 Severe AD F 88 19 
36 Severe AD M 75 17 
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state Sex Age(Years) PMD( Hours) 
1 Control F 55 24 
2 Control M 55 24 
3 Control M 65 24 
4 Control M 69 24 
5 Control M 86 6 
6 Control M 65 24 
7 Control M 71 5 
8 Control M 81 18 
9 Control F 92 17 
10 Control M 78 10 
11 Control M 85 16 
12 Control F 76 28 
13 Severe AD F 69 16.3 
14 Severe AD F 71 21 
15 Severe AD F 80 4 
16 Severe AD F 81 24 
17 Severe AD F 82 4.5 
18 Severe AD F 82 12 
19 Severe AD F 88 19 
20 Severe AD F 91 23 
21 Severe AD M 75 17 
22 Severe AD M 64 23 
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23 Severe AD F 68 11 
24 Severe AD M 80 15 
25 Severe AD F 69 16 





state Sex Age(Years) PMD( Hours) 
1 Control M 73 23 
2 Control F 92 23 
3 Control F 55 12 
4 Control M 77 11 
5 Control M 54 30 
6 Control M 81 18 
7 Control F 92 17 
8 Control M 78 10 
9 Control M 85 16 
10 Control F 76 28 
11 Mild AD M 81 12 
12 Mild AD F 92 9 
13 Mild AD F 80 3 
14 Mild AD F 55 12 
15 Mild AD F 81 17 
16 Mild AD M 93 14 
17 Mild AD F 84 24 
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18 Mild AD F 92 20 
19 Mild AD M 92 11 
20 Mild AD M 63 16 
21 Severe AD M 70 20 
22 Severe AD F 71 18 
23 Severe AD F 92 11 
24 Severe AD F 61 3 
25 Severe AD F 95 13 
26 Severe AD M 64 23 
27 Severe AD F 68 11 
28 Severe AD M 80 15 
29 Severe AD F 69 16 














Cerebellum (FTLD) - 
There were no known mutations in any of the patient samples.  One patient showed 
Tau-positive frontotemporal dementia with parkinsonism (FTDP-17) and another 
showed tau negative , ubiquitin immunoreactive neuronal changes ( FTLD – U). The 
ubiquinated protein is now known to be TAR- DNA- binding protein 43 (TDP-43 ). 
Two patients had FTD caused by FTLD-TDP43. Fifth one had FTLD-TDP43 with 




Cerebellum ( FTLD)         









1 Control A127/11 M 73 23  
2 Control A144/10 F 92 23  
3 Control A358/08 F 55 12  
4 Control A053/11 M 77 11  
5 Control A130/09 M 54 30  
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Cerebellum (healthy ageing) -  
S.No Age Category Sex Age(Years) PMD( Hours) 
1 
Young 
Control M 18 24.5 
2 
Young 
Control M 22 45 
3 
Young 
Control M 21 37 
4 
Young 
Control M 16 14 






Control F 26 10 
7 Old Control F 102 44 
8 Old Control M 97 44 
9 Old Control F 99 32 
10 Old Control F 96 16 
11 Old Control F 92 9 
12 Old Control F 92 23 
13 Old Control M 95 44 
 





Dilution Secondary Antibody  Primary 
Antibody 
manufacturer 
1 CSPα  
(for 
immunoblotting) 


























CYFIP2 1:1000 1:2000, Peroxidase 
conjugated, Goat-Antirabbit 
p0448, DAKO Ltd) 
GTX110897, 
GeneTex 
5 Synaptophysin  
(for 
immunoblotting) 


















7 NSE 1:60,000 1:5000, Peroxidase 
conjugated, Goat-Antirabbit 

































Chapter 3 - CYFIP1/2 are 
dysregulated in Alzheimer’s disease 
3.1. Introduction 
 
3.1.1. What is CYFIP1/2?  
 
Cytoplasmic FMR Interacting Protein -1 (CYFIP1) (also called Sra1) and Cytoplasmic 
FMR interacting Protein -2 (CYFIP2) (also called PIR121) are co-activators of FMRP 
(Fragile-X Mental Retardation Protein) and members of a highly conserved protein 
family in humans (Schenck et al., 2001). CYFIP1/2 co-localizes with FMRP and is 
found in the cytoplasm as well as synapses/dendrites (Schenck et al., 2001). Even 
though the amino acid sequence is 87.7% identical between CYFIP1 and CYFIP2, the 
binding affinities of these proteins differ. CYFIP1 binds only to FMRP whereas 
CYFIP2 binds FMRP and the FMRP related proteins FXR1 and FXR2 (Schenck et al., 
2001). CYFIP1 acts as a EIF4E (Eukaryotic Initiation Factor 4E) binding protein (4E-
BP) inhibiting the translation of FMRP bound mRNA (Napoli et al., 2008). CYFIP 
family proteins are also part of the actin cytoskeletal modulating WAVE complex, 
binding to the constituent of WAVE complex (Cory and Ridley, 2002, Derivery et al., 
2009). Binding of the small Rho GTPase Rac1 to CYFIP1 and 2 removes these proteins 
from the WAVE complex so that WAVE can activate actin polymerization via Arp2/3 
(De Rubeis et al., 2013). Additionally in non-neuronal cells (human colorectal 
adenocarcinoma cell line), CYFIP2 was shown to be a p53 inducible protein which 
causes apoptotic cell death (Jackson et al., 2007). CYFIP1 on the other hand is not p53 
inducible in these cells (Jackson et al., 2007). In Drosophila there is a single orthologue 
of the CYFIP family of molecules, which is exclusively expressed in the nervous 
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system (Schenck et al., 2003), implicating that during the course of evolution CYFIP1 
and 2 might have acquired different functions in humans. CYFIP1 gene is located on 
chromosome 15 (Nowicki et al., 2007)  and CYFIP2 gene is located on chromosome 5 
(NCBI Gene ID: 26999).  
  
3.1.2. Discovery of CYFIP1/2  
 
Tabata’s group cloned the CYFIP1 gene while they were sequencing a cDNA library 
from an immature myeloid cell line (KG-1) (Nomura et al., 1994) . This was designated 
as KIAA0068. The same group mapped the gene to chromosome 15. In subsequent 
years the CYFIP1 gene was mapped to the locus- chromosome 15q11.2 (Chai et al., 
2003).  Jean-Louis Mandel’s group in 2001 isolated CYFIP1 and CYFIP2 proteins 
when they tried to identify novel proteins that interact with Fragile X-mental 
Retardation Protein (FMRP) (Schenck et al., 2001). They used a yeast 2-hybrid screen 
based on a mouse embryonic expression library using the N-terminus of FMRP as bait. 
 The CYFIP 2 gene was mapped on chromosome 5 by International Radiation 
Hybrid Mapping Consortium (Map element – stSG9917). The precise location is at 
5q33.3 locus.  
 
3.1.3. What is the expression pattern of CYFIP1/2?   
 
Both the members of CYFIP family are expressed in the hippocampus and forebrain. 
However, in the cerebellum, only CYFIP1 and not CYFIP2 is expressed (Hoeffer et al., 
2012). Both CYFIP1 and CYFIP2 show co-localization with FMRP and ribosomes in 
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neurons. Apart from the perinuclear space, they are also reported to be present in 
synapses and dendrites (Schenck et al., 2001, Cajigas et al., 2012) .  
 
3.1.4. What are the functions of CYFIP1/2 at the synapse? 
 
CYFIP1/2 were discovered relatively recently and the precise function of these 
molecules in normal physiology is not well known. However, there are two distinct 
roles in which both these molecules have been implicated (though with slight variations 
between CYFIP1 and CYFIP2 within these). Two differing schools of thought arising 
from the common pioneer group of Mandel ((Schenck et al., 2001) stress differently on 
the contribution of the CYFIPs to each of these functions. Whereas De rubies et al (De 
Rubeis and Bagni, 2011, Napoli et al., 2008) have reported on the local translation 
modulatory functions of CYFIP , Bardoni et al have reported on the  role of CYFIP1/2 
as more relevant to the regulation of actin cytoskeletal dynamics (Abekhoukh and 
Bardoni, 2014, Schenck et al., 2003). However, a recent paper from Claudia Bagni’s 
group reveals a link between both these reported functions of CYFIPs (De Rubeis et al., 
2013). The detailed descriptions of both the functions assigned to CYFIP1/2 are as 
following -  
1) Actin cytoskeletal remodeling - CYFIP1/2  are components of the WAVE 
regulatory complex (WRC) (Fig.3.1) that also consists of  WAVE protein , NAP1 
(NCKAP1) subunit, ABI1/ABI2 protein  and BRK1 (also known as HSPC300) 
(Cory and Ridley, 2002, Derivery et al., 2009). The transduction of  Rac Signalling 
by WAVE complex to trigger Arp2/3 dependent actin nucleation is mediated by 
CYFIP1 (Derivery et al., 2009) (and possibly CYFIP2) – a process important for 
modulating actin dynamics, leading to  proper cell polarity and migration. The 
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WAVE proteins are part of WASP family (Wiskott-Aldrich syndrome protein), 
which consists of 5 members – WASP, N-WASP, WAVE1, WAVE2 and WAVE3 
proteins. All these proteins can activate Arp2/3 by a VCA (Verprolin homology, 
Central and Acidic region) domain present in all the WASP members. The 
interaction of CYFIP1/2 with the small RhoGTPase Rac1 leads to cleavage of the 
sub-complex consisting of CYFIP1/2,NAP1, ABI1 from the inactive WAVE 
holocomplex This cleavage results in availability of WAVE holocomplex for 
interaction with Arp2/3 (leading to actin nucleation), and the availability of 
CYFIP1/2 for interactions with other proteins, such as FMRP (as discussed in 
second function) (Abekhoukh and Bardoni, 2014, Schenck et al., 2001, Schenck et 
al., 2003).  The WAVE complex has been shown to be involved in actin 
cytoskeletal dynamics by assisting the remodeling of lamellipodia via interaction 
with CHC (Clathirin Heavy Chain Protein) (Gautier et al., 2011). In MCF10A cells 
(an immortalized mammary epithelial cell line), CYFIP1 activation leads to 
abnormal acini structures. A similar phenotype is observed following knockdown of 
the WRC component – WAVE2 and NCKAP 1 (Silva et al., 2009). However 
knocking down FMRP (the CYFIP interacting partner) in the same cell line doesn’t 
lead to a similar phenotype (Silva et al., 2009).  Chen et al have recently reported a 
study which emphasizes the relevance of CYFIP1/2 in actin cytoskeletal dynamics 
in Drosophila. A new class of motif – WIRS (WRC-interacting receptor sequence) - 
was identified in drosophila and defines a new class of ligands for Wave regulatory 
Complex. The WIRS peptide specifically interacts with the surface formed from the 
complex between CYFIP1/2 and Abi2.  Alterations in these interaction lead to 
disruption of actin reorganization and egg morphology in Drosophila causing 







Figure 3.1. The WAVE regulatory complex. Under Rac-GDP condition CYFIP is a 
component of WAVE regulatory complex (WRC). Rac GTP interacts with CYFIP 
leading to  cleavage of CYFIP along with Abi2 and Nap from WRC leaving behind a 
WAVE holocomplex which interacts with Arp2/3 causing actin nucleation. Taken from 















 Figure 3.2. The translational repression complex. CYFIP binds to EIF4E and 
FMRP to form a translation repression complex at the postsynaptic end. This 
complex binds to locally regulated pool of mRNA molecules at synapse/dendrites 
and keeps them repressed in an activity dependent manner. During synaptic 
activity, this complex breaks down liberating mRNA to be accessed and translated 














Figure 3.3. Chromosome locus 15q11- q13.CYFIP is present in the region between 
breakpoint 1 (BP1) and breakpoint 2 (BP2).The BP1-BP2 deletion is present at 




Figure 3.4. Specific binding of anti-CYFIP1/2 antibodies. The full blot containing 
the human hippocampal lysates showing the specific binding of anti-CYFIP1 , anti-
CYFIP2 and loading control anti-NSE antibodies. For all three antibodies,  bands are 





Figure 3.5. CYFIP1 expression is specifically increased in hippocampus in 
severe, but not mild AD. (a) Significant up-regulation of CYFIP1 expression 
in hippocampal lysates from severe AD patients (n=12) and control subjects 
(n=12).  (b) CYFIP1 expression in lysates of superior temporal gyri from severe 
AD (n=13) and control subjects (n=12). (c)  CYFIP1 expression in cerebellar 
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lysates from severe AD (n=10) and control subjects (n=10). (d) Similar levels of 
CYFIP1 expression in hippocampal lysates from mild AD patients (n=12) and 
control subjects (n=12). All the samples were normalized against neuron 
specific marker NSE. Panel (e) shows the representative blots. Means ± s.e.m. 























Figure 3.6. Age-dependent down-regulation of CYFIP1 in forebrain of 
Tg2576 mice. (a) CYFIP1 expression in hippocampal cortical lysates of 12 
month-old wild type (n=4) and Tg2576 (n=3) mice.  (b) The expression of 
CYFIP1 in hippocampal cortical lysates of 4 month -old wild-type mice (n=4) 
and Tg2576 (n=4) mice. Panel (c) shows representative western blots. All the 








Figure 3.7. CYFIP1 levels in Htau mouse brain are not changed. Hippocampus (A)  
from young mouse (3-4 months), frontal cortex (B) from young mouse (3-4 months) , 
cerebellum (C) from young mouse  and hippocampal frontal cortical region (D) from 
aged Htau mouse ( 24 months ) were probed with CYFIP1 antibody and there was no 





Figure 3.8. CYFIP1 expression does not change in cerebellum with normal 
ageing. CYFIP1 expression was normalized against NSE in cerebellum of 
young (15-30 years, n=6) and old (90-105 years, n=7) control patients. Means ± 















Figure 3.9. CYFIP2 expression is decreased in forebrain of severe AD 
patients. (a) CYFIP2 expression in hippocampal lysates from severe AD 
patients (n= 9) and control subjects (n=11). (b) CYFIP2 expression in lysates of 
STG from severe AD patients (n=13) and control subjects (n=12). (c) CYFIP2 
expression in hippocampal lysates of mild AD (n=12) and control subjects 
(n=12). (d) Representative western blots. CYFIP2 protein expression was 










Figure 3.10.  Age-dependent decrease of CYFIP2 expression in forebrain of 
Tg2576 mice. (a) CYFIP2 expression in hippocampal –cortical lysates of 12 
month-old wild-type mice (n=4) and Tg2576 (n=3). (b) CYFIP2 expression in 
hippocampal-cortical lysates of 4 month-old wild-type (n=4) and Tg2576 mice 
(n=4). Representative western blots are shown in panel (c). In all the panels, the 










Figure 3.11. CYFIP1 expression is not altered in crude hippocampal 
synaptosomes of CYFIP2
+/-
 mice. (a) CYFIP2 expression in crude 
synaptosomal (P2) fraction of hippocampal lysates from wild-type controls 
(n=7) and CYFIP2+/- mice (n=9). The same blot as in panel (a) was used to 
probe for CYFIP1 expression as shown in panel (b). The house keeping 
synaptic marker protein synaptophysin was used to normalize against CYFIP 
expression in both panels. Panel (c) shows the representative western blot. 








 animals are impaired in maintaining cued fear 
memory. (a) Freezing score before (Pretone) and during tone stimulus (Tone) 
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presentation of wild-type mice (n=18) and CYFIP2+/- mice (n=12) 1 hour after 
training. (b) The same mice as in panel (a) were tested 1 day after training for 
freezing score before and during the exposure to tone stimulus. (c) Freezing 
score (Pretone and tone) for the wild type (n=13) and CYFIP2+/- mice (n=15) 5 
















 animals are not impaired in formation and maintenance of 
contextual fear memory. (a) Freezing score during the context presentation for wild-
type (n=13) and CYFIP2+/- mice (n=15) for 5 subsequent days after training. (b) 
Freezing score 28 days after training on context presentation to wild-type (n=18) and 









 animals do not display impairments in visible platform 
test. (a) Latency (in seconds) test score of wild type (n=7) and CYFIP2 +/- mice (n=6) 
per quadrant on the probe test day (six days after training). (b) Latency (in second) 










Figure 3.15. CYIP2 antibody didn’t gave any detectable CYFIP2 signal from aged 






Figure 3.16. CYFIP2 is absent in glial cells. Glial culture ( first five lanes from left ) 
along with mouse cortical neuronal culture ( lane 6- 9 from left)  and human 
hippocampal lysate ( lane 10 and 11 from left ) was probed with anti-CYFIP2 
antibodies . Actin was used as the loading control. No signal was detected in the lanes 





2) Modulation of local translation at synapses – CYFIP1/2 have been reported to 
act as modulators of local mRNA translation near dendrites and synapses in an 
activity dependent manner. Claudia Bagni’s group in 2008 reported the existences 
of a translation repression complex consisting of the core component of a 5’mRNA 
cap binding protein eIF4E, CYFIP1 and FMRP binding at the 3‘ end of mRNA 
(Napoli et al., 2008) (Fig.3.2.) This core repressor complex is formed specifically in 
the brain and suggested to act as a translation repressor for an array of mRNA 
molecules that are regulated by interaction with FMRP. These include cytoskeletal 
proteins like MAP1B, p0071(Brown et al., 2001, Nolze et al., 2013), synaptic 
plasticity molecules like αCaMKII (Zalfa et al., 2003), Amyloid precursor protein 
(APP)  (Westmark and Malter, 2007),  and even CYFIP2 (Darnell et al., 2011) . 
FMRP bound to a specific mRNA recruits CYFIP1, which in turn binds to 
eIF4E, leading to repression of translation. Activation of Brain Derived 
Neurotrophic Factor / NT- 3 growth factor receptor (TrkB) or group 1 
metabotrophic glutamate receptors  (mGluRs), releases CYFIP1 from eIF4E and 
translation of the mRNA initiates (Napoli et al., 2008). CYFIP1 and CYFIP2 
interact with FMRP, but only CYFIP2 also interacts with the FMRP related 
proteins- FXR1 and FXR2 (Schenck et al., 2001). Also, the domain of CYFIP 
binding to FMRP is the site that is used for homo- and heteromerization in FMRP, 
hence there is a competition for the same site between CYFIP1/2 and FXR proteins 
(Schenck et al., 2001). 
 
A recent report by Claudia Bagni’s group establishes a link between the two aforesaid 
functions of CYFIP molecules whereby a BDNF driven synaptic signaling mechanism 
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releases CYFIP1 from the translation inhibition complex , allowing the translation of 
repressed mRNA and causing the free CYFIP1 to move into WAVE regulatory 
complex (De Rubeis et al., 2013) . Active Rac1 plays an important role in changing the 
equilibrium of the two CYFIP1 incorporating complexes – the translation modulating 
eIF4E-CYFIP1-FMRP complex and the actin cytoskeletal dynamics modulating 
WAVE regulatory complex (De Rubeis et al., 2013). Also, since a number of mRNAs 
responsible for actin cytoskeletal modifications including CYFIP2 (which is part of 
WAVE regulatory complex) are regulated by this translation repression complex, it 
seems that this complex on its own is also involved in cytoskeletal modification. 
 
3.1.5. What are the diseases in which CYFIP1/2 has been implicated?  
 
Cancer - CYFIP1 knockdown leads to dysregulation in epithelial morphogenesis and 
along with Ras leads to carcinomas (Silva et al., 2009) . CYFIP2 has also been reported 
to have a pro-apoptotic effect through its interaction with IMP-1 (Insulin like Growth 
Factor mRNA binding protein -1) (Mongroo et al., 2011). 
Neurodevelopmental disorders - No point mutations in CYFIP1/2 have been directly 
implicated in any disease. However, deletions in region 15q11-q13 (which includes 
CYFIP1 gene) are associated with Autism spectrum disorders (Fig.3.3). The paternal 
deletion of this region leads to Prader-Willi Syndrome ( PWS) , whereas the maternal 
deletion of this region leads to Angelmann syndrome (Cassidy et al., 2000).  The 
interstitial duplication of maternal region which includes the region relevant to Prader-
Willi syndrome and Angelmann syndrome, leads to a behavioral phenotype more 
variable than Prader-Willi Syndrome and Angelmann Syndrome on their own. This 
includes developmental delays, seizures, ataxia, autism or atypical autism with minor 
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features of dysmorphism. On the other hand the duplication in paternal region of the 
same locus does not lead to any abnormal phenotype (Browne et al., 1997, Abekhoukh 
and Bardoni, 2014). A microdeletion of a region consisting of 4 genes – 
NIPA1,NIPA2,CYFIP1,TUBGCP5- and a non-coding mRNA WHAMML1 - between 
the breakpoint1 and breakpoint 2 on 15q11-13 locus, does not lead to Prader-Willi 
Syndrome but shares common features of learning disabilities, behavioral problems and 
dysmorphisms (Leblond et al., 2012, Kirov et al., 2009, Madrigal et al., 2012). Hence, 
the genes between breakpoint 1 and breakpoint 2, of which CYFIP1 is important, play 
important roles in cognitive and behavioral functions. The importance of CYFIP1 in 
neurodevelopment is further emphasized by the work of Hagerman’s group, which 
reported a decreased level of CYFIP1mRNA in patients with FragileX syndrome and 
Prader Willi Syndrome (Nowicki et al., 2007).  
      CYFIP2 has been reported to be overexpressed in Fragile X patients at the protein 
level without any change detected in the mRNA level, suggesting an FMRP dependent 
dysregulation of  CYFIP2 expression (Hoeffer et al., 2012). There results were reported 
in lymphocytes, although a similar result is observed in the postmortem forebrains of 
Fragile X patients. 
Neurodegenerative disorders – To our knowledge, no other group has specifically 
studied the role of CYFIP1/2 molecules in neurodegenerative disorders. Genome Wide 
Association studies (GWAS) of Copy Number Variations (CNV’s) by Rogaeva’s group 
in Alzheimer’s disease using a patient cohort from a Caribbean hispanic population 
have identified a duplication at the locus 15q11-q13 ( consisting of TUBGCP5,CYFIP1, 
NIPA2, NIPA1 and WHAMML1 genes) which showed significant association with 
Alzheimer’s disease. Quantitative PCR confirmed an increase in CYFIP1 levels in this 
cohort(Ghani et al., 2012). Apart from amyloid precursor protein , widely implicated in 
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Alzheimer’s disease, Bagni’s group has also reported an array of other proteins 
suspected to be involved in Alzheimer’s disease onset – Elav protein 3, Elav protein 4, 
Nck Associated protein 1 and Cholesterol 24- hydroxylase  to be regulated by the 
CYFIP constituting mRNA translation repression complex (De Rubeis et al., 2013). 
 
3.1.6. What kind of animal models have been used until now to study 
CYFIP1/2functions? 
 
Mandel’s group developed a fly knockout model of CYFIP proteins to understand the 
role of this protein. Drosophila has just one homolog of the CYFIP family – dCYFIP 
and one homolog of FXR family – dFXR. The expression of dCYFIP is specific to 
central nervous system and shows interaction with dFMRP and dRac. It is 67% 
identical to human CYFIP1/2. Loss of function mutations in dCYFIP affects axonal 
growth and branching, establishing the importance of CYFIP in neuronal connectivity 
(Schenck et al., 2003). There is impaired synapse growth at the neuromuscular junction 
in dCYFIP mutants as indicated by shorter synapse terminals and increased number of 
buds when compared with wild types  (Schenck et al., 2003) . FMRP and CYFIP serve 
opposite molecular functions as evident by neuro-muscular junction phenotypes in 
dFMR1 mutants which are opposite to dCYFIP null flies (Zhang et al., 2001). Schenck 
et al have shown that overexpression of this morphological phenotype (such as short 
synapses) of dFMR1 is rescued by co-overexpression of dCYFIP. They proposed that 
dRac1 controls dCYFIP which in turn controls dFMR1 (Schenck et al., 2003). Zhao et 
al established in dCYFIP fly mutants, that neuro-muscular junction development is 
regulated by CYFIP (Zhao et al., 2013). They showed that synaptic vesicle size in 
dCYFIP mutants is larger and the numbers of cisternae are elevated, though the number 
of synaptic vesicles is not changed between wild-type and mutant flies. This shows that 
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CYFIP may modulate F-actin machinery leading to the regulation of endocytosis and 
synaptic vesicle recycling (Zhao et al., 2013) . This study helped us to narrow down 
and screen for the second candidate molecule – Cysteine String Protein α (described in 
chapter 4) – in our post mortem study. This is a synaptic vesicle protein which showed 
a significant difference in mass spectrometric analysis of  p25 transgenic mice 
synaptosomes, carried out in lab before this project started (Engmann et al., 2011). 
Inactivation of dCYFIP also results in reduced expression of WAVE complex member 
proteins like Nckap1 (Kette) and WAVE (Scar) (Bogdan et al., 2004, De Rubeis et al., 
2013). 
     Pittman et al , obtained the first mutant in a vertebrate of CYFIP family proteins  in 
2010 (Pittman et al., 2010). This mutation was in CYFIP2 functions which were 
specifically investigated in Zebrafish. In a genetic screen to identify the pathways 
involved in retinotectal axon pathfinding , to understand eye –brain development, a nev 
( CYFIP2)  mutant was identified that had impairments in the positional information of 
dorsonasal axons while projecting through optic tract (Pittman et al., 2010) . This 
phenotype is similar to the axon branching phenotype reported by Schenck et al in fly 
mutants of dCYFIP gene (Schenck et al., 2001). Pittman et al also showed that CYFIP2 
is broadly expressed in central nervous system with a suggested role in protein 
translation at synapses. 
     In mice, both the CYFIP1 and CYFIP2 null mutations are lethal (Kumar et al., 
2013b, Pathania et al., 2014) . Buxbaum’s group has studied haploinsufficient CYFIP1 
mice and demonstrate that this model mimics the features like more rapid extinction in 
inhibitory avoidance testing, unaltered LTP in CA1 induced by high frequency 
stimulation and enhanced mGluR-LTD of FMR1 knockout mice (Bozdagi et al., 2012). 
Indeed, mGluR-dependent LTD was significantly increased in CYFIP1 heterozygous 
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mice as compared to wild type. Similar to FMR1 knockouts, these mice showed an 
enhanced extinction of inhibitory avoidance. However, there was no difference in 
learning in the Y-maze and Morris water maze tests (Bozdagi et al., 2012). Bagni’s 
group has shown that siRNA mediated knockdown of CYFIP1 expression in primary 
cortical neurons leads to a change in dendritic spine morphology (more immature 
spines) without affecting spine density (De Rubeis et al., 2013). This was also observed 
in hippocampal neurons of CYFIP1 heterozygous knockout mice (Pathania et al., 
2014).  Additionally, reduced CYFIP1 expression decreases the complexity of 
dendrites on CA1 pyramidal neurons (Pathania et al., 2014). As previously 
demonstrated with dCYFIP mutants in the fly , in the case of rat hippocampal neurons 
,inactivation of CYFIP1 resulted in impairment of axonal growth , which was similar to 
the phenotype observed with WAVE inactivation(Kawano et al., 2005).  
     To study CYFIP2 functions in haploinsufficient state, we have used CYFIP2 
heterozygote mice on a C57BL/6 N genetic background. In 2013, Kumar et al studied 
these mice and proposed cocaine response behavior as one of the functions in which 
CYFIP2 plays an important role. They also showed that the presence of the S968F 
mutation in the CYFIP2 gene within C57BL/6 N train destabilizes the CYFIP2 
proteins, reducing the protein half-life to 2.8 hours as compared to 8.5 hours in 
C57BL/6Jmice(Kumar et al., 2013b). 
 
3.1.7. Previous studies in the lab that lead to the reported study on 
role of CYFIP1/2   
 
Prior studies in the Giese lab have investigated the role of the CdK5 activator p25 in 
Alzheimer’s disease (Engmann et al., 2011). A mass spectrometric analysis of 
synaptosomes isolated from hippocampus of p25 transgenic mice (in a C57BL/6J 
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genetic background) yielded candidate molecules that may be putative downstream 
molecules to p25. This project began with the aim of investigating synaptic pathology 
in Alzheimer’s disease and dementia. The synaptic proteins from the mass 
spectrometric study were screened to identify novel molecules responsible for 
Alzheimer’s onset and to investigate their role in Alzheimer’s disease. CYFIP2 was one 
of the synaptic proteins which were identified. Since CYFIP1 belongs to the same 
protein family, this was also screened. In the subsequent part of the study CSPα (as 
described chapter 4) –a pre synaptic protein was also studied because Zhao et al’s result 
hinted at the role of synaptic vesicle proteins in Alzheimer’s disease (Zhao et al., 2013). 
The hypothesis we developed for the project reported in this chapter was – “Local 
translation modulators of dendritic mRNA (CYFIP1/2) are dysregulated in Alzheimer’s 
disease “. 
 
The aims of the study described in this chapter were – 
1) To investigate the relevance of CYFIP1/2 in Alzheimer’s disease by 
performing a case-control study using post-mortem brain tissues to analyse 
the levels of CYFIP1/2 in different regions of the brain at different stages of 
Alzheimer’s disease. 
2) To investigate the relevance of CYFIP1/2 in cognitive decline associated 
with normal aging by analyzing the levels of CYFIP1/2 in postmortem 
brain from young and aged subjects. 
3) To investigate the validity of the hypothesis that functional compensation 
between CYFIP1 and CYFIP2 may exist by biochemical analysis of brain 
tissue lysates from CYFIP2 heterozygote mice. 
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4) To understand the role of CYFIP2 in memory as well as dementia 
associated with Alzheimer’s disease by behavioral testing of CYFIP2 




3.2.1. CYFIP1 is upregulated and CYFIP2 is downregulated in the 
hippocampus of severe stages of AD 
  
The medial temporal lobe, specifically, the hippocampus is one of the first and most 
severely affected regions  in the brain during the course of AD progression  (Braak and 
Braak, 1991a). Onset of AD is characterized by the loss of memory and defects in 
cognitive skills. These defects are attributed to the loss of synapses at the onset of AD, 
particularly in the hippocampus (Arendt, 2009) . This synaptic loss precedes the 
neuronal death. Therefore, we decided to analyze the changes in the levels of CYFIPs 
in the hippocampal neurons.  
We obtained hippocampus samples of severe (Braak stage 5-6) AD cases and controls 
in two sets from London Neurodegenerative Brain Bank. For the mild cases, the patient 
sample was obtained in one set. The patient sample details are listed in Table 2. 1. We 
tried to obtain the samples with lowest possible post-mortem delays available.  Since 
the immunoblots from two sets were analyzed on different scanners, the data obtained 
from them was pooled together and analyzed using regression statistics described in 
Chapter 2.  
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 We studied first whether in the late stages of AD CYFIP protein expression in 
hippocampus is affected, comparing post-mortem samples from severe AD patients and 
control subjects using western blot analysis. The expression of CYFIP was normalized 
to the neuronal marker NSE (Neuron Specific Enolase) (Fig.3.5a, 3.9a). The levels of 
CYFIP1 were found to be significantly increased in the hippocampus of severe AD 
patients (F(2,21)=39.471, p<0.01). In contrast, CYFIP2 levels were significantly 
decreased in the hippocampus of severe AD patients (F(2,17)=3.905,p<0.05). To 
investigate if these dysregulations are already present in the early stages of the disease, 
we analysed hippocampal lysates from patients with mild AD (Fig.3.5d, Fig.3.9c). 
Western blot analysis revealed no change in the expression of CYFIP1 in these cases 
(F(2,21)=1.014,p=0.206) . CYFIP2 expression was numerically reduced reduced in 
these cases, but just failed to reach statistical significance, possible due to the small 
sample size (F(2,21)=36.047,p= 0.056). This data may suggest that CYFIP2 
downregulation is an early event in AD, though CYFIP1 upregulation is not. 
 
3.2.2. CYFIP1 expression is unaltered whilst CYFIP2 is downregulated 
in the Superior Temporal Gyrus in severe AD 
 
We next studied CYFIP expression in the superior temporal gyrus (STG), which is 
affected later at moderate stages of AD and to a lesser extent than the hippocampus 
(Braak and Braak, 1991a).  
     In a western blot analysis we compared CYFIP expression in post-mortem STG 
from severe AD to patient controls. The levels of CYFIP expression were normalised 
with NSE (Fig. 3.5b, Fig. 3.9b). In the case of CYFIP1, there were no changes 
observed between severe AD cases and control subjects (F(2,22)=81.180;p=0.263). 
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When CYFIP2 expression was probed, a downregulation was observed in severe AD 
cases as compared to control (F(2,22)=10.505,p<0.01), replicating our findings in the 
hippocampus. 
 
3.2.3. CYFIP1 expression is unchanged and CYFIP2 was expressed at 
undetectable levels in the cerebellum of severe AD cases 
 
The cerebellum is one of the least affected regions in AD pathology (Larner, 1997). 
Though diffuse amyloid plaques  and  increased numbers of activated microglia have 
been reported, there is no neurofibrillary tangle pathology reported in the cerebellum 
(Larner, 1997) . Furthermore, motor disturbances that can be assigned to cerebellum 
dysfunction are not observed in AD. These features make it a good internal control in a 
case-control study of AD patients. To investigate if CYFIP could be one of the factor(s) 
that play a role in the disease mechanism affecting forebrain but not the cerebellum in 
AD, we performed case-control studies on cerebellum. 
     We obtained cerebellum samples from severe AD cases and controls in two sets 
from the London Neurodegenerative Brain Bank. For the mild cases, the patient sample 
was obtained in one set. As with hippocampal samples, We tried to obtain the samples 
with lowest possible post-mortem delays available. Again, since the immunoblots from 
two sets were analyzed on different scanners, the data obtained from them was pooled 
together and analyzed using regression statistics described in Chapter 2.  
      We investigated the levels of CYFIP in post-mortem cerebellum from severe AD 
patients and compared with controls, using western blot analysis. The normalization 
was carried out with NSE (Fig. 3.5c). CYFIP1 expression was not altered in cerebellum 
of severe AD patients as compared to control (F(2,17)=4.484,p=0.894). We were 
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unable to detect CYFIP2 expression in our immunoblots from these tissue samples in 
both cases and controls (Hoeffer et al., 2012).  
 
3.2.4. CYFIP1 expression is unchanged whilst CYFIP2 expression 
decreases with increasing age in Tg2576 mice 
 
Mouse models are useful to investigate some mechanisms of AD. However, not all 
aspects of AD can be modelled in mice, possibly due to the short life span of the mice. 
We studied whether abnormal APP processing in the hippocampus-forebrain is 
sufficient to induce CYFIP1 upregulation and CYFIP2 downregulation, using Tg2576 
mice, a widely used mouse model for abnormal APP processing.  
     We performed a western blot analysis at two time points, 4 and 12 months of age.  
At 4 months of age Tg2576 mice do not have amyloid plaques but do show some 
memory impairment, whereas at 12 months of age, Tg2576 mice memory deficits are 
more pronounced and amyloid plaques are detectable(Hsiao et al., 1996, Stewart et al., 
2011).  CYFIP expression at both ages was normalized against NSE.  This comparison 
revealed significant differences between genotypes. CYFIP1 was significantly reduced 
at the 12 month time point in Tg2576 mice (Fig.3.6a) (t=-5.487, p<0.01) but was 
unchanged  at the 4 month time point (Fig. 3.6b)( t=0.973,p=0.368).CYFIP2  was also 
significantly reduced by 50 % at the 12 month time point (Fig.3.10a)(t=-6.560,p<0.01) 
in Tg2576 mice with no change in 4 month old mice (Fig.3.10b)(t=-1.031,p=0.343).  
Aged Tg2576 mice therefore replicated the same result for CYFIP2 as observed in 
postmortem human brains, but not for CYFIP1. This suggests that the aged brain of 




3.2.5. CYFIP1 is unchanged in ageing cerebellum 
 
The increased CYFIP1 expression in hippocampus in AD indicates that CYFIP1 
expression is plastic. This raised the issue whether normal ageing also regulates 
CYFIP1 expression.   
     Hence, we analyzed the cerebellar lysates from healthy subjects belonging to two 
age groups, 15-30 years and 90-105 years (Fig. 3.8). We were unable to obtain the 
good quality hippocampal tissues from control subjects with short postmortem delays, 
so, we probed the available cerebellar lysates (with the pre existing limitation of no 
detectable CYFIP2 signals) in western blots. Western blot analysis and normalization 
with NSE showed that normal ageing has no effect on CYFIP1 expression in 
cerebellum (t=0.581,p=0.573).  
 
3.2.6. CYFIP2 expression is independent of CYFIP1 expression in 
CYFIP2+/- mice  synapses 
 
To perform further functional studies on the significance of CYFIP2 molecules in AD, 
we used CYFIP2+/- mouse model. The homozygous knockout of CYFIP2 gene is lethal 
at embryonic stage (Kumar et al., 2013b) . 
     Since CYFIP2  and CYFIP1 molecule have nearly 88 % sequence identity , we 
wanted to know if the expression of the two molecule are related and if overexpression 
of one molecule type  compensates for the underexpression of another molecule type or 
vice versa.  Crude hippocampal synaptosomal preparations (P2) from CYFIP2+/- mice 
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(as described in chapter 2) were probed for CYFIP2 and CYFIP1 expression in 
synaptosome (Fig.3.11a and Fig.3.11b). The normalization was carried out with 
synaptic marker synaptophysin. CYFIP2   expression showed a downregulation of 
about 50% in the mutant mice (t=-2.548,p<0.05) as compared to wild type. Also, these 
results show that the heterozygotic status at genetic level in these mutant mice is 
replicated at protein level for CYFIP2, making them a viable model to study the 
functional effect of CYFIP2 downregulation. The CYFIP1 expression on the other hand 
was relatively unaffected by the downregulation of CYFIP2 expression, as it was not 
different in mutant mice (t=0.090,p=0.929) synaptosomes as compared to wild type 
mice.   
 
3.2.7. CYFIP2 +/- mice show deficits in cued fear conditioning memory 
 
Fear conditioning memory tests are fast and precise behavioral tests to analyze the 
extent of learning and memory impairments in in vivo models (Maren, 2001, Maren, 
2008). CYFIP2+/- mice were tested in contextual and cued fear conditioning tasks. In 
the cued fear conditioning tasks the mice were tested at 1 hour (Fig.3.12a), 1 day 
(Fig.3.12b) and 5 day (Fig.3.12c) intervals after training (as described in chapter 2). 
The freezing score of the animal was the readout for learning and memory phenotype. 
One mouse group was used to score freezing   at   1 hour and 1 day after conditioning 
(Group 2) and another mouse group was  trained to be used for memory testing 5 days 
after conditioning (Group 1).  The freezing score at each time point was analyzed 
before (pretone) and during (tone) the presentation of cue while testing.  At 1 hour time 
point, there was no significant difference between wild type and CYFIP2+/- for pretone 
(t=-0.707,p=0.485) and tone (t=0.335,p=0.740) scores.  At 1 day time point , the same 
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mouse group was tested and there was no  difference between  wild type and mutant 
mice in pretone freezing score( U=85, Z=-0.976,p=0.329 ) and tone freezing score ( t 
=0.846,p=0.405). At 5 day time point, animals from group1 were tested for the first 
time after training for cued fear conditioning memory. Both mutant and wild type had 
learned  well during the training, since there was a significant difference between 
freezing pretone and tone score of the  group consisting of mutants as well as wild type 
( Z= -4.623,p<0.001).  The pretone freezing score was not different (U=68.50, Z=-
1.614,p=0.107) between mutant and wild type.  However, the freezing tone score was 
significantly reduced in CYFIP2+/- mice (t=2.213,p<0.05) indicating a defect in 
maintenance of cue dependent memory.  The effect of sex on the cue memory 
impairment at 5 day interval was also tested between 8 male and 20 female in the total 
sample of group 1 mouse. A  2 way ANOVA test followed by post-hoc test using 




3.2.8. CYFIP2+/- mice do not show any defects in formation and 
maintenance of context dependent fear memory 
 
In the second part of studying the fear conditioning memory defects in CYFIP2+/- mice, 
the mice were tested for contextual fear memory. The CYFIP2+/- and wild type mice 
from Group 1 were tested for 5 subsequent days after training at 24 hours time interval 
to plot the extinction curve for contextual fear memories (Fig.3.13a).  A 2 way repeated 
measure ANOVA test revealed that the animals have learned during the training but 




F(4,9)=1.510,p=0.279). To study contextual fear memory maintenance over a longer 
period, the mice from Group2 were tested 28 days after training ( Fig.3.13b).There was 
no significant difference  between freezing scores of CYFIP2+/- and wild type mice 
 (t=-0.117,p=0.907). 
 
3.2.9.CYFIP2+/- mice is not impaired in visible platform test and hence 
suitable for water maze tests 
 
Morris water maze test (D'Hooge and De Deyn, 2001) is the gold standard for studying 
spatial memories.  CYFIP2+/- mice will be tested for defects in hippocampal dependent 
spatial memories in future studies. To test the suitability of CYFIP2+/- mice for Morris 
water maze experiments, a preliminary set of experiment were performed which 
included training on water maze platform for six days followed by probe trial on sixth 
day ( as described in methods) (Fig.3.14a, ) and visible platform test ( Fig3.14b). The 
training for six days and the probe trial on sixth day didn’t reveal any significant 
difference in wild type and mutant  mice as well as showed that there was no learning 
in the mice group by sixth day ( Target quadrant time spent versus other quadrants, 
t=1.031,p=0.325 ; Target platform crossing, t=0.590,p=0.567 ). The same group of 
mice  were tested on a visible platform test to determine if the CYFIP2 +/- mice  have a 
phenotype apart from spatial memory  affecting their suitability for future longer water 
maze trials (like locomotor defects, visual defects, muscular defects). The visible 
platform test showed no difference in the performance of CYFIP2+/- mice as compared 
to wild type mice (t=1.671, p=0.123). Hence, these animals are suitable for future 






 Our investigation of CYFIP1/2 molecules have revealed the following important  
findings (1) CYFIP2  is downregulated in the milder stages of AD in forebrain and this 
downregulation may be responsible for dementia in AD as shown by memory 
impairment in behavioral studies  of CYFIP2 +/-  mice (2)  CYFIP1 is upregulated in the 
later stages of AD in hippocampus (3) CYFIP1 and CYFIP2 expression regulations are 
not dependent on each other (4) CYFIP1 expression in human cerebellum does not 
change with normal aging (5) CYFIP2 downregulation, but not CYFIP1 upregulation, 
is modeled in Tg2576 mice, an AD model that has abnormal APP processing . 
    With respect to the first finding, we have shown that CYFIP2 downregulation is an 
early event in AD hippocampus and STG as seen in the case control postmortem 
studies. In the milder stages of disease, hippocampus is one of the first brain regions to 
be affected, where we observed a trend (p<0.10; though not significant perhaps due to a 
smaller sample size) for downregulation of CYFIP2. In the later stages of disease 
CYFIP2 expression in the hippocampus and STG showed a very significant 
downregulation. 
 
    From the previous studies with p25 transgenic mouse as described previously 
(Engmann et al., 2011) , a downregulation of CYFIP2 expression was expected. In 
cultured hippocampal neurons CYFIP2 is expressed in dendritic spines and its 
expression is enriched at excitatory synapses (Pathania et al., 2014). Further CYFIP2 
overexpression in these hippocampal neurons tend to increase dendritic branching 
similar to CYFIP1 overexpression (Pathania et al., 2014). Thus, a downregulation of 
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CYFIP2 expression may reduce dendritic branching as was shown for a downregulation 
of CYFIP1 expression (Pathania et al., 2014). Further, CYFIP1 downregulation affects 
spine morphology in cortical and hippocampal neurons (De Rubeis et al., 2013, 
Pathania et al., 2014) in that mushroom spines are increased whereas long thin spines 
are reduced. We have modeled the CYFIP2 downregulation in AD in CYFIP2+/- mice. 
We found that CYFIP2+/- mice have normal memory formation of cued fear memory, 
but the maintenance of this memory is impaired, as it declines within 5 days after 
training. Interestingly, in the CYFIP2+/- mice memory loss was not found for contextual 
fear memory, which requires the amygdala and the hippocampus. Cued fear memory 
requires the amygdala and it is a matter of debate whether the  hippocampus  is also 
needed (Maren, 2008) . Our data suggest that downregulation of CYFIP2 expression in 
the hippocampus can lead to memory loss. A recent BSc project in our lab showed that 
spine morphology is affected in CA1 pyramidal neurons in CYFIP2+/- mice, in that 
there are more immature and less mature spines. This spine phenotype may have 
accounted for the observed memory loss in our fear conditioning studies. Moreover, 
Kumar et al have reported the presence of S968F mutation in C57BL/6 N strain of mice 
that we have used in the present study (Kumar et al., 2013b). This mutation reduces the 
half life of CYFIP2 to 2 hours as opposed to 8 hours in the C57BL/6 J strain. This data 
by Kumar et al was published by the end of this PhD study, hence we continued with 
the use of C57BL/6 N strain. If there are any minimal phenotypic differences as a result 
of the reduced half life of CYFIP2 molecules, they must have been accounted during 
the data analysis, since the test and control mice in our study have the same genetic 
background from the same strain. 
     One of the mechanisms by which CYFIP2 reduced expression might be leading to 
synaptic losses could be an altered activity of the WRC complex. As reported by 
Pathania et al group , CYFIP1+/- mice with reduced expression of CYFIP1, has been 
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known to be leading to altered WRC mediated actin cytoskeletal dynamics affecting 
cell viability and altered spine morphology (Pathania et al., 2014). This hints towards a 
similar phenotype for CYFIP2+/-  mice.   
     An alternative mechanism by which CYFIP2 haploinsufficieny could be leading to 
synaptic losses causing dementia in AD patients is by its involvement as a translation 
modulator of dendritically localized mRNA. Bagni’s group has shown the existence of 
a eIF4E-CYFIP-FMRP complex  acting  as a  modulator of  dendritically or 
synaptically localized mRNA s  in a synaptic activity dependent manner by inhibiting 
the translation of target mRNA (Zalfa et al., 2003, De Rubeis et al., 2013).  Thus, 
downregulation of CYFIP2 may reduce FMRP-mediated translation repression of 
mRNAs, which could results in overexpression of synaptic proteins that may become 
toxic for the synapse.    
      Our study with Tg2576 mice leads to two conclusions. First, the CYFIP2 
downregulation observed in postmortem studies of AD brain was modeled in Tg2576 
mice. This was at a developmental time point when the cognitive deficits in these mice 
have started to emerge like reduced spine density and impaired contextual fear 
conditioning (D'Amelio et al., 2011).  The CYFIP2 downregulation in Tg2576 mice is 
in agreement with a trend of a downregulation in postmortem hippocampus of mild 
AD. In contrast, Tg2576 mice do not model the CYFIP1 overexpression in 
hippocampus which occurs in postmortem hippocampus of late AD. Taken together, 
this suggests that Tg2576 mice model only the early stages of AD. Second, since 
CYFIP2 downregulation was detected in Tg2576 mice, it shows that abnormal APP 
processing is sufficient to cause this downregulation in AD.   
     CYFIP2 mRNA is itself one of the mRNAs regulated by FMRP based translation 
repression complex, leading us to speculate about a probable self correcting loop 
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(Darnell et al., 2011). But, at the same time APP mRNA translation may be regulated 
by FMRP and CYFIP2. This is suggested as a recent BSc project in our lab has shown 
that synaptic APP protein expression is increased in CYFIP2+/- mice. Taken together, 
the following model can be proposed: abnormal APP processing leads to a 
downregulation of CYFIP2 expression which in turn may lead to over expression of 
synaptic APP expression (Fig.5.1). This model suggests a feed-forward loop for 
amyloid toxicity at synapses; it was already proposed on the grounds that FMRP 
regulates APP mRNA translation, (Westmark, 2013). Fmr1 knockout mice have 
elevated levels of APP. The synaptic and behavior impairments in Fmr1  knockout 
mice could be rescued by rescue of APP overexpression in them. At the same time, in 
primary cultured neurons, amyloid β leads to elevation of APP levels in dendrites 
(Westmark et al., 2011).These studies suggest a role of CYFIP2 both as modulator of 
local translation mechanism as well as in actin cytoskeletal dynamics. As demonstrated 
by  Bagni’s group (De Rubeis et al., 2013) for CYFIP1 involvement in both these 
respective process, as well as by Kittler’s group showing  a dysregulation of CYFIP1 
expression levels that leads to pathological changes in CNS maturation and neuronal 
connectivity( (Pathania et al., 2014), it is very likely that CYFIP2 also plays a similar 
role especially in context with AD .  
     However, to what extent does could CYFIP1 overexpression compensate for 
CYFIP2 haploinsufficiency?  A survey of literature shows that apart from similarities 
in sequences, there are considerable parallels in terms of functional role. However, 
there are differences as stated in introduction -  CYFIP2 but not CYFIP1 can interact 
with the other members of FMRP family – FXR1 and FXR2 , as well as being one of 
the molecules regulated by p53 , which is not the case with CYFIP1 . Also, the results 
from Pathania et al have shown that CYFIP1 overexpression impairs dendritic 
branching and spine morphology in hippocampal neurons (in vivo). Thus, only if 
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CYFIP1 and CYFIP2 would have exactly the same functions in the hippocampus, then 
the CYFIP1 upregulation in late AD may compensate for the CYFIP2 downregulation. 
However, CYFIP1 upregulation was not found in postmortem STG. Further, CYFIP2+/- 
mice do not upregulate CYFIP1 in the hippocampus. Thus, it is more likely that the 
CYFIP1 upregulation in late AD hippocampus represents a further wave of 




Our studies with CYFIP1/2 molecules have suggested a relevance for both CYFIPs in 
synaptic degeneration in AD , using postmortem human brain analyses and mouse 
models. Our work has confirmed the hypothesis that CYFIP family proteins are 
dysregulated in AD.  Further functional studies with CYFIP2+/- mice as well using 
Adeno Associated Virus mediated CYFIP2 (Fig.2.2) knockdown studies are planned to 































Chapter 4: CSPα may be 
neuroprotective in AD 
4.1 Introduction 
4.1.1. What is CSPα? 
 
CSPα ( Cysteine String Protein  α)  is a  34 kDa synaptically located J- Domain 
containing protein (Zhao et al., 2008). It contains an N-Terminal  J domain and a string 
of 13-15 cysteine residues in the middle region (Braun and Scheller, 1995). The 
cysteine string residues undergo palmitoylation which anchors CSPα to synaptic 
vesicles (Ohyama et al., 2007). There are two other protein variants homologous  to 
CSPα sequence in the mammalian genome – CSPβ and CSPγ (Evans et al., 2003). 
However, these proteins are not expressed in brain (Fernandez-Chacon et al., 2004)  
 
4.1.2. Discovery of CSPα 
 
CSP was discovered in Eric Buchner’s lab in Drosophila using an ‘antibody to gene 
approach’ (Zinsmaier et al., 1990) . This approach was pioneered by Seymour Benzer 
and approximately 200 Drosophila brain-specific monoclonal antibodies were isolated 
from the mice immunized with Drosophila head protein homogenates (Buchner et al., 
1988). One of these antibodies, mAb ab49, bound to the neuropils and synaptic boutons 
in the neuro-muscular junction. The recovery of antigen cDNA was carried out by 
screening a cDNA expression library from the same group. Sequencing of the cDNA 
identified a string of 11 cysteine residues leading to the name Cysteine String Protein 
(Zinsmaier et al., 1990).  The first CSP protein in vertebrates was discovered by 
Umbach’s group in Torpedo fish (Gundersen and Umbach, 1992). 
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Subsequently, three isoforms of CSP were identified in the mammalian genome – 
CSPα, CSPβ and CSPγ. CSPα and CSPβ sequences  share a  high degree of sequence 
homology with each other and with the CSP sequence identified in Drosophila (Evans 
et al., 2003).In Drosophila there is only CSP isoform in contrast  to mammals. 
 
4.1.3. What is the expression pattern of CSPα ?   
 
CSPα is present in synaptic vesicles and constitutes about 1 % of total synaptic vesicle 
protein (Eybalin et al., 2002) . It is expressed in most synapses including the 
neuromuscular junctions and is abundant in central nervous system neuropils (Evans 
and Morgan, 2005). CSPα is also present in secretory vesicles of  endocrine, 
neuroendocrine and exocrine cells (Redecker et al., 1998, Zhang et al., 1998) The 
presence of CSPα has been detected in non-neuronal tissues like liver, pancreas and  
adrenal glands (Chamberlain et al., 1996) 
 
4.1.4. What are the functions of CSPα at the synapse?  
 
CSPα  has been shown to be involved in the following  functions in neurons- (1) 
Exocytosis -  It acts as a co-chaperone of a trimeric complex by interacting  with two 
other proteins : Heat Shock Protein 70 ( Hsc 70) and small glutamine –rich TPR-
containing protein( SGT) ( Figure 4.1 a) . Thomas Sudhof’s group has shown that this 
trimeric complex is involved in exocytosis by interacting and co-chaperoning the 
SNARE proteins leading to synaptic vesicle fusion in presynaptic   terminals (Sharma 
et al., 2011). SNARE proteins are a set of synaptically localized membrane fusion 
proteins involved in the vesicle recycling mechanism in presynaptic terminals.  In 
CSPα knockout mice, the levels of SNARE proteins (like α Synuclein, SNAP-25) are 
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reduced (Chandra et al., 2005).  (2) Endocytosis – CSPα interacts with dynamin 1 and 
facilitates the polymerization of dynamin,  which is important for endocytotic  vesicle 
fission (Zhang et al., 2012) (Figure 4.1b)  (3) Modulation of calcium dependent K +  
channels ( BK channels ) -  CSPα is important for modulation of presynaptic  BK  
channel expression (Kyle et al., 2013) ( Figure 4.2). CSPα knockout mouse models 
show upregulation of BK channels and hence aberrant synaptic activity and (4) 
Modulation of presynaptic calcium levels by regulating calcium channels (Ranjan et al., 
1998). 
 
4.1.5. What are the diseases in which CSPα has been implicated?  
 
Alzheimer’s disease, Parkinson’s disease and polyglutamine diseases (such as 
Huntington’s disease), are all characterized by mis-folded protein aggregates. These 
protein aggregates have been shown to be a result of a defect in chaperone machinery 
and, indeed,  molecular chaperones can act as neuroprotective factors  (Muchowski and 
Wacker, 2005). A number of abnormally folded proteins show co-localization with 
identical molecules of a molecular chaperone system. CSPα interacting partner Hsc70 
has been shown to be  important for regulating the accumulation and toxicity of 
misfolded protein aggregates in models of Alzheimer’s,  Parkinson’s and 
polyglutamine diseases (Muchowski and Wacker, 2005, Bonini and Fortini, 2003).  
Moreover, a recent study has shown that loss of function CSPα mutations are 
responsible for a hereditary neurodegenerative condition known as adult onset 






Figure 4.1 a.  CSPα-Hsc-70-SGT complex at the presynapse . CSPα forms a trimeric 
complex by interacting with two other proteins: Heat Shock Protein 70 (Hsc 70) and 
small glutamine –rich TPR-containing protein (SGT). This complex mediates the 

















Figure 4.1 b. CSPα regulates vesicle recycling. CSPα binds dynamin 1 leading to 
dynamin polymerization, which is important for endocytosis. CSPα forms a trimeric 
complex with SGT and Hsc70 , and this complex interacts with SNAP-25 leading to 








Figure 4.2  CSPα is involved in BK channel density regulation.  CSPα modulates 
BK channel density at pre-synapse and the defect in CSPα levels impact BK channel 
density thereby regulating the excitability at synapse. CSPα knockout leads to increased 







Figure 4.3. Specific binding of anti-CSPα antibodies. CSPα knockout mouse 
(Fernandez-Chacon et al., 2004) forebrain and cerebellum lysate was probed alongside 
forebrain and cerebellum from wild type mice with anti-CSPα antibody in an 
immunoblot study. There was no signal detected from the lanes containing CSPα 







Figure 4.4. CSPα expression is increased in Alzheimer’s disease cerebellum. (A) 
CSPα expression in post-mortem cerebellum from patients with severe Alzheimer’s 
disease (n = 10; average age at death = 74.7 ± 4.0 years) and control subjects (n = 10; 
average age at death = 76.3 ± 4.2 years). CSPα expression was normalized against 
NSE. (B) CSPα expression in post-mortem cerebellum from patients with mild 
Alzheimer’s disease (n = 10; average age at death = 81.3 ± 4.1 years) and control 
subjects (n = 10). CSPα expression was normalized against NSE. (C) The same 
samples as in panel (A) were used but CSPα expression was normalized against 
synaptophysin. (D) The same samples as in panel (B) were used but CSPα expression 
was normalized against synaptophysin. Panel (E) shows the representative western 





Figure 4.5. Increased CSPαimmunostaining in Alzheimer’s disease cerebellum. 
Fixed cerebellar cortex sections from a patient with severe Alzheimer’s disease (A,B) 
and a control subject (C,D) were probed with anti-CSPα antibodies for analysis of 
CSPα expression. CSPα expression in the cerebellar cortex of the Alzheimer’s disease 
patient appeared higher than in the control subject. In A and C ,the granule cells of the 
cerebellum show increased cytoplasmic and neuropil labelling in AD as compared to an 
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age-matched control case . In B and D, cerebellar cortex with the Purkinje cell layer 
and granule cells  are visible in the lower right corner . There is increased 
immunoreactivity in the neuropil in AD as compared to an age-matched control case. 
Negative control images  are shown in E and F (immunohistochemistry with omission 
of the primary antibody) and confirm the specificity of labelling in Figure 4.5, 4.6 and 






Figure 4.6. CSPα immunostaining in cerebellum is typical for synaptic expression. 
Immunohistochemical sections of cerebellar dentate nucleus region from a control 
patient were immunostained with anti-CSPα antibodies (A) and with antibodies against 
the synaptic marker synaptophysin (B). This comparison indicated that the CSPα 
immunostaining is synaptic as obtained for synaptophysin immunostaining. Scale bars 







Figure 4.7. CSPα protein expression is reduced in Alzheimer’s disease 
hippocampus when normalized against synaptophysin. (A) CSPα expression in 
post-mortem hippocampus from patients with severe Alzheimer’s disease (Braak stages 
V and VI; n = 12; average age at death = 75.2 ± 2.0 years) and control subjects (n = 12; 
average age at death = 76.5 ± 2.9 years). CSPα expression was normalized against the 
neuron specific house keeping marker protein NSE. (B) CSPα expression in post-
mortem hippocampus from patients with mild Alzheimer’s disease (Braak stages I and 
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II; n = 12; average age at death = 80.3 ± 3.2 years) and control subjects (n = 12). CSPα 
expression was normalized against NSE. (C) The same samples as in panel (A) were 
used but CSPα expression was normalized against the synaptic marker protein 
synaptophysin (severe Alzheimer’s disease, n = 11; control, n = 11). (D) The same 
samples as in panel (B) were used but CSPα expression was normalized against 
synaptophysin (mild Alzheimer’s disease, n = 12; control, n =  
11).  Panel (E) shows the representative western blots. Means ± s.e.m. are shown. *, 

























Figure 4.8. CSPα protein expression is reduced in Alzheimer’s disease superior 
temporal gyrus. (A) CSPα expression in post-mortem STG from patients with severe 
Alzheimer’s disease (n = 13; average age at death = 73.2 ± 3.4 years) and control 
subjects (n = 12; average age at death = 76.9 ± 2.1 years). CSPα expression was 
normalized against NSE. (B) The same samples as in panel (A) were used but CSPα 
expression was normalized against synaptophysin (severe Alzheimer’s disease, n = 13; 
control, n = 12). Panel (C) shows the representative western blots. Means ± s.e.m. are 






Figure 4.9.  Normal ageing reduces CSPα expression in healthy human 
cerebellum. (A) CSPα expression in post-mortem cerebellum from healthy young (n = 
6; average age at death = 21.3 ± 1.6 years) and aged (n = 7; average age at death = 96.1 
± 1.4 years) subjects. CSPα expression was normalized against NSE. (B) The same 
samples as in panel (A) were used but CSPα expression was normalized against 
synaptophysin. Panel (C) shows the representative western blots. Means ± s.e.m. are 







Figure 4.10.  Abnormal APP processing is not sufficient to cause CSPα 
upregulation in cerebellum. (A) CSPα expression in cerebellum of 4 month-old wild-
type (n = 4) and Tg2576 mice (n = 4). (B) CSPα expression in cerebellum of 10 month-
old wild-type (n = 3) and Tg2576 mice (n = 3). CSPα expression was normalized 











Figure 4.11. Mice expressing human tau have an age-dependent CSPα 
overexpression that correlates with neuroprotection.  (A) CSPα expression in 
hippocampus of young (3-4 months) wild type (n = 6) and htau mice (n = 6). (B) CSPα 
expression in cortex of young (3-4 months) wild type (n = 6) and htau mice (n = 6). (C) 
CSPα expression in cerebellum of the same mouse  sample as in panel (A) and (B). (D) 
CSPα expression in old (24 months) wild type (n = 4) and htau mice (n = 7). CSPα 
expression was normalized against NSE in all panels. Panel (E) shows the 





Figure 4.12.  CSPα expression in cerebellum is not changed in FTLD. CSPα 
expression in post-mortem cerebellum from patients with FTLD (n = 5; average age at 
death = 73.0 ± 3.0 years) and control subjects (n = 5; average age at death = 70.2 ± 7.2 
years). CSPα expression was normalized against NSE (A). Panel (B) shows the 











4.1.6. What kind of animal models have been used to date to study 
CSPα functions? 
 
Genetic studies carried out on mice and flies have provided critical insights into the 
synaptic role of CSP.  Deletion of the CSP gene in Drosophila causes paralysis and 
decreases life expectancy (Ranjan et al., 1998, Umbach et al., 1994).  At elevated 
temperatures, there is a complete loss of evoked neurotransmitter release and the flies 
paralyze within minutes. The loss of neurotransmitter release at the CSP mutant 
neuromuscular junction can be overcome by increased extracellular Ca2+  or 
accumulated intracellular Ca2+ level  during high-frequency stimulation (Nie et al., 
1999, Bronk et al., 2005) . 
 CSPα knockout mice also develop progressive motor and sensory impairments 
leading to paralysis, blindness and premature death by postnatal day 40-60 (Chandra et 
al., 2005, Fernandez-Chacon et al., 2004). Synapses of CSPα knockout mice display an 
age dependent deterioration of synaptic function that correlates well with breakdown of 
synaptic structure and the progressing neurological symptoms.  However, as opposed to 
Drosophila, the evoked neurotransmitter release is normal in young CSPα knockout 
mice and it progressively becomes asynchronous as well as deteriorates with age 
(Fernandez-Chacon et al., 2004, Ruiz et al., 2008). By age of P30 the level of evoked 
release at mutant mice neuromuscular junctions and Calyx of Held synapses is 
quantitatively equivalent to the levels in mutant Drosophila neuromuscular junctions. 
Similar to Drosophila , in the  knockout mice  as well the evoked neurotransmitter 
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release can be restored by high extracellular Ca2+  or with high frequency stimulation 
(Ruiz et al., 2008). 
 
 
4.1.7. Previous studies in the lab that lead to identification of CSPα  
 
A previous study in the lab showed that the truncated cyclin-dependent kinase 5 
activator p25 is reduced in AD (Engmann et al., 2011). Normally, p25 generation is 
linked to the synthesis of particular synaptic proteins, synaptogenesis and memory 
formation (Engmann et al., 2011). Thus, impaired p25 generation may cause early 
synaptic dysfunction in AD. Furthermore, the mass spectrometric study of 
synaptosomal fractions from P25 transgenic mice demonstrated that p25 generation 
regulates expression of the synaptic chaperone protein cysteine string protein (CSP)α 
(Engmann et al., 2011). 
 Based on the studies of neuroprotective mechanism of CSPα published in 
literature, we developed and began to explore the hypothesis that: CSPα might be 
involved in neuroprotective mechanisms in AD 
To investigate this hypothesis we performed case-control studies with post mortem 
brain tissues and with brain tissues from animal models of AD as described previously 
in chapter 2 ( Methods).  
Our objectives for this study were –  
1) To investigate the  relevance of CSPα in Alzheimer’s disease by performing 
a case-control study using post-mortem brain tissues to analyse the levels of 




2) To investigate the relevance of CSPα in cognitive decline associated with 
normal aging by analyzing the levels of CSPα in  postmortem brain from 
young and aged subjects 
3) To  find a suitable mice model of AD that replicates the CSPα results 




4.2.1. CSPα is upregulated in Cerebellum 
 
Cerebellar regions are one of the least affected regions in AD pathology (Larner, 1997). 
Though diffused amyloid plaques  and  increased microglia have been reported, there is 
no neurofibrillary tangle pathology reported in the cerebellum (Larner, 1997) . Further, 
motor disturbances that can be assigned to cerebellar dysfunction are not observed in 
AD. These features suggest that there are mechanisms in cerebellar regions that provide 
neuroprotection against AD and hence make it a good internal control in case-control 
study of AD patients. To investigate if CSPα could be one of the factors that might be 
playing a role in the neuroprotective mechanism in cerebellar regions in AD, we 
performed case-control studies on cerebellum. 
       We obtained cerebellar samples of severe AD cases and controls in two sets from 
the London Neurodegenerative Diseases brain bank. For the mild cases, the patient 
samples were obtained in one set. The details of the patient samples have been provided 
in Table.2.1. We tried to obtain the samples with lowest possible post-mortem delays.  
Since the immunoblots from two sets were analyzed on different scanners, the data 
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obtained from them was pooled together and analyzed using regression statistics 
described in Chapter 2.  
 
    We investigated the levels of CSPα in post-mortem cerebellum from severe AD 
patients and compared with controls, using western blot analysis. The normalization 
was carried out with NSE and synaptophysin (Fig. 4.4. A, C). In both cases CSPα 
levels were significantly increased by about 50% (referring to NSE expression: 
F(2,17)=2.761; p<0.05; referring to synaptophysin expression: F(2,17)=5.281, p<0.01). 
This surprising finding suggested that already in early AD there could be an 
upregulation of CSPα expression in cerebellum. Therefore, we also analysed CSPα 
expression in mild AD (Fig. 4.4.B, D). We found that the levels of CSPα were 
significantly increased in the cerebellum when normalized with both NSE and 
synaptophysin (referring to NSE expression:F(2,17)=7.245; p<0.05; referring to 
synaptophysin expression: F(2,17)=4.179, p<0.05)( Fig.4.7). This finding was opposite 
to the changes observed in hippocampus of mild AD patients.  
 
4.2.2. Immunohistochemical studies 
 
To further investigate cellular localization of CSPα, qualitative immunohistochemical 
studies were performed on cerebellar sections from an AD case and control. To confirm 
the cerebellar expression changes, we carried out a qualitative immunohistochemical 
analysis with post-mortem cerebellar cortical tissues from one severe AD patient (n=1) 
and one control subject (n=1) (Fig. 4.5). A neuropathologist blind to the disease state of 
the tissue performed a qualitative comparison of CSPα signal. A similar comparison 
was carried out with hippocampal and STG sections of control (n=1) and AD patients 
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(n=1) ( Fig.S1).  This qualitative comparison confirmed an increase in CSPα levels in 
cerebellum in severe AD compared to a healthy control case as well as a decrease of 
CSPα in forebrain of severe AD patients.   
 
 
4.2.3. CSPα has synaptic expression 
 
To validate the synaptic specificity of the anti-CSPα antibodies, the 
immunohistochemistry was compared with synaptophysin expression patterns (Fig.4. 
6). Staining of cerebellar dentate nucleus from a control subject showed similar results 
with both antibodies, confirming that the CSPα immunostaining was typical for 
synaptic staining and is increased in AD.   
 
4.2.4. CSPα is downregulated in the hippocampus 
 
The hippocampus  is one of the first and most severely affected regions  in the brain 
during the course of AD progression  (Braak and Braak, 1991a). AD onset is 
characterized by the loss of memory and defects in cognitive skills. These defects are 
attributed to the loss of synapses at the onset of AD. Synaptic loss precedes the 
neuronal loss. Based on this, we decided to analyze the changes in the levels of CSPα 
in hippocampal neurons.  
      We obtained hippocampal samples of severe AD cases and controls in two sets 
from the London Neurodegenerative Diseases brain bank. For the mild cases, the 
patient samples were obtained in one set. The details of the patient samples have been 
provided in Table.2.1. We tried to obtain the samples with lowest possible post mortem 
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delays.  Since the immunoblots from two sets were analyzed on different scanners, the 
data obtained from them was pooled together and analyzed using regression statistics 
described in Chapter 2.  
      We first studied whether, in the late stages of AD, CSPα protein expression in the 
hippocampus is affected, comparing post-mortem samples from severe AD patients and 
control subjects in a western analysis. As with the Cerebellum, the CSPα expression 
was normalized to either the neuronal marker NSE or the synaptic marker 
synaptophysin (Fig. 4.7. A, C). In both cases CSPα levels were significantly decreased 
in the hippocampus of severe AD patients (referring to NSE expression: 
F(2,21)=21.287; p<0.01; referring to synaptophysin expression: F(2,19)=14.622, 
p<0.05). This result suggests that in severe AD CSPα expression is not simply reduced 
due to neuronal or synaptic loss, and it suggests that reduced CSPα may precede 
synaptic loss during AD progression. Therefore, we also analysed CSPα expression in 
mild AD (Fig. 4.7. B, D). Western analysis revealed a significant decrease in CSPα 
levels in the hippocampus of patients when normalized with synaptophysin 
(F(2,20=4.257; P<0.05), but showed no difference when normalized with NSE 
(F(2,21=0.366, p=0.427), which indicates that the drop in CSPα level in hippocampus 
is an early event in AD. 
 
4.2.5. CSPα is downregulated in the Superior Temporal Gyrus 
 
After investigating the expression of CSPα in hippocampus, which is the earliest as 
well as most severely affected in AD, we studied CSPα expression in the superior 
temporal gyrus (STG), which is affected later at moderate stages of the disease and less 
severely than the hippocampus (Braak and Braak, 1991a) .  
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In a western blot analysis we compared CSPα expression in post-mortem STG from 
severe AD patients and controls. The level of CSPα expression was normalised with 
NSE or synaptophysin (Fig. 4.8). In both cases there was a significant reduction in 
CSPα expression (referring to NSE expression: F (2,22)=14.827; p<0.01; referring to 
synaptophysin expression: F(2,22)=7.481, p<0.001), similar to the result seen in the 
hippocampus (Fig. 4.8. A, C). 
 
4.2.6. CSPα decreases during ageing in the cerebellum 
 
The increased CSPα expression in the cerebellum in AD patient tissue indicates that 
CSPα expression is plastic. This raised the question as to whether normal ageing also 
regulates CSPα expression in the cerebellum.   
To investigate this, we analysed the cerebellar lysates from healthy subjects belonging 
to two age groups, 15-30 years and 90-105 years (Fig. 4.9).Normalization with NSE 
showed that normal ageing significantly downregulates CSPα expression by approx. 
50%  in the cerebellum (t =2.443 ; p<0.05 ). When normalized to synaptophysin levels 
the average CSPα expression in the aged cerebellum was much smaller than in the 
young cerebellum, although this did not reach significance (t=1.351 ; p=0.234), due to 
large variability  in young cerebellum . Taken together, we found an age-dependent 
decrease of CSPα expression in healthy cerebellum samples. Interestingly, the CSPα 
expression level in AD cerebellum is similar to the expression level in young healthy 
cerebellum. 
 




Mouse models are useful to investigate some mechanisms of AD. However, not all 
aspects of AD can be modelled in mice, possibly due to the short life span of the mice. 
We studied whether abnormal APP processing in the cerebellum is sufficient to induce 
CSPα upregulation, using Tg2576 mice, a widely used mouse model for abnormal APP 
processing.  
We performed a western blot analysis at two age points, 4 and 10 months (Fig.4.10).  
At 4 months of age Tg2576 mice do not have amyloid plaques but have some memory 
impairment, whereas at 10 months of age Tg2576 mice memory deficits are more 
pronounced and amyloid plaques are detectable(Hsiao et al., 1996, Stewart et al., 
2011).  CSPα expression in cerebellum at both ages was normalized against NSE as 
well as synaptophysin.  This comparison did not reveal any significant difference 
between genotypes (p=0.169). Therefore, abnormal APP processing does not appear to 
be sufficient to cause CSPα upregulation in cerebellum.   
A similar study was carried out with the forebrain of 4 month and 10-12 month old 
mice forebrain lysates (Fig S2). There was no change in the forebrain CSPα level at 4 
month ( t=1.935 , p =0.101 ) or 12 month  (t= -0.449 , p= 0.672 ) stage of Tg2576 
mice. 
 
4.2.8. CSPα shows age dependent downregulation  in htau mouse 
forebrain 
 
Neurofibrillary tangles (NFT) and hyperphosphorylated tau are the other hallmarks of 
Alzheimer’s disease apart from amyloid plaques.  Formation of NFTs leads to neuronal 
loss.  We investigated the levels of CSPα in a mouse model overexpressing human tau 
(Andorfer et al., 2005)- the htau mice. These mice progressively develop 
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hyperphosphorylated tau and neurofibrillary tangles, predominantly in the cortex and 
hippocampus and widespread neuronal loss is apparent in aged mice (Andorfer et al., 
2003, Kelleher et al., 2007). The tau pathology is visible from 3 weeks of age, but the 
neuronal loss starts from 17 months onwards.  
     We looked at CSPα levels in the hippocampus (Fig. 4.11 A), frontal cortex (Fig. 
4.11 B) and cerebellum (Fig.4.11 C) of these mice at 3- 4 months of age. At the same 
time we also looked at CSPα levels at 24 months age in hippocampal-cortical lysates of 
these mice (Fig.4.11 D). We were unable to procure the cerebellar tissues of these mice 
at the 24 month age time point. 
     The samples were normalised with NSE levels. We saw a significant upregulation of 
CSPα levels in hippocampus (Fig.4.11 A,  t=6.539 , p<0.001) , frontal cortex ( Fig.4.11 
B , t=8.005, p<0.001)  and cerebellum (Fig. 4.11 C,  t=5.200 , p < 0.001)  in the mice 
at the 3-4 month time point. At this stage there is no neuronal loss in these mice and the 
result replicates the result observed in the cerebellum of AD patients. At 24 months of 
age, there is no difference in the levels of CSPα between hippocampal –cortical regions 
from wild type and from htau mice (Fig.4.11 D. t = -0.220, p =0.831). This result 
suggests that a CSPα based neuroprotective mechanism that was preventing neuronal 
loss in the hippocampal-cortical region in the younger age (inspite of the presence of 
tau pathology), is eliminated in the old age, possibly making the neurons more prone to 
tau based toxicity.  The cerebellum at the young age is protected by elevated CSPα 
level as in humans. 
To study the levels of previously studied CYFIP protein in Htau mouse, all the mouse 
tissue samples in figure 4.11 were probed with anti CYFIP2 and anti CYFIP1 
antibodies. The CYFIP2 levels in the membranes with htau forebrain lysates were 
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undetectable (Fig.3.15). CYFIP1 levels did not change in htau mice forebrain or 
cerebellum at any age point ( Fig.3.7) 
 
4.2.9. CSPα is unchanged in FTLD cerebellum 
 
Frontotemporal lobar degeneration (FTLD) is a prominent form of dementia that is 
characterized by  neurodegeneration of the frontotemporal region(Cruts et al., 2013). 
Additionally, as opposed to AD, the cerebellum may be affected (King et al., 2009).  
      We performed a western blot analysis to study whether altered CSPα expression is 
linked to neuropathology of the cerebellum in FTLD (Fig. 4.12). CSPα levels were 
normalized with NSE, and no significant difference was found (t= - 0.373, p=0.719). 




The main findings of our study are that 1) expression of CSPα is reduced in 
degenerating forebrain in mild and severe AD, and 2) CSPα expression is upregulated 
in AD cerebellum, a brain region not affected in AD. Taken together, these findings 
link CSPα expression with neurodegeneration, and suggest that CSPα upregulation may 
be neuroprotective.  
 CSPα is a p25-regulated protein, and we have previously shown that p25 
expression is downregulated in AD forebrain (Engmann et al., 2011). In addition, CSPα 
mutations cause a hereditary neurodegenerative condition (Benitez et al., 2011). We 
therefore hypothesized that CSPα expression could be altered in AD. Here, we confirm 
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this hypothesis. We found that CSPα expression is reduced in hippocampus and STG in 
severe AD when normalized to expression of a neuronal or synaptic marker. This 
finding is consistent with another study, which was published after we started our 
project, showing that in Brodmann area 9 of severe AD CSPα expression is reduced by 
about 40% (Zhang et al., 2012). Furthermore, we also detected a downregulation of 
CSPα expression in hippocampus in mild AD when CSPα amounts were normalized to 
the synaptic marker synaptophysin. Traditionally, synaptophysin is used as a marker of 
synaptic degeneration in AD (Arendt, 2009). However, our finding that CSPα levels are 
reduced prior to noticeable changes in synaptophysin expression, and considering the 
importance of CSPα for synaptic function (Fernandez-Chacon et al., 2004), indicates 
that CSPα is likely to be a better marker of synaptic degeneration than synaptophysin. 
We obtained double bands of CSPα in our immunoblot studies and for quantification 
and analysis of the toal CSPα amount both the bands were included. The presence of 
double bands in our CSPα blots have been reported by and explained by studies from 
other groups. The specificity study of our antibodies with CSP α knockout mouse have 
shown that both the bands are from CSP α isoform and not the beta or gamma isoform 
of CSP α (Fig.4.3). The double bands in our CSP α blot could be explained by two 
posttranslational event that CSP α goes through. Palmitoylation in CSP α has been 
described in great detail in previous reports and this posttranslational modification is 
important for intracellular functions of CSP α (Greaves et al., 2008). CSP  undergoes 
extensive palmitoylation on 14  cysteine residues present within central cysteine rich 
domain(Umbach et al., 1994). The palmitoylated form is essential for sorting of CSP α, 
though the mechanism is not yet well understood (Greaves and Chamberlain, 2007, 
Greaves et al., 2008). To determine, which band to study, at the start of the project, I 
analyzed the level of difference in either palmitoylated or unpalmitoylated protein 
states between cases and control. However, the ratio of playmitoylated versus 
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unpalmitoylated protein varies with the individual cases having a degree of standard 
deviation which made the difference between patient versus control insignificant.  
Hence, I analyzed the total CSP α level, irrespective of their palmitoylation status. 
The second posttranslational event is oligomerization of CSP α which might be 
important for its role in synapses (Swayne et al., 2003). In my studies, I have only 
encountered double bands and the higher band was always less than 70 kD (a CSP α 
dimer molecular weight ), so the oligomeric CSP α was either present in undetectable 
amount in my samples or was cleaved to the monomeric form during sample 
preparation.  
 
 CSPα, along with its interacting partners Hsc-70 and SGT, is involved in 
exocytotic mechanisms in pre-synaptic terminals that are mediated by its interactions 
with SNARE complexes (Evans et al., 2003). Downregulation of CSPα may therefore 
lead to reductions in the number of synaptic vesicles binding at presynaptic 
membranes, thereby affecting synaptic activity. Further, CSP α is also important for 
endocytosis of synaptic vesicles. CSPα interacts with dynamin to facilitate dynamin 
polymerization which is important for endocytotic vesicle fission (Rozas et al., 2012, 
Zhang et al., 2012). This is important for normal synaptic function since the number of 
synaptic vesicles readily available for exocytosis is reduced when there are defects in 
endocytotic fission (Wu et al., 2009).  This suggests that defects observed in exocytotic 
mechanisms in CSPα knockout mice could be explained by deficits in CSPα-dependent 
endocytotic mechanisms. Hence, CSPα downregulation could lead to loss of function at 
different stages of synaptic vesicular recycling to contribute to synaptic loss. 
Additionally, reduced CSPα expression is expected to increase BK channel density at 
synapses, which reduces excitability at presynaptic terminals (Kyle et al., 2013). Loss 
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of synaptic activity is thought to be lethal for synapses, therefore, the downregulation in 
CSPα expression we observe in AD hippocampus could be closely associated with 
synaptic degeneration and the resulting impaired memory formation in early AD.  
 CSPα modulates the calcium dependent K+ (BK ) channel expression and 
current density (Kyle et al., 2013). CSPα knockout mice show aberrant activity due to 
increased BK channel expression at synapses. This contributes to synaptic degeneration 
and neuronal loss. Animal models of AD display epileptic seizures and network 
dysfunctions, (Palop and Mucke, 2010, Palop et al., 2007) and, based on our results, it 
is highly likely that the decrease in CSPα levels in cortical regions may lead to aberrant 
network functions of cortical circuits by dysregulation of BK channel expression at 
synapses. 
 The second major finding from our study is the identification of CSPα 
overexpression in AD cerebellum. The cerebellum is relatively protected from 
neurodegeneration in AD. For example, there is no synaptic and neuronal loss in this 
area, although there are some diffuse amyloid plaques present in the cerebellum 
(Larner, 1997). The molecular mechanisms that impart neuroprotection to the 
cerebellum in AD are not known.  Our results suggest that CSPα may be one of the 
factors contributing to this neuroprotection. We observed an overexpression of CSPα in 
cerebellum in mild and severe AD. Importantly, we found that the level of 
overexpression in this region is comparable to the amount of CSPα expression detected 
in young, healthy cerebellum, in contrast to an age-dependent decrease in CSPα 
expression in normal cerebellum. Additional experimental support for the suggestion 
that CSPα overexpression could be neuroprotective comes from our analysis of CSPα 
expression in cerebellum from patients with FTLD. These patients have 
neuropathology in the cerebellum unlike AD patients (Al-Sarraj et al., 2011; King et 
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al., 2013). This report mentions the FTLD cases with C9orf72 hexanucleotide repeat. 
However, this suggests that FTLD effects cerebellum as opposed to AD. We found that 
CSPα expression is unchanged in degenerating FTLD cerebellum, thereby supporting 
our hypothesis. Additional support for our hypothesis comes from analysis of htau 
mutant mice, where we found that CSPα overexpression occurs only at times when no 
neuronal loss is observed. Taken together, the evidence we present here suggests that 
CSPα overexpression in AD cerebellum may be neuroprotective and additional 
functional studies are needed to investigate this hypothesis. 
 How could CSPα overexpression protect synapses and consequently neurons in 
AD cerebellum? In AD forebrain, amyloid-induced aberrations in synaptic activity are 
one of the causes of synaptic toxicity (Westmark, 2013). In particular, dysfunctional 
synaptic machinery could be an after-effect of impaired synaptic vesicle trafficking. 
Chang’s group has shown that amyloid β oligomers impair synaptic vesicle recycling 
by hindering endocytosis as well as the formation of fusion-competent vesicles (Park et 
al., 2013). Considering the role of CSPα in endocytosis and vesicle recycling, an 
upregulation of CSPα in AD cerebellum could be a compensatory mechanism that 
prevents impairments in synaptic vesicle recycling that are induced by factors causing 
AD. This would result in protection of synapses and neurons from degeneration. Also, 
the effect of CSPα in modulating BK channel activity could also be important for 
protection from neurodegeneration.  CSPα knockout mice have an increase in BK 
channel density which causes synaptic and neuronal loss (Kyle et al., 2013), therefore, 
an upregulation of CSPα protein at synapses in AD cerebellum may lead to 
maintenance of normal BK channel density, hence avoiding any damage to the synaptic 






Our studies have shown that CSPα is an early marker for synaptic degeneration in AD 
forebrain, and suggest that CSPα overexpression is neuroprotective in AD cerebellum. 
CSPα is a synapse-specific protein that has multiple functions at the presynapse. Thus, 
our results are in agreement with the idea that presynaptic degeneration is pivotal in 
AD, as suggested by studies using transgenic mouse models of AD (Zhang et al., 
2009). Further functional studies with CSPα knockout and overexpression models will 








































Chapter 5: Discussion 
5.1. Revisiting the questions  
 
AD is a devastating neurodegenerative condition and an increasing number of reports 
have shown that synaptotoxicity is one the first pathological changes apparent in AD, 
preceding neuronal loss and leading to the emergence of cognitive as well as memory 
impairments (Arendt, 2009). However, the molecular mechanisms leading to this 
synaptotoxicity are not yet fully known. The broad theme of this PhD study was to 
investigate novel molecular mechanisms leading to degeneration of synapses in AD.  
P25 is a Cdk5 activator that has been shown to be an important molecule in AD onset 
by several groups (Tandon et al., 2003, Engmann et al., 2011, Yoo and Lubec, 2001). 
Our lab has previously shown that p25 levels are downregulated in the post-mortem 
early-stage AD brain (Engmann et al., 2011). Furthermore, p25 is generated during 
memory formation and it is linked with synaptogenesis (Engmann et al., 2011). A mass 
spectrometric study of synaptosomes isolated from p25 transgenic mice identified 
proteins that are regulated by p25 and that may also be dysregulated in AD and 
therefore could contribute to synaptic degeneration in AD (Giese, 2014). 
 With the broad aim of identifying the novel molecular mechanisms of synaptic 
pathology in AD, we screened molecules from the aforementioned mass spectrometric 
study  and began to focus on CYFIP2,  since amounts of this protein were significantly 
altered in synaptosomes prepared from male p25 transgenic mice relative to wild-types 
(Engmann et al., 2011). CYFIP2, and the structurally related protein CYFIP1, bind to 
the mRNA binding protein FMRP that regulates local translation of dendritic/synaptic 
mRNA, including APP encoding mRNA (Westmark and Malter, 2007). This suggested 
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the hypothesis that dysregulation of local translation may lead to synaptotoxicity in 
AD. CYFIP1 being a member of the same family as CYFIP2 was also a molecule for 
interest for us. Within the framework of this broad hypothesis, we decided the 
following objectives for our project –  
1)  To investigate the relevance of CYFIP1/2 in Alzheimer’s disease by 
performing a case-control study using post-mortem brain tissues to analyze the 
levels of CYFIP1/2 in different regions of the brain at different stages of 
Alzheimer’s disease. 
2) To investigate the relevance of CYFIP1/2 in cognitive decline associated 
with normal aging by analyzing the levels of CYFIP1/2 in postmortem brain 
from young and aged subjects. 
3) To investigate the validity of the hypothesis that functional compensation 
between CYFIP1 and CYFIP2 may exist by biochemical analysis of brain 
tissue lysates from CYFIP2 heterozygote mice. 
4)  To understand the role of CYFIP2 in memory as well as dementia 
associated with Alzheimer’s disease by behavioral testing of CYFIP2 
heterozygous knockout mice. 
In the same mass spectrometric study with p25 transgenic mice mentioned before, 
another molecule that showed a marked difference in female p25 transgenic mouse 
versus wild-type mice was CSPα. Since, both CYFIP and CSPα have no reported linkage 
to sex chromosomes and have never been reported to have an association with the sex of 
the animal, we concluded that this sex associated difference (with synaptosomes from 
male p25 mice showing the largest increase in CYFIP2 and synaptosomes from female 
p25 mice showing the largest increase in CSPα) might be a result of noise from the 
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experiment. Mouse model studies have implicated CSPα in synaptic degeneration but it 
was unknown whether CSPα expression is altered in Alzheimer’s disease. We not only 
found that CSPα expression is downregulated in post-mortem AD forebrain, we also 
identified an upregulation of CSPα in post-mortem cerebellum of AD patients – a 
relatively protected brain region in AD.  Hence, we hypothesized that CSPα might be 
neuroprotective in AD.  To study this second protein, we added the following objectives 
for this project – 
1)  To investigate the  relevance of CSPα in Alzheimer’s disease by performing 
a case-control study using post-mortem brain tissues to analyze the levels of 
CSPα in different regions of the brain at different stages of Alzheimer’s 
disease 
2) To investigate the relevance of CSPα in cognitive decline associated with 
normal aging by analyzing the levels of CSPα in postmortem brain from young 
and aged subjects 
3)  To find a suitable mice model of AD that replicates the CSPα results 
observed in postmortem human brain tissue for future studies 
Hence, we have tried to look for answers to these questions in this study and in doing 
so, we discovered some novel molecular mechanisms that likely contribute to 






5.2. Answers for discussion 
 
5.2.1. Dysregulation of p25 regulated molecules was observed in AD 
postmortem brain tissues 
 
Our screening of CYFIP1/2 and CSPα molecules through western blot analysis of post-
mortem brain (case-control studies) has yielded several interesting results about these 
synaptic molecules in AD.  In the hippocampus, there is a trend of downregulation of 
CYFIP2 in the early stages of AD and this downregulation becomes significant in the 
severe stages of the disease. CYFIP1 expression, on the other hand, does not change in 
the early stages of disease but it is significantly decreased in the severe stages. CSPα , 
which is a pre-synaptic molecule as opposed to post-synaptically reported CYFIP , also 
shows a significant downregulation (with respect to a synaptic marker –synaptophysin ) 
in the hippocampus in the early stages of disease and stays reduced up to and including 
the severe stages of disease (with respect to a synaptic marker – synaptophysin and a 
neuronal marker- NSE). This finding shows that CSPα could be a more sensitive 
marker for synaptic degeneration in the early stages of AD than synaptophysin.  
 We also analysed the expression of these molecules in the STG, a brain region 
that is affected later in the progression of AD. CYFIP2 expression is downregulated in 
severe AD STG, whereas CYFIP1 amounts do not change in this brain area at any stage 
of disease. Similar to CYFIP2 expression, CSPα expression is downregulated in the 
STG at severe stages of AD.  
 The downregulation of the p25-regulated proteins CSPα and CYFIP2 in post-
mortem AD forebrain that was identified here suggests that these proteins could 
contribute to synaptic degeneration in the disease. If this assumption is correct, then 
this would suggest that synapses in AD forebrain undergo differential degeneration 
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processes – which means that the mechanism that are impaired and lead to the amyloid 
induced synaptic toxicity on the pre and post synaptic side are different.  Pre- and post-
synaptic degeneration in AD is consistent with the observation that oligomeric amyloid 
peptide binds to both sides of the synapse (Dinamarca et al., 2012, Russell et al., 2012). 
 The cerebellum is a relatively protected region in AD, hence it was used as a 
control tissue in our case-control studies. We studied all three molecules in post-
mortem AD cerebellum. Surprisingly, CSPα expression was significantly upregulated 
in cerebellum in the mild and severe stages of the disease. This finding was confirmed 
with qualitative immunohistochemical analysis. No changes in the expression levels of 
CYFIP1 were detected in control, mild or severe AD cerebellum relative to control 
brain. As reported by some other authors in literature (Hoeffer et al., 2012), CYFIP2 
expression level was undetectable in cerebellum and hence couldn’t be quantified in 
this tissue.   
 CSPα expression was also studied in the cerebellar region from FTLD patients 
where cerebellar pathology has been observed, as an additional control. CSPα levels 
were not changed in FTLD tissue relative to control brain. 
 Another important question was to look for the effect of ageing on the 
expression of these molecules. Since only cerebellar tissues were available from young 
control patients, we screened CYFIP1 and CSPα in cerebellar postmortem tissues from 
young (<30 years) and old (> 90 years) patients.  There were no changes in CYFIP1 
amounts with ageing in healthy cerebellum. However, CSPα levels in healthy 
cerebellum were found to decrease with ageing. 
 The differential expression of CSPα in AD versus control cerebellum, and in the 
cerebellum during normal aging suggests the novel hypothesis that CSPα may be 
neuroprotective for synapses.  
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An important question that can be raised here is about the impact of postmortem delay 
(PMD), age of patients, gender of patients and pH of the tissues, on our results. In this 
study, we have tried to acquire the samples with lowest PMD that were available to us 
and as far as possible; we used the samples with PMD of less than 24 hours. Since the 
data used in this project involved pooling the data from two different sets, and hence 
utilized the regression analysis model for statistical studies, it was not suitable to 
perform a co-relation study between different aforesaid parameters and the protein 
levels observed in post-mortem tissues.  Hence, I adopted the strategy of comparing the 
significant difference between the age, PMD and Gender (nonparametric analysis) of 
patient samples grouped into different pathological state of disease– control, mild, 
severe AD. The analysis for pH couldn’t be performed as some of the samples I used in 
my study were from a previous published study in lab where the pH data was not 
recorded or analysed. Statistical analysis discussed in Chapter 2 (section 2.9) shows 
that the impact of PMD, age and gender of the patient is statistically insignificant and 
these parameters have not affected our results.  
  Since the differential results we have obtained for CYFIP1 and CYFIP2 are 
from the same patient samples and same tissues region, and CYFIP2 levels were 
downregulated in forebrain but at the same time CYFIP1 was upregulated in forebrain, 
therefore it is highly unlikely that PMD is skewing our results in any particular 
direction. Also, CSPα from the same patient samples showed downregulation in 
cerebellar regions whereas it was upregulated in the forebrain. Furthermore, the results 
from analysis of CYFIP (1/2) and CSPα amounts show that wide-spread proteolytic 
degradation due to PMD have not influenced our results since in the same tissue 
regions from same patients we observed upregulation of one protein and 
downregulation of the other. One of the experiments that could have been ideally 
performed was to analyze the impact of PMD on CYFIP and CSP degradation using 
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5.2.2. Different mouse models of AD confirmed the results observed 
obtained from postmortem brain 
 
We next investigated if the expression changes observed in post-mortem AD brain 
could be replicated in mouse models of AD. We first studied CYFIP1, CYFIP2 and 
CSPα expression in the Tg2576 mouse model of AD that has abnormal APP processing 
and deposits Aβ in senile plaques with age (Hsiao et al., 1996) .  The CYFIP1/2 
molecules showed an age-dependent decline in expression in the hippocampus and 
associated cortex of Tg2576 mice relative to background controls, with no changes 
detectable at 4 months of age, but significant reductions in CYFIP1/2 expression at 12 
months of age, an age at which cognitive decline as well as amyloid plaque pathology 
has been reported in this mouse model. Thus, Tg2576 mice model the CYFIP2 
downregulation observed in post-mortem AD brain, but they do not model the 
upregulation of CYFIP1 expression observed in post-mortem AD hippocampus. 
Furthermore, analysis of CSPα expression in Tg2576 cerebellum (both at 4 months and 
10 months of age) did not show any changes in protein expression when compared to 
age-matched wild-type mice. Thus, it seems that abnormal APP processing on its own 
is insufficient to cause upregulation of CYFIP1 in the hippocampus or to upregulate 
CSPα expression in cerebellum, whereas it appears to be sufficient for modelling the 
CYFIP2 downregulation observed in AD brain.  Since CYFIP2 downregulation is an 
early event in AD, 10 month-old Tg2576 mice could be a good model for examining 
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the early stages of AD. It is conceivable that Tg2576 mice do not model AD accurately 
since they still express endogenous mouse APP. Thus, transgene expression will not 
only result in abnormal APP processing but also in an overexpression of C-terminal 
fragments. A very recent paper has shown that knock-in of the Swedish APP mutations 
results in a different phenotype from that observed in Tg2576 mice (Saito et al., 2014). 
However, these knock-in mutants do not develop memory impairment at 18 months of 
age, suggesting that the life span of mice is too short to fully model AD. 
  Since the CSPα upregulation observed in AD cerebellum was not modelled in 
Tg2576 mice, we studied another mouse model of AD, which does not develop 
amyloid pathology, but instead develops AD-like tau pathology- the htau mouse model. 
CSPα  expression was analyzed at two time points in forebrain tissue from these mice –  
at 3/4 months of age when there is no neuronal loss but visible tau pathology,  and at 24 
months of age, a time point when there is cognitive deficits, neuronal loss and tau 
pathology (Andorfer et al., 2003, Polydoro et al., 2009). There was an upregulation of 
CSPα in the forebrain of young htau mice, but at older ages when neuronal loss occurs, 
this upregulation is absent. In the cerebellum of young htau mice this upregulation was 
also observed. Hence, htau mice model the CSPα upregulation observed in AD 
cerebellum and this upregulation again correlates with a stage of disease which 
precedes substantial neuronal loss. This again suggests that CSPα may play a role in 
protecting tissues from neuronal loss.  
 
5.2.3. CYFIP2 functional study revealed its significance for synaptic 




 To understand the mechanistic relevance of the p25 downregulated molecules in AD, 
amongst the three candidate molecules identified (CYFIP1, CYFIP2 and CSPα), we 
focused on CYFIP2 – the least studied of them yet. We performed functional studies 
with CYFIP2+/- mutant mice that are heterozygous for a null mutation. Homozygous 
CYFIP2 knockout mice are lethal at embryonic stage. We showed that the 
heterozygotes express reduced CYFIP2 amounts in crude synaptosome fractions, 
without showing any changes in CYFIP1 expression. Fear conditioning studies have 
demonstrated that these mice are significantly impaired in retaining memory after cued 
fear conditioning. Hence, downregulation of CYFIP2 by about 50 % (as observed in the 
AD postmortem brain in mild and severe stages as well as in aged Tg2576 animal 
model) is likely to lead to memory loss. Further follow-up studies in this lab have 
shown that this behavioural readout correlates with altered synapse morphology 
(reduction in stable, mushroom dendritic spines and increase in ‘immature’ long thin 
spines) and protein expression (upregulation of APP protein expression in 
synaptosomes). Hence, these results suggest that reduced levels of CYFIP2 expression 
contribute to memory impairments in AD.  
 
5.3. CYFIP2 and CSPα  downregulation follows p25 
downregulation in the forebrain of mild AD  
  
In a previously published study from the Giese group, it was shown that the p25 is 
downregulated in AD at the mild stage of disease (Engmann et al., 2011).  CYFIP2 and 
CSPα were shown to be candidate p25-regulated molecules from a mass spectrometric 
analysis of brain from p25 transgenic mice. In this PhD project it has been shown that 
CYFIP2 as well as CSPα are downregulated in forebrain regions in the early stages of 
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AD, and this downregulation persists until the severe stages of disease. Hence, it can be 
inferred that downregulation of p25 in the forebrain in the mild stages of AD leads to 
the downregulation of CSPα in pre-synaptic sites and CYFIP2 in the post-synaptic side. 
The p25 dowregulation itself could be an amyloid-induced mechanism but this has yet 
to be investigated. 
 A question that could be raised here is why CYFIP2 but not CSPα 
downregulation is modelled in Tg2576 mice? Tg2576 mice model abnormal APP 
processing, which is only part of the AD pathophysiology seen in human disease. For 
example, these mice do not have substantial changes in tau processing, develop NFTs 
or show marked neuronal loss. In contrast to Tg2576 mice, htau mice, which 
recapitulate many tau aspects of human AD, model the CSPα downregulation observed 
in AD forebrain. Hence, it is likely that abnormal APP processing is not sufficient for 
CSPα downregulation and that modulation of CSPα amounts may involve some 
mechanism downstream of APP processing that is more relevant to the development of 
tau pathology. 
 
5.4. CYFIP1 upregulation may be a second wave of 
neurodegeneration 
 
CYFIP1 expression is upregulated in the severe stages of AD and this upregulation was 
found only in the post-mortem hippocampus.  Since CYFIP1 and CYFIP2 are very 
similar proteins, it is likely that these proteins can compensate for each others function, 
although CYFIP2 and not CYFIP1 can bind to FXR1 and FXR2 (Schenck et al., 2001, 
Napoli et al., 2008). Furthermore, CYFIP1 downregulation and overexpression have 
similar, not opposite, effects on dendritic branching  (Pathania et al., 2014). We 
168 
 
therefore tested whether a reduction of CYFIP2 expression can induce an upregulation 
of CYFIP1 expression, using CYFIP2+/- mice. In hippocampal synaptosomes of the 
mutant mice there was no upregulation of CYFIP1, demonstrating that reduced 
CYFIP2 does not cause CYFIP1 upregulation. A collaborative study conducted in 
parallel to this project has shown that overexpression of CYFIP1 appears to be toxic in 
vitro. Since the most neuronal loss occurs in the hippocampus in end-stage AD, we can 
infer that CYFIP1 upregulation may be a factor contributing to neurodegeneration and 
it might represent a second wave of neurotoxic processes that emerge in the severe 
stages of AD. This conclusion is strengthened by the results obtained from analysis of 
brain tissues from aged Tg2576 mice. As discussed before, aged Tg2586 mice display 
CYFIP2 downregulation similar to that observed in the mild stages of AD.  
Furthermore, there is no CYFIP1 upregulation in this mouse model and no neuronal 
loss. It is conceivable that upregulation of CYFIP1 expression is needed to cause 
neuronal cytotoxicity and that this is lacking in Tg2576 mice. However, to what extent 
CYFIP1 upregulation is p25-dependent and what factors are downstream of CYFIP1 
upregulation is a question to be addressed in future studies.  
 
5.5. A p25-CYFIP2-CSPα feed-forward model of AD 
synaptotoxicity 
 
How can we mechanistically explain all the results from this PhD study? The results 
from our studies have led us to propose a feed-forward model similar to the one 
proposed by Westmark (Westmark, 2013) (Fig.1.3) but including novel insights from 
this study. According to this p25-CYFIP2-CSPα model - in the milder stages of AD, 
there is a downregulation of p25 molecules in the forebrain. The amyloid oligomers 
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could be leading to decreased calpain-mediated p25 formation as suggested by the 
reports of amyloid-induced reduction of calcium signaling due to increased 
internalization and desensitization of NMDA receptors (Palop and Mucke, 2010, Paula-
Lima et al., 2013, Giese, 2014). However, the exact upstream factors of this p25 
downregulation are not yet identified but may have a parallel affect on other pathways 
as well, leading to AD pathology.  
 P25 is a cleavage product of p35 which is membrane bound and is not present in 
the nucleus. P25 on the other hand is not membrane bound and has been reported in 
both the nucleus and cytoplasm (O'Hare et al., 2005). Thus, p25 could be acting as a 
signaling molecule from the synapse to the nucleus (O'Hare et al., 2005). 
 P25 downregulation may lead to a decrease in the concentration of p25 in the 
nucleus. It is possible that p25 is essential for the transcriptional expression of many 
genes and among them CSPα on the pre-synaptic side and CYFIP2 on the postsynaptic 
side. In the future, it will be important to study whether CYFIP2 and CSPα expression 
are reduced in AD brain at the transcriptional level to support this model.  
Acetylation of lysine residues in histone protein , relaxes the chromatin structure, 
exposing the genes to the transcription factors(Brownell and Allis, 1996) ( Brownell, 
Allis, Curr Opinio Gen Development, 1996) . Histone acetylation is regulated by 
opposing activities of Histone Deacetylase (HDAC) and Histone Acetyl Tranferase 
enzyme (Berger et al., 2009) . A segment in N-terminal region of HDAC1 within its 
catalytic site for histone deacetylation, binds directly with p25 and this interaction 
impairs HDAC1 activity (Kim et al., 2008). P25 down regulation will lead to increased 
HDAC activity. Reduced HDAC may lead to reduced transcription of  genes as less of 
those genes will be accessible to the transcription factors. CYFIP and CSP α could be 
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one of those genes which might be regulated by this mechanism, causing the reduction 
in their levels, though this hasn’t been studied by any group yet.  
Ubiquitin-Proteasomal machinery could be another pathway that might be effected by 
decreased p25-CDK5 activity. P25-CDK5 in nucleus might be involved in regulation of 
genes that inhibit the proteasomal activity. Also, It has been shown that p25/CDK5 
activity on its own is sufficient for the stability of cyclin B1 proteins in cortical 
neurons(Maestre et al., 2008).  A decrease in P25 levels could lead to increase in 
proteasomal degradation of synaptic proteins ( which may include CYFIP and CSP α 
proteins ) either by reduced availability of P25 for target protein stabilization or by  
reduced transcription of proteasomal inhibitor genes . However, many studies have 
shown that proteasomal mechanism is inhibited in AD, leading to increased amyloid 
beta(Kumar et al., 2007, Kaneko et al., 2010, Gong et al., 2010). So, the impact of p25 
mediated proteasomal degradation of CYFIP and CSPα in AD is an open question. 
 
 The downregulation of CSPα on the presynaptic side will lead to impaired 
synaptic vesicular trafficking as well as reduced clearance of amyloid species from the 
pre-synaptic side, thereby causing synaptic impairments. On the post synaptic side, the 
downregulation of CYFIP2 can have two types of effect. First , it might impair the 
cytoskeletal machinery by affecting the working of WAVE complexes, since CYFIP2 
is an essential component of this complex (Derivery et al., 2009). This is evident from 
the results obtained in a recent B.Sc project on dendritic spine morphology in the 
hippocampal CA1 region in CYFIP2+/- mice, which showed a reduction of 
stubby/mushroom spines, the type needed for long-term memory retention. The 
reduction in mushroom/ stubby spines observed in this work suggests there may be a 
defect in cytoskeletal structure.  Second, the CYFIP2 downregulation might lead to a 
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toxic, unrepressed translation of dendritically localized mRNA since CYFIP molecules 
are part of a FMRP based local translation repression complex (Schenck et al., 2001, 
Napoli et al., 2008). These locally regulated mRNA molecules consist of cytoskeletal 
proteins like MAP1B, which will again affect dendritic or synaptic structure (Brown et 
al., 2001, Nolze et al., 2013). Also, APP mRNA is regulated by this translation 
repression complex (Westmark and Malter, 2007).  Downregulation of CYFIP2 will 
lead to overexpression of APP proteins at synapses. Towards the end of this PhD study, 
this overexpression was demonstrated by a recent B.Sc project in our lab following 
analysis of crude hippocampal synaptosomes isolated from the CYFIP2+/- mice. 
Overexpression of APP may lead to increased release of toxic amyloid species at the 
synapse. Toxic amyloid oligomers may further interact on both presynaptic and post 
synaptic sides, leading to synaptic loss as well as aggravating the p25-dependent 













(A)  Control  subjects                                  (B) Alzheimer’s Disease 
                                                                                                                                                                 
        
    
Figure 5.1. p25-CYFIP2-CSPα feed-forward model of AD synaptotoxicity. (A) In 
normal individuals, p25 may act as a signal from the synapse to the nucleus leading to 
transcriptional expression of presynaptic genes ( e.g. CSPα) or postsynaptic genes (e.g. 
CYFIP2). CSPα is involved in synaptic vesicule trafficking and clearance of toxic 
species. CYFIP2 is a component of local translation repression complex which 
regulates expression of many mRNAs at the synapse in an activity-dependent 
manner.These mRNAs encode APP as well as many cytoskeltal proteins like MAP1B. 
(B)  In patients with Alzheimer’s disease (mild stage) , there is a downregulation of p25 
molecules, possibly due to the effect of amyloid oligomers on NMDA receptor function. 
This downregulation leads to reductions in CSPα and CYFIP2 mRNA expression. 
Downregulation of CSPα is synaptoxic. At the same time downregulation of CYFIP2 
leads to removal of local translation repression and toxic overexpression of many 
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mRNAs. Overexpression of MAP1B mRNA would affect the cytoskeletal mechanisms 
influencing spine structure. At the other end, overexpression of APP would lead to 
more amyloidogenic processing releasing amyloid β monomers and oligomers into the 
synapse. This toxic release of amyloid species would further impair pre- and post- 
synaptic mechanisms leading to synaptotoxicity. Also, the amyloid species may 
complete this feed-forward loop by causing further downregulation of p25 molecules. 
 
 
5.6. Future studies 
 
To test the above model, as well as to develop better mechanistic insights about how 
CYFIP1/2 and CSPα contribute to synaptic impairments, a number of studies can be 
performed in the future. Specifically, it is of interest to address the following questions: 
1) Is CYFIP2 important for spatial memory? Our studies have shown that CYFIP2+/- 
mice are not impaired in visible platform tests, which makes them suitable for 
performing Morris water maze tests – the gold standard for testing spatial memory. 
Impaired spatial memory formation in CYFIP2+/- mice would point to hippocampal 
impairments and would provide a functional link with the synapse morphology 
phenotype which was detected in area CA1.  
2) What are the molecules downstream of CYFIP2 at synapses? More biochemical 
studies using CYFIP2+/- synaptosomes will have to be performed to understand the 
downstream impact of CYFIP2 expression at synapses. A mass spectrometric study 




3) What is the synaptic phenotype of CYFIP2+/- mice and is there an effect of age?  This 
could be ascertained by performing electrophysiological studies at different age points 
to assess whether synaptic plasticity, such as long-term potentiation, is affected by 
reduced CYFIP2 expression.  
4)  What kind of changes occurs in the synaptic biochemistry, dendritic morphology, 
synaptic electrophysiology and behaviour of models if CYFIP2 is knocked-down 
conditionally at different ages rather than globally?  During my PhD project, I have 
developed CYFIP2 shRNA packaged in an adeno-associated viral delivery system. This 
could be used to perform conditional knock-down of CYFIP2 expression, followed by a 
multi-level analysis of the phenotype.  
5) Could overexpression of CYFIP2 rescue synaptic and behavioural impairments? 
This could be studied by virus-mediated overexpression of CYFIP2 in the CYFIP2+/- 
mouse model and determining if the phenotypes have been rescued. 
6) Is local protein translation impaired in AD mouse models? This could be tested by 
incorporating radioactive lysine and monitoring the level and distribution of different 
proteins at synapse in mouse models of AD. 
7) Is CSPα overexpression neuroprotective as suggested from observations in 
cerebellum of AD patients? I have cloned a CSPα overexpressing plasmid (a gift from 
Prof. Sudhof’s lab), which could be packaged in a lentiviral delivery system to be 
injected in the hippocampus of mouse models of AD. This approach could analyze if 







Synaptotoxicity in AD is an important event that precedes neurodegeneration, however 
the factors leading to it are not well known. This PhD study was aimed at uncovering 
novel candidate molecular pathways that could be involved in synaptotoxicity (or 
synaptic protection) in AD.  From this study, CYFIP2 and CSPα have emerged as two 
novel p25-regulated synaptic molecules at the opposite sides of synaptic clefts, which 
might play an important role in synaptotoxicity from the onset of AD.  Furthermore, a 
new role for CYFIP2 in memory retention has been established. CYFIP1 has emerged 
as one of the late markers of AD, possibly contributing to synaptotoxicity in severe 
stages.  At the same time, CSPα upregulation has emerged as a possible 
neuroprotective factor in AD. Further detailed functional analysis is proposed to be 
carried out in future to build on this study as well as to establish the validity of the p25-
CYFIP2-CSPα feed-forward model of AD proposed in this project.  If the proposed 
model were correct, it would lead to novel diagnostic and therapeutic targets for 










Table S1. The details of mice used in this study. Cb- Cerebellum, Hc- 
Hippocampus, Fx- Frontal cortex. 
A. Young hTau mice 
S.No Genotype Age Sex Tissue 
1 hTau 3-4 Months F Cb,Hc,Fx 
2 hTau 3-4 Months M Cb,Hc,Fx 
3 hTau 3-4 Months M Cb,Hc,Fx 
4 hTau 3-4 Months M Cb,Hc,Fx 
5 hTau 3-4 Months M Cb,Hc,Fx 
6 hTau 3-4 Months M Cb,Hc,Fx 
7 Wild 3-4 Months F Cb,Hc,Fx 
8 Wild 3-4 Months M Cb,Hc,Fx 
9 Wild 3-4 Months M Cb,Hc,Fx 
10 Wild 3-4 Months M Cb,Hc,Fx 
11 Wild 3-4 Months M Cb,Hc,Fx 




B. Aged hTau mice  
  
S.No Genotype Age Sex Tissue 
1 Wild 24 Months F Hc,Fx 
2 Wild 24 Months F Hc,Fx 
3 Wild 24 Months M Hc,Fx 
4 Wild 24 Months M Hc,Fx 
5 hTau 24 Months M Hc,Fx 
6 hTau 24 Months M Hc,Fx 
7 hTau 24 Months F Hc,Fx 
8 hTau 24 Months F Hc,Fx 
9 hTau 24 Months M Hc,Fx 
10 hTau 24 Months F Hc,Fx 






C. Tg276 mice  
 
  
S.No Genotype Age Sex Tissue 
1 Tg2576 10-12 Months M Cb,Fx,Hc 
2 Tg2576 10-12 Months M Cb,Fx,Hc 
3 Tg2576 10-12 Months F Cb,Fx,Hc 
4 Wild 10-12 Months M Cb,Fx,Hc 
5 Wild 10-12 Months M Cb,Fx,Hc 
6 Wild 10-12 Months M Cb,Fx,Hc 
7 Wild 10-12 Months F Cb,Fx,Hc 
8 Tg2576 4 Months F Cb,Fx,Hc 
9 Tg2576 4 Months M Cb,Fx,Hc 
10 Tg2576 4 Months F Cb,Fx,Hc 
11 Tg2576 4 Months M Cb,Fx,Hc 
12 Wild 4 Months M Cb,Fx,Hc 
13 Wild 4 Months M Cb,Fx,Hc 
14 Wild 4 Months F Cb,Fx,Hc 






















Figure S1. Decreased CSPα immunostaining in Alzheimer’s disease hippocampus 
and STG. Fixed hippocampal sections from a patient with severe Alzheimer’s disease 
(A) and a control subject( C) were probed with anti-CSPα antibodies for analysis of 
CSPα expression. Sections from the hippocampus with the granular cell layer show 
decreased immunoreactivity with a synaptic staining pattern in AD as compared to age-
matched control case. A similar analysis was carried out with STG from a patient with 
severe Alzheimer’s Disease (B) and a control subject (D). In the STG there is decreased 
immunoreactivity in AD as compared to age-matched controls. CSPα expression in 
both the regions from the AD patient appeared lower than in the control subject. 
Haematoxylin counterstain. Original magnification:  x400. Scale bars represent 20 µm. 
 
  Figure S2. CSPα levels are not changed in Tg2576 mouse forebrain.
levels in 4 month old Tg2576 mouse forebrain, (B)
Tg2576 mouse forebrain. The statistics from forebrain of Tg2576 , 4 month 
showed no change compared to wild type 
NSE ( t=1.935 , p =0.101 ).
(wild,n=4;Tg2576,n=3)







 CSPα levels in 12 month old 
(n=4) in CSP levels when normalized with 
 There was also no change in the CSP levels at 12 month
  stage in Tg2576 forebrain compared to control 
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 (A) CSPα  
(n=4) 
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Evidence that the presynaptic vesicle protein
CSPalpha is a key player in synaptic degeneration
and protection in Alzheimer’s disease
Sachin S Tiwari1, Marie d’Orange1, Claire Troakes2, Badrun N Shurovi1, Olivia Engmann1, Wendy Noble3,
Tibor Hortobágyi2,4 and Karl P Giese1,5*
Abstract
Background: In Alzheimer’s disease synapse loss precedes neuronal loss and correlates best with impaired memory
formation. However, the mechanisms underlying synaptic degeneration in Alzheimer’s disease are not well known.
Further, it is unclear why synapses in AD cerebellum are protected from degeneration. Our recent work on the
cyclin-dependent kinase 5 activator p25 suggested that expression of the multifunctional presynaptic molecule
cysteine string protein alpha (CSPalpha) may be affected in Alzheimer’s disease.
Results: Using western blots and immunohistochemistry, we found that CSPalpha expression is reduced in
hippocampus and superior temporal gyrus in Alzheimer’s disease. Reduced CSPalpha expression occurred
before synaptophysin levels drop, suggesting that it contributes to the initial stages of synaptic degeneration.
Surprisingly, we also found that CSPalpha expression is upregulated in cerebellum in Alzheimer’s disease. This
CSPalpha upregulation reached the same level as in young, healthy cerebellum. We tested the idea whether
CSPalpha upregulation might be neuroprotective, using htau mice, a model of tauopathy that expresses the
entire wild-type human tau gene in the absence of mouse tau. In htau mice CSPalpha expression was found to
be elevated at times when neuronal loss did not occur.
Conclusion: Our findings provide evidence that the presynaptic vesicle protein CSPalpha is a key player in
synaptic degeneration and protection in Alzheimer’s disease. In the forebrain CSPalpha expression is reduced
early in the disease and this may contribute to the initial stages of synaptic degeneration. In the cerebellum
CSPalpha expression is upregulated to young, healthy levels and this may protect cerebellar synapses and
neurons to survive. Accordingly, CSPalpha upregulation also occurs in a mouse model of tauopathy only at time
when neuronal loss does not take place.
Keywords: Alzheimer’s disease, Cerebellum, Cysteine string protein, Hippocampus, Synapses, Neuroprotection
Introduction
Alzheimer’s disease is a devastating neurodegenerative con-
dition and the most prominent cause of dementia. The
neuropathological features of Alzheimer’s disease are sub-
stantial neuronal death in the forebrain, but almost no neu-
rodegeneration in the cerebellum [1,2]. In the forebrain
extracellular amyloid plaques and intracellular neurofibrillary
tangles are characteristic of Alzheimer’s disease. Further, syn-
aptic loss precedes neuronal loss and the former correlates
best with early deficits in memory formation [3,4]. Our re-
cent research provided a novel window into the mechanisms
underlying synaptic degeneration in Alzheimer’s disease [5].
We found that the truncated cyclin-dependent kinase 5 acti-
vator p25 is reduced in Alzheimer’s disease [6]. Normally,
p25 generation is linked to the synthesis of particular synap-
tic proteins, synaptogenesis and memory formation [6].
Thus, impaired p25 generation may cause early synaptic
dysfunction in Alzheimer’s disease. Furthermore, we dem-
onstrated that p25 generation regulates expression of the
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synaptic chaperone protein cysteine string protein (CSP)
alpha [6]. CSPalpha is a synaptic vesicle protein that be-
longs to a conserved gene family [7,8] that includes CSPalpha,
CSPbeta and CSPgamma of which only CSPalpha is
expressed in the brain [9,10]. CSPalpha function is essen-
tial for synaptic survival as indicated in mouse knockout
studies [10]. Furthermore, loss-of-function CSPalpha mu-
tations are responsible for autosomal dominant Kufs
disease, an adult-onset neurodegenerative disorder with
associated dementia [11,12]. CSPalpha is proposed to
serve various functions at the presynapse, including: 1)
Formation of a trimeric complex with SGT and Hsc 70,
resulting in a CSP/SGT/Hsc70 chaperone complex that is
localised at synaptic vesicles [13] and interacts with
SNARE proteins leading to calcium-triggered synaptic
vesicle exocytosis [14,15]. 2) Modulation of presynaptic
calcium levels by regulating the activity of presynaptic
calcium channels [8,16]. 3) Regulation of endocytosis
by facilitating dynamin 1 polymerization [17]. 4) Regu-
lation of the density of calcium-dependent K+ (BK)
channel at the presynaptic terminal, controlling the ex-
citability there [18,19].
Our finding that CSPalpha is a p25-regulated protein
[6] suggested that CSPalpha expression may be impaired
in Alzheimer’s disease. Here we tested this hypothesis by
examination of post-mortem human tissues. As expected,
we found that CSPalpha expression is reduced in forebrain
of early and late Alzheimer’s disease. Interestingly, CSPalpha
expression was reduced before synaptophysin levels
drop, suggesting that it contributes to the initial stages of
synaptic degeneration. Surprisingly, we discovered an up-
regulation of CSPalpha expression in Alzheimer’s disease
cerebellum, a brain area that is protected from synaptic
degeneration. Further post-mortem investigations and work
with a mouse model of tauopathy established a novel correl-
ation between CSPalpha upregulation and neuroprotection.
Results
Specificity of anti-CSPalpha antibody
To study CSPalpha protein expression we performed
western blots and immunohistochemistry with an anti-
CSPalpha antibody, which does not react with other pro-
tein in CSPalpha knockout mice [10] (Figure 1).
CSPalpha expression is reduced in post-mortem Alzheimer’s
disease hippocampus
The hippocampus is one of the earliest and one of the
most severely affected brain regions in Alzheimer’s disease
[20]. We studied whether CSPalpha protein expression is
affected in this brain region, comparing post-mortem
samples from severe Alzheimer’s disease patients (Braak
stages 5 and 6) and age-matched control subjects by west-
ern blot analysis. CSPalpha expression was normalized to
either the neuronal marker NSE or the synaptic marker
synaptophysin (Figure 2A, C). In both cases CSPalpha
levels were significantly decreased in the hippocampus of
severe Alzheimer’s disease patients (referring to NSE ex-
pression: F(2,21) = 21.3; p < 0.01; referring to synaptophysin
expression: F(2,19) = 14.6, p < 0.05). This result suggests
that in severe Alzheimer’s disease CSPalpha expression is
not simply reduced as a result of neuronal or synaptic loss,
and that reduced CSPalpha expression may precede synap-
tic loss during the progression of Alzheimer’s disease.
Interestingly, we did not find that synaptopysin levels
are reduced in Alzheimer’s disease when normalized to
NSE expression (Additional file 1: Figure S1). In contrast
synaptophysin levels are reduced when absolute expression
levels are considered (e.g., [21-23]). Therefore, neuronal
loss in Alzheimer’s disease appears to mainly contribute to
reduced expression of synaptophysin, which can be cor-
rected for when expression is normalized to NSE.
We also analysed CSPalpha expression in mild Alzheimer’s
disease (Braak stages 1 and 2) (Figure 2B, D). Analysis of
western blot results revealed a significant decrease in
CSPalpha levels in the mild Alzheimer’s disease hippo-
campus when normalized with synaptophysin (F(2,20 =
4.26; P < 0.05), but showed no difference when normalized
with NSE (F(2,21 = 0.366, p = 0.427). These results indicate
that decreases in CSPalpha expression in the hippocam-
pus is an early event in Alzheimer’s disease.
Figure 1 Specificity of the anti-CSPalpha antibody used in
this study. The anti-CSPalpha antibody did not react with any
protein in forebrain and cerebellum from CSPalpha knockout (KO)
mice. In wild-type mice (WT) the antibody recognized a smear of
bands at an approximate molecular weight of 35 kiloDalton, indicating
complex postranslational modification of CSPalpha.
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CSPalpha expression is reduced in Alzheimer’s disease
superior temporal gyrus
We next studied CSPalpha expression in the superior
temporal gyrus (STG), which is affected later and less se-
verely than the hippocampus in Alzheimer’s disease. In a
western blot analysis we compared CSPalpha expression
in severe Alzheimer’s disease and control STG. The level
of CSPalpha expression was again normalised to NSE or
synaptophysin (Figure 3). In both cases, there was a
significant reduction in CSPalpha expression (referring
to NSE expression: F(2,22) = 14.8; p < 0.01; referring to
synaptophysin expression: F(2,22) = 7.48, p < 0.001), simi-
lar to that found in the hippocampus (Figure 2A, C).
These results show that changes in CSP levels are not
limited to the hippocampus in Alzheimer’s disease
brain, but are also found in other degenerating fore-
brain regions.
CSPalpha expression is increased in Alzheimer’s disease
cerebellum
The cerebellum is the least affected brain structure in
Alzheimer’s disease [1,2]. There is no synapse and neur-
onal loss in this brain region in this disease. We investi-
gated the levels of CSPalpha expression in cerebellum
from severe Alzheimer’s disease and controls, using west-
ern blot analysis. As in the case of hippocampus,
CSPalpha amounts were normalized against NSE and
synaptophysin (Figure 4A, C). In both cases CSPalpha
levels were significantly increased by about 50% (referring
to NSE expression: F(2,17) = 2.76; p < 0.05; referring to
synaptophysin expression: F(2,17) = 5.28, p < 0.01). We
also analysed CSPalpha expression in mild Alzheimer’s
diseaseand control cerebellum (Figure 4B, D). We found
that the level of CSPalpha expression was significantly in-
creased in mild Alzheimer’s disease cerebellum when
Figure 2 CSPalpha protein expression is reduced in Alzheimer’s disease hippocampus. (A) CSPalpha expression in post-mortem hippocampus
from patients with severe Alzheimer’s disease (Braak stages 5 and 6; n = 12; average age at death = 75.2 ± 2.0 years) and control subjects (n = 12; average
age at death = 76.5 ± 2.9 years). CSPalpha expression was normalized against the neuron-specific house keeping marker protein NSE. (B) CSPalpha
expression in post-mortem hippocampus from patients with mild Alzheimer’s disease (Braak stages 1 and 2; n = 12; average age at death = 80.3 ± 3.2 years)
and control subjects (n = 12). CSPalpha expression was normalized against NSE. (C) The same samples as in panel (A) were used but CSPalpha expression
was normalized against the synaptic marker protein synaptophysin (severe Alzheimer’s disease, n = 11; control, n = 11). (D) The same samples as in
panel (B) were used but CSPalpha expression was normalized against synaptophysin (mild Alzheimer’s disease, n = 12; control, n = 11). Panel
(E) shows the representative western blots for 7 controls, 7 patients with severe AD and 7 patients with mild AD. Note that the anti-CSPalpha
antibody recognizes two bands at an approximate molecular weight range of 35 kiloDalton, which are likely to represent distinct post-translational
modifications of CSPalpha. Means ± s.e.m. are shown. *, p < 0.05; **, p < 0.01.
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Figure 3 CSPalpha protein expression is reduced in Alzheimer’s disease superior temporal gyrus. (A) CSPalpha expression in post-mortem
STG from patients with severe Alzheimer’s disease (n = 13; average age at death = 73.2 ± 3.4 years) and control subjects (n = 12; average age at
death = 76.9 ± 2.1 years). CSPalpha expression was normalized against NSE. (B) The same samples as in panel (A) were used but CSPalpha expression
was normalized against synaptophysin (severe Alzheimer’s disease, n = 13; control, n = 12). Panel (C) shows the representative western blots for
5 controls and 5 patients with severe AD. Means ± s.e.m. are shown. **, p < 0.01; ***, p < 0.001.
Figure 4 CSPalpha expression is increased in Alzheimer’s disease cerebellum. (A) CSPalpha expression in post-mortem cerebellum from patients
with severe Alzheimer’s disease (n = 10; average age at death = 74.7 ± 4.0 years) and control subjects (n = 10; average age at death = 76.3 ± 4.2 years).
CSPalpha expression was normalized against NSE. (B) CSPalpha expression in post-mortem cerebellum from patients with mild Alzheimer’s
disease (n = 10; average age at death = 81.3 ± 4.1 years) and control subjects (n = 10). CSPalpha expression was normalized against NSE. (C) The
same samples as in panel (A) were used but CSPalpha expression was normalized against synaptophysin. (D) The same samples as in panel (B) were
used but CSPalpha expression was normalized against synaptophysin. Panel (E) shows the representative western blots for 5 controls, 5 patients with
mild AD and 5 patients with severe AD. Means ± s.e.m. are shown. *, p < 0.05; **, p < 0.01.
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normalized with both NSE and synaptophysin (referring
to NSE expression: F(2,17) = 7.25; p < 0.05; referring to
synaptophysin expression: F(2,17) = 4.18, p < 0.05). There-
fore, we have observed reduced CSPalpha amounts in de-
generating regions of early and severe Alzheimer’s disease
brain, and increased levels of CSPalpha in areas of
Alzheimer’s disease brain that are relatively spared from
degeneration. These findings suggest that there may be a
mechanistic link between CSPalpha expression levels and
neuroprotection in Alzheimer’s disease.
Immunohistochemical analysis confirms CSPalpha
downregulation in forebrain and upregulation in
cerebellum in Alzheimer’s disease
To confirm the changes in CSPalpha protein amounts
determined by western blotting, we carried out a qualita-
tive immunohistochemical analysis with post-mortem cere-
bellum, hippocampus and STG from a severe Alzheimer’s
disease patients and a control subject (Figure 5; Additional
file 2: Figure S4). A neuropathologist blinded to the
disease state of the tissue performed a qualitative
Figure 5 Increased CSPalpha immunostaining in Alzheimer’s disease cerebellum. Fixed cerebellar cortex sections from a patient with
severe Alzheimer’s disease (B, D) and a control subject (A, C) were probed with anti-CSPalpha antibodies for analysis of CSPalpha expression.
CSPalpha expression in the cerebellar cortex of the Alzheimer’s disease patient appeared higher than in the control subject. In A and B cerebellar
cortex with the Purkinje cell layer and granule cells are visible in the lower right corner. There is increased immunoreactivity in the neuropil in
Alzheimer’s disease as compared to an age-matched control case. In C and D the granule cells of the cerebellum show increased cytoplasmic
and neuropil labeling in Alzheimer’s disease as compared to an age-matched control. Negative control images are shown in E and F (immunohistochemistry
with omission of the primary antibody) and confirm the specificity of labeling in Figure 5 and Additional file 1: Figure S1. Haematoxylin counterstaining
is also shown. Original magnification: 400×. Scale bars represent 20 μm.
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comparison of CSPalpha expession. This comparison
confirmed an increase in CSPalpha levels in cerebellar
regions (Figure 5) and a decrease in hippocampus and
STG in severe Alzheimer’s disease compared to control
(Additional file 2: Figure S4). To validate the synaptic
specificity of the anti-CSPalpha antibodies, the immu-
nohistochemistry was compared with synaptophysin ex-
pression patterns (Additional file 3: Figure S2). Staining
of cerebellar dentate nucleus from a control subject
showed similar results with both antibodies, confirming
that the CSPalpha immunostaining was typical for syn-
aptic staining.
CSPalpha expression is not changed in frontotemporal
lobar degeneration (FTLD) cerebellum
Frontotemporal lobar degeneration (FTLD) is a promin-
ent form of dementia that is characterized by neurode-
generation of the frontotemporal region [24]. In addition
to frontal lobe degeneration, the cerebellum is also re-
ported to be affected in FTLD cases [25]. This disparity
provided an opportunity to test the specificity of our ob-
servation that CSPalpha is upregulated in Alzheimer’s
disease cerebellum. We performed a western blot ana-
lysis to study whether altered CSPalpha expression is
linked to cerebellar neuropathology in FTLD (Figure 6).
CSPalpha expression levels did not differ between FTLD
and control cerebellum (t = − 0.373, p = 0.72). Hence, in-
creased CSPalpha expression in the cerebellum is not a
common feature of neurodegenerative disease, but ap-
pears to be specific for Alzheimer’s disease.
Normal ageing reduces CSPalpha expression in human
cerebellum
The difference in CSPalpha expression in the hippocampus
and cerebellum of Alzheimer’s disease brain suggests that
CSPalpha expression may be differentially regulated under
physiological and/or pathological conditions. Therefore, we
studied whether normal ageing also regulates CSPalpha ex-
pression in cerebellum. Using western blots, we analysed
CSPalpha protein expression in cerebellum from healthy
subjects belonging to two age groups, 15–30 years (21.3 ±
1.6 years) and 90–105 years (96.1 ± 1.4 years) (Figure 7).
CSPalpha expression was reduced by approximately 50% in
the aged cerebellum when expression was normalized to
NSE expression (t = 2.443; p < 0.05). Similarly, when nor-
malized to synaptophysin levels the average CSPalpha ex-
pression in the aged cerebellum appeared lower than in
young cerebellum, although this did not reach significance
(t = 1.351; p = 0.23), most likely due to a large variability of
CSPalpha amounts in young cerebellum. Taken together,
our results suggest that CSPalpha amounts are subject to
age-dependent decreases in healthy cerebellum. Interest-
ingly, the CSPalpha expression level in Alzheimer’s disease
cerebellum is similar to the expression level found in
young healthy cerebellum.
Overexpression of human tau leads to an age-dependent
decline in hippocampal-cortical CSPalpha levels
Together with amyloid plaques, neurofibrillary tangles
containing hyperphosphorylated tau aggregates are a
pathological hallmark of Alzheimer’s disease. We investi-
gated the levels of CSPalpha in a mouse model of tauo-
pathy that which expresses the entire wild-type human
tau gene in the absence of mouse tau [26]. These mu-
tants progressively develop hyperphosphorylated tau and
form neurofibrillary tangles predominantly in the cortex
and hippocampus. This model also has deficits in basal
synaptic transmission, long-term potentiation and mem-
ory, and a widespread neuronal loss in old age [27,28].
The tau pathology is visible with biochemical analysis
from 3 weeks of age, but neuronal loss is only appar-
ent from 17 months of age onwards. We studied CSPalpha
expression in the hippocampus/overlying cortex
(Figure 8A, Additional file 4: Figure S3), frontal cortex
(Figure 8B) and cerebellum (Figure 8C) of htau mu-
tants and wild-type mice at 3–4 months of age. We
found a significant upregulation of CSPalpha expression
in hippocampus (Figure 8A, t = 6.539, p < 0.001), frontal
cortex (Figure 8B, t = 8.005, p < 0.001) and cerebellum
(Figure 8C, t = 5.200, p < 0.001) in 3–4 month-old htau
Figure 6 CSPalpha expression in cerebellum is not changed in
FTLD. CSPalpha expression in post-mortem cerebellum from patients
with FTLD (n = 5; average age at death = 73.0 ± 3.0 years) and control
subjects (n = 5; average age at death = 70.2 ± 7.2 years).CSPalpha
expression was normalized against NSE (A). Panel (B) shows the
representative western blots for 5 controls and 5 patients with
FTLD. Means ± s.e.m. are shown.
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Figure 7 Normal ageing reduces CSPalpha expression in healthy human cerebellum. (A) CSPalpha expression in post-mortem cerebellum
from healthy young (n = 6; average age at death = 21.3 ± 1.6 years) and aged (n = 7; average age at death = 96.1 ± 1.4 years) subjects. CSPalpha
expression was normalized against NSE. (B) The same samples as in panel (A) were used but CSPalpha expression was normalized against synaptophysin.
Panel (C) shows the representative western blot for 6 young subjects and 7 aged subjects. Means ± s.e.m. are shown. *, p < 0.05.
Figure 8 Mice expressing human tau have an age-dependent CSPalpha upregulation that correlates with neuroprotection. (A) CSPalpha
expression in hippocampus of young (3–4 months) wild type (n = 6) and htau mice (n = 6). (B) CSPalpha expression in cortex of young (3–4 months)
wild type (n = 6) and htau mice (n = 6). (C) CSPalpha expression in cerebellum of the same mouse sample as in panel (A) and (B). (D) CSP alpha
expression in old (24 months) wild type (n = 4) and htau mice (n = 7). CSPalpha expression was normalized against NSE in all panels. Panel (E) shows
the representative western blots. Means ± s.e.m are shown. ***, p < 0.001.
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mice relative to controls. At this age there is no neuronal
loss in htau mice, and therefore this findings is in agree-
ment with the idea that increased CSPalpha expression
may be a neuroprotective mechanism. We also investigated
CSPalpha expression at 24 months of age in hippocampal/
overlying cortex lysates prepared from htau and wild type
mice (Figure 8D). At this age point no differences in the
levels of CSPalpha in the hippocampus from wild type and
htau mice was apparent (Figure 8D, t = −0.220, p =0.83).
Thus, at a time point when neuronal loss is observed,
CSPalpha expression is no longer elevated.
Discussion
The main findings of our study are that 1) expression of
CSPalpha is reduced in degenerating forebrain in mild
and severe Alzheimer’s disease. This downregulation oc-
curs before synaptophysin levels drop. 2) CSPalpha expres-
sion is upregulated in Alzheimer’s disease cerebellum, a
brain region protected from synaptic and neuronal loss in
Alzheimer’s disease. This upregulation is at a level that oc-
curs in young healthy cerebellum. 3) CSPalpha expression
is not upregulated in FTLD cerebellum where neuropath-
ology occurs. 4) In a mouse model of tauopathy CSPalpha
upregulation inversely correlates with neurodegeneration.
Taken together, these findings provide evidence that CSPalpha
is a critical player of synaptic degeneration and synaptic
survival in Alzheimer’s disease.
CSPalpha is a p25-regulated protein, and we have pre-
viously shown that p25 expression is downregulated in
Alzheimer’s disease forebrain [6]. In addition, loss-of-
function CSPalpha mutations cause adult-onset Kufs dis-
ease that is associated with dementia [11,12]. We therefore
speculated that CSPalpha expression could be altered in
Alzheimer’s disease. Here we confirm this idea. We found
that CSPalpha expression is reduced in hippocampus and
STG in severe Alzheimer’s disease. In western blots we de-
tected CSPalpha as two bands due to posttranslational
modifications. The posttranslational modifications and the
levels of CSPalpha appear variable within a given group.
However, when normalized to NSE or synaptophysin and
when outliers were excluded (see, Material and methods)
significant differences in expression between groups were
identified. Our finding that CSPalpha expression is re-
duced in AD hippocampus and STG is consistent with an-
other study, which was published after we started our
project, showing that in Brodmann area 9 of severe
Alzheimer’s disease CSPalpha expression is reduced by
about 40% [29]. Furthermore, we also detected a down-
regulation of CSPalpha expression in hippocampus in
mild Alzheimer’s disease when CSPalpha amounts were
normalized to the synaptic marker synaptophysin. Trad-
itionally, synaptophysin is used as a neuropathological
marker of synaptic degeneration in Alzheimer’s disease
[3]. However, our finding that CSPalpha levels are reduced
without noticeable changes in synaptophysin expres-
sion, when relative neuronal expression rather than abso-
lute protein expression is analyzed. When considering the
importance of CSPalpha for synaptic function [10], our
findings suggest that reduced CSPalpha expression is
likely to be involved in the initial stages of synaptic de-
generation. Further, for investigating synaptic degener-
ation in Alzheimer’s disease analysis CSPalpha expression
appears more suitable than assessing synaptophysin
expression.
CSPalpha, along with its interacting partners Hsc-70
and SGT, is involved in exocytotic mechanisms in pre-
synaptic terminals that are mediated by its interactions
with SNARE complexes [9]. Downregulation of CSPalpha
may therefore lead to reductions in the number of syn-
aptic vesicles binding at presynaptic membranes, thereby
affecting synaptic activity. Further, CSPalpha is also import-
ant for endocytosis of synaptic vesicles. CSPalpha interacts
with dynamin to facilitate the of dynamin polymerization
which is important for endocytotic vesicle fission [17,29].
This is important for normal synaptic function since the
number of synaptic vesicles readily available for exocytosis
is reduced when there are defects in endocytotic fission
[30]. This suggests that defects observed in exocytotic
mechanisms in CSPalpha knockout mice could be ex-
plained by deficits in CSPalpha-dependent endocytotic
mechanisms. Hence, CSPalpha downregulation could lead
to loss of function at different stages of synaptic vesicular
recycling to contribute to synaptic loss. Additionally, re-
duced CSPalpha expression is expected to increase BK
channel density at synapses, which reduces excitability at
presynaptic terminals [18,19]. BK channel activation has
been reported to decrease basal synaptic transmission in
hippocampal CA1 region of a mouse model of Alzheimer’s
disease [31]. Loss of synaptic activity is thought to be lethal
for synapses, therefore, the downregulation in CSPalpha ex-
pression we observe in Alzheimer’s disease hippocampus
could be closely associated with synaptic degeneration
and the resulting impaired memory formation in early
Alzheimer’s disease.
The second major finding from our study is the identi-
fication of CSPalpha upregulation in Alzheimer’s disease
cerebellum. The cerebellum is relatively protected from
neurodegeneration in Alzheimer’s disease. For example,
there is no synaptic and neuronal loss in this area, al-
though there are some diffuse amyloid plaques [1]. The
molecular mechanisms that impart neuroprotection to
the cerebellum in Alzheimer’s disease are not known.
Our results suggest that CSPalpha may be a factor con-
tributing to this neuroprotection. We observed an up-
regulation of CSPalpha in cerebellum both in mild and
severe Alzheimer’s disease. Importantly, we found that
the level of upregulation in this region is comparable to
the amounts of CSPalpha expression detected in young,
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healthy cerebellum, in contrast to an age-dependent
decrease in CSPalpha expression in normal cerebellum.
Additional experimental support for the suggestion
that CSPalpha upregulation could be neuroprotective
in Alzheimer’s disease comes from our finding that
CSPalpha expression is not altered in cerebellum from
patients with FTLD, although there is neuropathology
in the cerebellum in this disease [25,32,33]. Additional
support for our hypothesis comes from analysis of htau
mutant mice, where we found that CSPalpha upregula-
tion occurs only at times when no neuronal loss is ob-
served. Taken together, the evidence we present here
suggests that CSPalpha upregulation in Alzheimer’s
disease cerebellum might be neuroprotective, although
in future functional studies in model systems are needed
to support this idea.
How could CSPalpha upregulation protect synapses and
consequently neurons in Alzheimer’s disease cerebellum?
In Alzheimer’s disease forebrain, amyloid-induced aberra-
tions in synaptic activity are one of the causes of synaptic
toxicity [34]. In particular, dysfunctional synaptic machin-
ery could be an after-effect of impaired synaptic vesicle
trafficking. Aβ oligomers impair synaptic vesicle recycling
by hindering endocytosis as well as the formation of
fusion-competent vesicles [35]. Furthermore, transgenic
mouse studies have suggested that presynaptic degener-
ation is pivotal in Alzheimer’s disease [36]. Considering
the role of CSPalpha in endocytosis and vesicle recycling,
an up regulation of CSPalpha in Alzheimer’s disease cere-
bellum could be a compensatory mechanism that prevents
impairments in synaptic vesicle recycling that are induced
by factors causing Alzheimer’s disease. This might result
in protection of synapses and neurons from degeneration.
Functional studies with CSPalpha knockout and upregula-
tion models will provide further insights into the mechan-
istic basis of our observations.
Conclusion
Synapse loss in forebrain, but not cerebellum, is a key
hallmark of in Alzheimer’s disease. However, the mecha-
nisms causing brain region-dependent synapse loss and
protection are unknown. Here we provide evidence that
the presynaptic vesicle protein CSPalpha is a critical
player in Alzheimer’s disease. In the forebrain CSPalpha
expression reduces in the initial stages of synaptic de-
generation before synaptophysin levels drop. In cerebel-
lum CSPalpha expression is upregulated both in mild and
severe Alzheimer’s disease. This upregulation of CSPalpha
is to a level that occurs in young health cerebellum. In a
mouse model of tauopathy we confirmed a lack of
neuronal loss when CSPalpha expression is elevated.
Taken together, these findings point to critical role for
CSPalpha in synaptic degeneration and protection in
Alzheimer’s disease.
Material and methods
Post-mortem human brain samples
Brain tissues in 10% (v/v) formalin-fixed, paraffin-embedded
tissue blocks and as frozen tissues were available from the
Medical Research Council (MRC) London Neurodegenera-
tive Diseases Brain Bank (Institute of Psychiatry, King’s
College London, UK). All tissue collection and processing
was carried out under the regulations and licensing of the
Human Tissue Authority and in accordance with the Hu-
man Tissue Act, 2004. Frozen samples were received in
two sets for western blot analysis. The first set contained
hippocampal tissue from control subjects, mild Alzheimer’s
disease (Braak stages 1–2) and severe Alzheimer’s disease
(Braak stages 5–6) [n = 7 for each group], as well as su-
perior temporal gyrus (STG) samples from controls and
severe Alzheimer’s disease [n = 7 and n = 9, respect-
ively]. The second set comprised hippocampus, STG
and cerebellum samples from control, mild and severe
Alzheimer’s disease patients (n = 5 for each group). To
increase the sample size of cerebellum, a new cohort
(n = 5 per group) was later added to the analysis. Cerebel-
lum samples (n = 5) were obtained from frontotemporal
lobar degeneration (FTLD) patients. Cerebellum tissues
were also obtained from healthy subjects less than 30 years
old (n = 6) and older than 90 years (n = 7). Additional file 5:
Table S1 summarizes the details.
Lysate preparation from human brain samples
Frozen brain samples were lysed at 4°C in RIPA lysis
buffer (Santa Cruz Biotechnology, Inc., USA) consisting
of 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate
and 0.004% sodium azide in TBS (pH 7.5). Protease inhibi-
tors cocktail, sodium orthovanadate and α-toluenesulphonyl
fluoride in DMSO (all Santa Cruz Biotechnology, Inc., USA)
were added to the buffer, diluted to 0.01%. The SDS concen-
tration was increased to 0.25%. Approximately 100 mg of
brain tissue was lysed in 300 μl buffer. Samples were ho-
mogenized using a dounce homogenizer (12 up and down
strokes, 700 rotations per minute) at 4°C, and centrifuged at
3,000 rpm for 10 minutes at 4°C. Supernatants were immu-
noblotted and the bands from protein of interest were nor-
malized with housekeeping proteins.
Mouse brain samples
Frontal cortex, cerebellum and hippocampus/overlying cor-
tex was isolated from 3–4 month old human tau (htau)
mice in the C57BL/6 J background (Jackson Laboratories,
Bar Harbor, Maine USA; Stock number: 005 491). Mice
were genotyped by PCR to confirm the presence of the hu-
man MAPT transgene and the mouse Mapt null back-
ground using primers for the MAPT gene (forward 5′-AC
TTTGAACCAGGATGGCTGAGCCC-3′, reverse 5′-CTG
TGCATGGCTGTCCCTACCTT-3′), and the mouse Mapt
gene (forward 5′-CTCAGCATCCCACCTGTAAC-3′,
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reverse 5′-CCAGTTGTGTATGTCCACCC-3′), as de-
scribed in [20]. The primers for the disrupted Mapt
gene were: forward 5′-AAGTTCATCTGCACCACC
G-3′, reverse 5′-TCCTTGAAGAAGATGGTG CG-3′.
Mice were housed on 12 h light:12 h dark cycles with food
and water available ad libitum. Mice were killed by cervical
dislocation and brain regions snap frozen on dry ice. All ani-
mal procedures were conducted in accordance with the UK
Home Office, Animals Scientific Procedures Act 1986.
Lysate preparation from mouse brain samples
Frozen tissue was homogenised at 100 mg/ml in 2× sample
buffer (0.5 M Tris–HCl, pH 6.8, 4.4% SDS, 20% glycerol,
2% 2-mercaptoethanol, 0.01% bromophenol blue, and
complete mini-protease inhibitor cocktail (Roche Products
Ltd., UK). Following brief sonication, homogenates were
centrifuged at 25,000 g for 20 minutes at 4°C, and the
supernatant was collected.
Western blot analysis
The same protein amounts were separated on criterion
TGX precast gels (4-15%) gels (BioRad) and the protein
was transferred onto a methanol activated PVDF mem-
brane (BioRad), using standard protocols. Non-specific
binding was blocked by 5% non-fat dried milk in TBST
for 1 hour at room temperature. Subsequently, mem-
branes were incubated overnight at 4°C in primary anti-
body solution prepared in blocking buffer. After three
ten minute washes in TBST at room temperature, mem-
branes were incubated for two hours at room temperature
with horse-radish peroxidase conjugated secondary anti-
bodies in blocking buffer. After three ten minute washes
with TBST, the membrane was incubated for 3 minutes in
ECL reagent (Thermo Scientific) and then exposed to an
X-ray film (Amersham) in the linear range. To probe the
membranes with other primary antibodies, membranes
were treated with a stripping buffer (Santa Cruz Biotech-
nology) for one hour at room temperature, followed by
three washes with TBST of 10 minutes each and subse-
quent labelling as described above. Primary antibodies
against CSPalpha (1:50,000, AB1576 Merck Millipore),
synaptophysin (1:1000, 4329 Cell Signalling Technology)
and neuron specific enolase (NSE) (1:60,000, AB 951 Merck
Millipore) were used. Signals were analyzed using ImageJ
software (NIH). With the antibodies against CSPalpha
sometimes two bands were detected in human post-
mortem brain. These bands are not CSPbeta and
CSPgamma since these proteins are not expressed in
brain [10]. For standardization CSPalpha was normal-
ized against NSE or synaptophysin.
Immunohistochemistry
Sections of human brain of 7 μm thickness were cut
from paraffin-embedded tissue blocks. Sections were
deparaffinised in xylene and rehydrated in ethanol. En-
dogenous peroxidase activity was blocked by incubation
of sections with 2.5% H2O2 in methanol. To enhance
antigen retrieval sections were exposed to citrate buffer
(2.94 g/L, pH 6.0) for 16 minutes microwave treatment
(6 minutes high, two 5 minutes simmer). After blocking
in normal swine serum (DAKO Ltd), primary antibodies
against CSPalpha (1:500, AB1576 Merck Millipore), and
synaptophysin (1:100, SY38 DAKO Ltd) were applied
overnight at 4°C. Following rinsing and two five minutes
washes in TBS, sections were incubated with appropriate
biotinylated secondary antibodies (1:100, Swine anti-rabbit
immunoglobulin/biotinylated, E0353 DAKO Ltd), followed
by incubation with avidin:biotin enzyme complex (Vectas-
tain Elite ABC kit, Vector Laboratories, Peterborough,
UK). Following washing, sections were incubated for
10–15 min with 0.5 mg/ml 3,3′-diaminobenzidine
chromogen (Sigma-Aldrich Company Ltd, Dorset UK)
in Tris-buffered saline (pH 7.6) containing 0.05% H2O2.
Sections were counterstained with Harris’s haematoxylin.
Statistical analysis
Un-paired t tests were used for comparison of data from
samples tested in one western blot. – In some cases, the
sample size was so large so that data from more than
one western blot needed to be pooled. To allow pooling










¼ β0 þ β1  X1i þ β2  X2i þ εi
Where X1i is the categorical predictor coding for the
group difference (e.g. Control versus Severe), and X2i is
the categorical predictor coding for the different experi-
ments (“1stcohort” versus “2ndcohort”).
This regression model allowed us to pool the CSPalpha
score from two different set of samples by eliminating the
contribution made by the difference in experimental con-
ditions. This analysis was performed using SPSS (version
20), which provides the output as an ANOVA score. The
contribution and the significance of the factor of interest
(e.g. the disease pathology) to the overall significance is
subsequently determined by the score from this output.
The level of significance for the analysis was 0.05 and out-
liers were decided by using mean ± 4*SD as threshold. See
Additional file 6 in supplementary information for analysis
of post-mortem brain tissue.
Additional files
Additional file 1: Figure S1. Synaptophysin protein expression in
reference to NSE expression is unchanged in Alzheimer’s disease
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hippocampus. (A) Synaptophysin expression in post-mortem hippocampus
from patients with severe AD (n = 12) and control subjects (n = 12) was
normalized against the neuron specific house keeping marker protein NSE.
(B) Synaptophysin expression in post-mortem hippocampus from patients
with mild AD (n = 12) and control subjects (n = 12) was normalized against
NSE. Means ± s.e.m. are shown. *, p < 0.05; **, p < 0.01.
Additional file 2: Figure S4. Decreased CSPalpha immunostaining in
Alzheimer’s disease hippocampus and STG. Fixed hippocampal sections
from a patient with severe Alzheimer’s disease (D) and an age-matched
control subject (C) were probed with anti-CSPalpha antibodies for analysis
of CSPalpha expression.Sections from the hippocampus with the granule
cell layer show decreased immunoreactivity with a synaptic staining pattern
in Alzheimer’s disease as compared to the control case. A similar analysis
was carried out for expression in superior temporal gyrus (STG) from a
patient with severe Alzheimer’s disease (B) and an age-matched control
subject (A). In the STG there is decreased immunoreactivity in Alzheimer’s
disease as compared to control. Haematoxylin counterstain is included in
the analysis. Original magnification: ×400. Scale bars represent 20 μm.
Additional file 3: Figure S2. CSPalpha immunostaining in cerebellum
is typical for synaptic expression. Immunohistochemical sections of
cerebellar dentate nucleus region from a control patient were
immunostained with anti-CSPalpha antibodies (A) and with antibodies
against the synaptic marker synaptophysin (B). This comparison indicated
that the CSPalphaimmunostaining is synaptic as obtained for synaptophysin
immunostaining. Scale bars represent 200 μm.
Additional file 4: Figure S3. Synaptophysin levels relative to NSE
expression are unchanged in hTau mutant mouse hippocampus.
Synaptophysin expression in hippocampus of young (3–4 months) wild
type (n = 6) and hTau mice (n = 6) was normalized against NSE in all
panels. Means ± s.e.m are shown.
Additional file 5: Table S1. Details of post-mortem brain tissues for
western blots. PMD refers to post-mortem delay.
Additional file 6: Statistical analysis of the effect of age, gender and
post mortem delay on post-mortem brain tissues used in this study.
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